---
document_datetime: 2023-09-21 20:31:52
document_pages: 92
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/tecentriq-h-c-004143-ii-0033-epar-assessment-report-variation_en.pdf
document_name: tecentriq-h-c-004143-ii-0033-epar-assessment-report-variation_en.pdf
version: success
processing_time: 202.3426862
conversion_datetime: 2026-01-01 22:07:16.267275
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

25 March 2021 EMA/275323/2021 Committee for Medicinal Products for Human Use (CHMP)

## CHMP extension of indication variation assessment report

Invented name: Tecentriq

International non-proprietary name: atezolizumab

Procedure No. EMEA/H/C/004143/II/0033

Marketing authorisation holder (MAH): Roche Registration GmbH

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                                  | ..............................................5                                                         |
|-----------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ..................................................................................................5  |                                                                                                         |
| 1.2. Steps taken for the assessment of the product.........................................................5                |                                                                                                         |
| 2. Scientific discussion                                                                                                    | ................................................................................6                       |
| 2.1. Introduction.........................................................................................................6 |                                                                                                         |
| 2.1.1. Problem statement                                                                                                    | ............................................................................................6           |
| 2.1.2. About the product..............................................................................................8     |                                                                                                         |
| 2.1.3. The development programme/compliance with CHMP guidance/scientific advice                                            | ........8                                                                                               |
| 2.1.4. General comments on compliance with                                                                                  | GCP..........................................................9                                          |
| 2.2. Non-clinical aspects                                                                                                   | ..............................................................................................9         |
| 2.2.1. Ecotoxicity/environmental risk assessment                                                                            | ...........................................................9                                            |
| 2.2.2. Discussion and conclusion on non-clinical aspects..................................................9                 |                                                                                                         |
| 2.3. Clinical aspects                                                                                                       | ....................................................................................................9   |
| 2.3.1. Introduction......................................................................................................9  |                                                                                                         |
| 2.3.2. Pharmacokinetics.............................................................................................10      |                                                                                                         |
| 2.3.3. Pharmacodynamics..........................................................................................23         |                                                                                                         |
| 2.3.4. Discussion on clinical pharmacology...................................................................24             |                                                                                                         |
| 2.3.5. Conclusions on clinical pharmacology.................................................................25              |                                                                                                         |
| 2.4. Clinical efficacy                                                                                                      | ..................................................................................................25    |
| 2.4.1. Dose response study........................................................................................25        |                                                                                                         |
| 2.4.2. Main study......................................................................................................25   |                                                                                                         |
| 2.4.3. Discussion on clinical efficacy............................................................................55        |                                                                                                         |
| 2.4.4. Conclusions on the clinical efficacy.....................................................................58          |                                                                                                         |
| 2.5. Clinical safety                                                                                                        | ....................................................................................................58  |
| 2.5.1. Discussion on clinical safety                                                                                        | ..............................................................................77                        |
| 2.5.2. Conclusions on clinical safety                                                                                       | ............................................................................78                          |
| 2.5.3. PSUR cycle                                                                                                           | .....................................................................................................78 |
| 2.6. Risk management plan........................................................................................79         |                                                                                                         |
| 2.7. Update of the Product information                                                                                      | ........................................................................86                              |
| 2.7.1. User consultation.............................................................................................86     |                                                                                                         |
| 3. Benefit-Risk Balance..............................................................................87                     |                                                                                                         |
| 3.1. Therapeutic Context                                                                                                    | ...........................................................................................87           |
| 3.1.1. Disease or condition.........................................................................................87      |                                                                                                         |
| 3.1.2. Available therapies and unmet medical need.......................................................87                  |                                                                                                         |
| 3.1.3. Main clinical studies                                                                                                | .........................................................................................87             |
| 3.2. Favourable effects                                                                                                     | ..............................................................................................88        |
| 3.3. Uncertainties and limitations about favourable effects.............................................88                  |                                                                                                         |
| 3.4. Unfavourable effects...........................................................................................88      |                                                                                                         |
| 3.5. Uncertainties and limitations about unfavourable effects                                                               | .........................................89                                                             |
| 3.6. Effects Table......................................................................................................89  |                                                                                                         |
| 3.7. Benefit-risk assessment and discussion.................................................................90              |                                                                                                         |
| 3.7.1. Importance of favourable and unfavourable effects..............................................90                    |                                                                                                         |
| 3.7.2. Balance of benefits and risks.............................................................................91         |                                                                                                         |

<div style=\"page-break-after: always\"></div>

3.7.3. Additional considerations on the benefit-risk balance ...........................................  91

3.8. Conclusions .......................................................................................................  91

4. Recommendations .................................................................................  91

5. EPAR changes  ........................................................................................  92

<div style=\"page-break-after: always\"></div>

## List of abbreviations

1L

first-line second-line second-line and beyond anti-drug antibody, also called anti-therapeutic antibody adverse drug reaction adverse event adverse event of special interest anaplastic lymphoma kinase clinical cutoff date maximum concentration minimum concentration Clinical Study Report duration of response Eastern Cooperative Oncology Group epidermal growth factor receptor European Medicines Agency European Organisation for the Research and Treatment of Cancer hazard ratio tumor-infiltrating immune cell independent Data Coordinating Center independent Data Monitoring Committee immunohistochemistry Interactive Web/Voice Response System multiple ascending dose Marketing Authorization Holder metastatic urothelial carcinoma National Comprehensive Cancer Network National Cancer Institute non - small cell lung cancer objective response rate overall survival programmed death - 1 programmed death - ligand 1 progression-free survival pharmacokinetic population pharmacokinetic every 2 weeks every 3 weeks every 4 weeks Quality-of-Life Questionnaire Core Quality-of-Life Questionnaire Lung Cancer Module Response Evaluation Criteria in Solid Tumors serious adverse event Statistical Analysis Plan small cell lung cancer Summary of Clinical Pharmacology Summary of Clinical Safety Symptoms in Lung Cancer Summary of Product Characteristics treatment assignment information tumor cell triple-negative breast cancer tumor proportion score urothelial carcinoma U.S. Prescribing Information wild type

2L

2L +

ADA

ADR

AE

AESI

ALK

CCOD

Cmax

Cmin

CSR

DOR

ECOG

EGFR

EMA

EORTC

HR

IC

iDCC

iDMC

IHC

IxRS

MAD

MAH

mUC

NCCN

NCI

NSCLC

ORR

OS

PD-1

PD-L1

PFS

PK

popPK

q2w

q3w

q4w

QLQ-C30

QLQ-LC13

RECIST

SAE

SAP

SCLC

SCP

SCS

SILC

SmPC

TAI

TC

TNBC

TPS

UC

USPI

WT

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Roche Registration GmbH submitted to the European Medicines Agency on 27 November 2019 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours express PD-L1 for Tecentriq based on the results of the pivotal study GO29431 (IMpower110), comparing atezolizumab monotherapy to platinum-based chemotherapy. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated accordingly. The RMP version 12.0 has also been submitted.

The variation requested amendments to the Summary of Product Characteristics and Package Leaflet.

## Information on paediatric requirements

Pursuant  to  Article  8  of  Regulation  (EC)  No  1901/2006,  the  application  included  an  EMA  Decision P/0207/2019 on the granting of a (product-specific) waiver.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Scientific advice

The applicant received the following Scientific Advice on the clinical development relevant for the indication subject to the present application: EMEA/H/SA/2522/3/2014/II

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Sinan B. Sarac

Co-Rapporteur:

Jan Mueller-Berghaus

<div style=\"page-break-after: always\"></div>

| Timetable                                            | Actual dates     |
|------------------------------------------------------|------------------|
| Submission date                                      | 27 November 2019 |
| Start of procedure:                                  | 28 December 2019 |
| CHMP Co-Rapporteur Assessment Report                 | 21 February 2020 |
| CHMP Rapporteur Assessment Report                    | 21 February 2020 |
| PRAC Rapporteur Assessment Report                    | 27 February 2020 |
| PRAC members comments                                | 4 March 2020     |
| Updated PRAC Rapporteur Assessment Report            | 5 March 2020     |
| PRAC Outcome                                         | 12 March 2020    |
| CHMP members comments                                | 16 March 2020    |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report | 20 March 2020    |
| Request for supplementary information (RSI)          | 26 March 2020    |
| CHMP Rapporteur Assessment Report                    | 22 December 2020 |
| CHMP members comments                                | 18 January 2021  |
| Updated CHMP Rapporteur Assessment Report            | 21 January 2021  |
| Request for supplementary information (RSI)          | 28 January 2021  |
| CHMP Rapporteur Assessment Report                    | 10 March 2021    |
| CHMP members comments                                | 15 March 2021    |
| Updated CHMP Rapporteur Assessment Report            | n/a              |
| Opinion                                              | 25 March 2021    |

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1. Problem statement

## Disease or condition

The MAH applied for the following indication:

'Tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression ≥ 50% tumour cells (TC) or ≥ 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC (see section 5.1).'

<div style=\"page-break-after: always\"></div>

## Epidemiology

Lung cancer remains the leading cause of cancer death worldwide, estimated to be responsible for nearly one in five cancer deaths globally (1.8 million deaths, 18% of the total; Globocan 2020). There were estimated to be 2.2 million new cases in 2020 (11.4% of the total). This disease is the most common cancer in men worldwide (1.4 million, 15% of the total cancers in men) and accounts for the highest absolute number of cancer deaths globally (1.2 million deaths, 24% of cancer deaths in men).

## Biologic features

Non-small cell lung cancer (NSCLC) is the predominant subtype, accounting for approximately 85% of all cases. NSCLC can be divided into two major histologic types: non-squamous and squamous cell carcinoma. Non-squamous histology accounts for more than half of all NSCLC, whereas squamous histology accounts for approximately 30% (Brambilla et al, 2014 and Schrump DS et al. NSCLC; Principles and Practice of Oncology. 9th Edition. 2011).

## Clinical presentation, diagnosis and stage/prognosis

More than half of the patients are diagnosed at an advanced stage of disease, which directly contributes to poor survival, as expressed by an untreated median OS of 4 months and a metastatic 5year survival rate of &lt;5% (Lindsey A. et al, 2016). Poor prognostic factors for survival in patients with NSCLC include advanced stage of disease at the time of initial diagnosis, poor performance status (PS), and a history of unintentional weight loss. More than half of the patients with NSCLC are diagnosed with distant metastatic disease, which directly contributes to poor survival prospects.

## Management

Platinum-based chemotherapy partnered with agents such as taxanes, vinorelbine, gemcitabine, or pemetrexed, with or without bevacizumab, remain standard 1L treatment options for patients with locally advanced or metastatic NSCLC whose tumours do not harbour EGFR mutations or ALK translocations (Hanna et al. 2017; Planchard et al. 2018).  However, these regimens are associated with substantial toxicities and are generally poorly tolerated by elderly patients and those with poor performance status.  Furthermore, the survival benefit conferred by cytotoxic chemotherapy has reached a plateau, with overall response rates of approximately 20% and 1-year survival ranging from 31% to 36% (Schiller et al. 2002), leaving considerable room for improvement.

Over the past 4 years, immune checkpoint inhibitors, such as PD-1/PD-L1-blocking antibodies, have emerged as effective alternatives to chemotherapy for many tumour types. In second-line and beyond (2L+) NSCLC, PD-1 and PD-L1 inhibitors demonstrated superiority over docetaxel as monotherapy. Subsequently, results from the KEYNOTE-024 study showed that pembrolizumab monotherapy is effective in the 1L setting for patients who express high levels of PD-L1 (Reck et al. 2016). On the basis of the KEYNOTE 024 study, pembrolizumab was approved in the United States and European Union as monotherapy for the 1L treatment of patients with NSCLC whose tumours express PD L1 (tumour proportion score [TPS] ≥ 50%) and do not harbour EGFR mutations or ALK rearrangement.

More recently, results from the KEYNOTE-042 study have shown that the benefit of pembrolizumab monotherapy can be extended to patients with low TPS scores ( ≥ 1%). However, the clinical benefit is driven by the subgroups of patients with high PD-L1 expression (TPS ≥ 50%; Mok et al. 2019), suggesting that the greater treatment benefit correlates with higher tumour PD-L1 expression.

<div style=\"page-break-after: always\"></div>

Overall, additional treatment options are still needed for patients with advanced NSCLC. For patients with NSCLC, regardless of histology, who are considered ineligible for combination therapy, monotherapy with a checkpoint inhibitor is an attractive treatment option. In this regard, data from the Phase II BIRCH study showed clinically meaningful OS benefit with atezolizumab in PD-L1-selected patients in NSCLC, across lines of therapy (Peters et al. 2017). The Phase III IMpower110 study was designed to evaluate the efficacy and safety of atezolizumab monotherapy versus platinum-based chemotherapy in PD-L1 selected, chemotherapy-naïve patients with advanced NSCLC, regardless of histology.

## 2.1.2. About the product

Atezolizumab (TECENTRIQ) is a humanized IgG1 monoclonal antibody that targets human PD-L1 on tumor-infiltrating immune cells (ICs) and tumor cells (TCs). TECENTRIQ is globally approved for the treatment of patients with metastatic squamous and non-squamous non-small cell lung cancer (NSCLC) after prior chemotherapy, as well as first-line (1L) treatment of metastatic non-squamous NSCLC in combination  with  chemotherapy  either  with  or  without  bevacizumab.  Atezolizumab  is  also  globally approved  for  the  treatment  of  a  variety  of  other  cancers,  including  small  cell  lung  cancer  (SCLC), urothelial cancer (UC), and triple-negative breast cancer (TNBC).

The CHMP approved the following indication:

Tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic nonsmall cell lung cancer (NSCLC) whose tumours have a PDL1 expression ≥ 50% tumour cells (TC) or ≥ 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC.

Patients with first-line (1L) NSCLC should be selected for treatment based on the tumour expression of PD-L1 confirmed by a validated test (see section 5.1).

The recommended dose of Tecentriq is:

- 840 mg administered intravenously every two weeks, or
- 1,200 mg administered intravenously every three weeks, or
- 1,680 mg administered intravenously every four weeks.

It is recommended that patients are treated with Tecentriq until disease progression or unmanageable toxicity.

## 2.1.3. The development programme/compliance with CHMP guidance/scientific advice

Several interactions between the Marketing Authorization Holder (MAH) and the European Medicines Agency (EMA) have been held to discuss the atezolizumab development plan for the 1L treatment of NSCLC, including IMpower110.

The MAH received a written CHMP Scientific Advice on 22 January 2015 on the proposed clinical study design and Statistical Analysis Plan (SAP) of IMpower110.  On 19 December 2016 and 20 December 2016, the MAH held meetings with the Rapporteur (Danish Health and Medicine Authority, DHMA, Denmark) and Co Rapporteur (Paul-Ehrlich-Institute, PEI, Germany) to discuss and obtain agreement on proposed changes to the statistical analyses in ongoing 1L and adjuvant NSCLC Phase III studies, including IMpower110. On 2 May 2019, the MAH held a meeting with the (Co-)Rapporteurs to discuss registrational clinical trials, including Study IMpower110, investigating atezolizumab in which PD-L1 status was determined with Ventana's investigational PD L1 (SP142) assay using an impacted

<div style=\"page-break-after: always\"></div>

detection dispenser lot.

## 2.1.4. General comments on compliance with GCP

A request for GCP inspection was adopted by CHMP for the following study: GO29431 (IMpower110).

Sites were inspected in Switzerland and Greece between July and August 2020. The outcome of this triggered GCP inspection was that the Applicant was not able to demonstrate that the change of the primary analysis population, finally leading to a statistically significant result in the TC/IC 3 population, was not influenced by study knowledge. However, it is acknowledged that analyses of external data could have indeed resulted in the late change of the primary analysis population. The choice of the selected subgroup is supported by external data and is based on a strong biological rationale. Thus, it can be accepted that the presented Impower110 data in the sought TC3/IC3 population are plausible.

## 2.2. Non-clinical aspects

No new non-clinical data have been submitted in this application, which was considered acceptable by the CHMP.

## 2.2.1. Ecotoxicity/environmental risk assessment

Atezolizumab is an IgG1 monoclonal antibody produced by recombinant DNA technology, a protein with a molecular mass of ~150 kDa. As an unaltered protein, being extensively degraded in the patient's body by regular proteolytic mechanisms before excretion, atezolizumab is unlikely to result in a significant environmental exposure. Atezolizumab is expected to biodegrade in the environment and does not pose a significant risk to the environment. Thus, according to the 'Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use' (EMEA/CHMP/SWP/4447/00), atezolizumab is exempt from the submission of Environmental Risk Assessment studies as the product and excipients do not pose a significant risk to the environment.

## 2.2.2. Discussion and conclusion on non-clinical aspects

The applicant did not submit studies for the ERA. According to the relevant guideline, in the case of products containing proteins as active pharmaceutical ingredient(s), this is acceptable.

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

Table 1: A summary of atezolizumab studies conducted in monotherapy settings

<div style=\"page-break-after: always\"></div>

| Atezolizumab Monotherapy Studies   | Phase   | Indication            | N Enrolled/PK evaluable (Total3239/3184)   | Design/Dose/Primary Clinical Endpoint                            |
|------------------------------------|---------|-----------------------|--------------------------------------------|------------------------------------------------------------------|
| PCD4989g (GO27831)a                |         | Multiple solid tumors | 481/473                                    | Dose-escalation/ up to 20 mg/kg q3w/ PK and safety               |
| JO28944*                           |         | Multiple solid tumors | 6/6                                        | Dose-escalation/ 10mg&20mgq3w/ PK and safety                     |
| IMvigor210 (GO29293)-              | II1     | 1L&2L+ mUc            | 438/427                                    | 1L,2L+cohorts/ 1200mgq3w/ORR                                     |
| IMvigor211 (GO29294)*              | III     | 2L/3L mUc             | 467/455                                    | 2-arm study/ 1200mgq3wvs.vinflunine, paclitaxel,ordocetaxel/os   |
| FIR (GO28625)a                     | II1     | 1L,2L+ NSCLC          | 138/137                                    | Single-arm study/ 1200mgq3w/ORR                                  |
| BIRCH (GO28754)-                   | I1      | 1L,2L+ NSCLC          | 667/654                                    | Single-arm study/ 1200mgq3w/ORR                                  |
| POPLAR (GO28753)*                  | I1      | 2L/3L NSCLC           | 144/142                                    | 2-arm study/ 1200mgq3wvsdocetaxel/ OS                            |
| OAK (GO28915)b                     | III     | 2L/3L NSCLC           | 613/606                                    | 2-arm study/ 1200 mg q3w vs.docetaxel/ OS                        |
| IMpower110 (GO29431)               | III1I   | 1L NSCLC              | 285/284                                    | 1200mgq3wvs. (Cisplatin/Carboplatin + Pemetrexed/Gemcitabine)/os |

1L=first-line;2L=second-line;2L+=Second-line and beyond;CSR=clinical studyreport;MAA=Marketing AuthorisationApplication;muC=metastaticurothelialcarcinoma;NSCLC=non-smallcallungcancer,

ORR=overallresponserate;q3w=every3weeks;OS=overallsurvival;PK=pharmacokinetic.

MAAprocedurenumberEMEA/H/C/4143eCTDSequence0000

bMAAprocedurenumberEMEA/H/C/4143eCTDSequence0002.

Cisplatin-ineligiblepatients.

dFor randomized studies (i.e., IMvigor211, POPLAR, OAK), number enrolled corresponds to the number of patientsenrolled intothe atezolizumab am.

CSRFIR,CSROAKandCSRIMpower110

## 2.3.2. Pharmacokinetics

The clinical pharmacology properties of atezolizumab were originally characterized using previous studies where atezolizumab was administered as 1200 mg IV every three weeks (q3w) as monotherapy in patients with predominantly mUC and NSCLC.  Previous assessments have determined that atezolizumab pharmacokinetics is linear over a dose range of 1 to 20 mg/kg. A target efficacy serum concentration of 6 µg/mL has been identified.

## IMpower110

IMpower110 is a randomized, Phase III, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab as monotherapy in PD-L1 selected patients with chemotherapy-naive Stage IV squamous or non-squamous NSCLC. The pharmacokinetics in IMpower110 was based on data from Arm A where atezolizumab was administered as 1200 mg IV q3w.

## Bioanalytical methods

<div style=\"page-break-after: always\"></div>

For  IMpower110,  a  validated  sandwich  ELISA  method  was  used  to  determine  the  concentration  of atezolizumab  in  human  serum  samples.  Validated  ELISA  methods  were  also  used  to  detect  antiatezolizumab antibodies in human serum samples from IMpower110 and to confirm and determine the titer of detected anti-atezolizumab antibodies.

PD-L1 expression in tumour tissue was measured using a validated immunohistochemistry assay. Table 2 show the sampling schedule in IMpower110.

Table 2: Schedule of pharmacokinetic, biomarker and anti-therapeutic antibody assessments

<!-- image -->

| Study Visit                                                                           | Time                                                   | Patients Randomized to Chemotherapy   | Patients Randomized to Atezolizumab            |
|---------------------------------------------------------------------------------------|--------------------------------------------------------|---------------------------------------|------------------------------------------------|
| Screening                                                                             |                                                        | Biomarkers                            | Biomarkers                                     |
| Cycle 1, Day 1                                                                        | Prior to dosing (same day as treatment administration) | Biomarkers b                          | ATA Atezolizumab pharmacokinetics Biomarkers b |
|                                                                                       | 30 (±10) minutes after end of atezolizumab infusion    |                                       | Atezolizumal pharmacokinetics                  |
| Cycles 2,3,4,8 and 16, Day 1                                                          | Prior to dosing (same day as treatment administration) | Biomarkers b                          | ATA Atezolizumal pharmacokinetics Biomarkers b |
| After Cycle 16, every eighth cycle，Day1                                               | Prior to dosing (same day as treatment administration) | Biomarkers b                          | ATA Atezolizumab pharmacokinetics Biomarkers b |
| At time of fresh biopsy (on-treatment, or at progression, including during follow-up) | At visit                                               | Biomarkers b                          | Biomarkers b                                   |
| Treatment discontinuation visit                                                       | At visit                                               | Biomarkers b                          | ATA Atezolizumab pharmacokinetics Biomarkers b |
| 120±30days after last dose of atezolizumab                                            | At visit                                               |                                       | ATA Atezolizumab pharmacokinetics Biomarkers b |
| Any time point during the study (RCR consent required)                                |                                                        | Optional RCR blood (DNA extraction) b | Optional RCR blood (DNA extraction) b          |

ATA=anti-therapeutic antibody; RCR=Roche Clinical Repository.

- Whole blood for biomarkers.

Plasma and serum for biomarkers.

## ADME properties of atezolizumab

Atezolizumab is administered as an IV infusion. There have been no clinical studies performed with other routes of administration. A popPK analysis indicates that V1 is 3.28 L and Vss is 6.91 L in the typical patient, and that the typical CL of atezolizumab was 0.200 L/day and the typical terminal t1/2 was 27 days. An NCA indicates that doses ≥ 1 mg/kg display dose proportional pharmacokinetics.

## Phamacokinetics in the target population

The descriptive statistics of the available, Cmax (30 minutes following the end of the infusion) and Cmin (pre-dose) serum concentrations of atezolizumab following 1200 mg q3w IV administration are summarized in Table 3. Of the 286 patients treated with atezolizumab, a total of 284 (99%) were evaluable for atezolizumab pharmacokinetics.  Mean serum atezolizumab concentrations over time are shown in Figure . The PK results observed in IMpower110 are consistent with the known PK of atezolizumab.

<div style=\"page-break-after: always\"></div>

Table 3 Summary Statistics for Atezolizumab Cmax and Cmin Following Multiple IV Doses of Atezolizumab 1200 mg, Administered Every 3 Weeks

| Atezo N = 284                | Atezo N = 284                      | Atezo N = 284   | Atezo N = 284   | Atezo N = 284   | Atezo N = 284   | Atezo N = 284   | Atezo N = 284   | Atezo N = 284    | Atezo N = 284   |
|------------------------------|------------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|------------------|-----------------|
| Visit 1                      | Nominal Time from First Dose (Day) | N               | AM ( µ g/mL)    | AM SD ( µ g/mL) | GM ( µ g/mL)    | GM %CV          | Min ( µ g/mL)   | Median ( µ g/mL) | Max ( µ g/mL)   |
| Cycle 1 Predose C1D1         | 0                                  | 262             | NR              | NR              | NE              | NR              | NR              | 0.00             | 0.00            |
| Cycle 1C max / C1D1          | 0.0625                             | 270             | 411             | 163             | 274             | 614             | 0.0300          | 403              | 1510            |
| Cycle 1 C min / Predose C2D1 | 21                                 | 256             | 76.7            | 57.6            | 56.4            | 175             | 0.0300          | 72.1             | 604             |
| Cycle 2 C min / Predose C3D1 | 42                                 | 215             | 121             | 57.7            | 106             | 71.0            | 1.17            | 122              | 560             |
| Cycle 3 C min / Predose C4D1 | 63                                 | 207             | 154             | 90.1            | 128             | 97.4            | 0.0678          | 144              | 844             |
| Cycle 7 C min / Predose C8D1 | 147                                | 145             | 201             | 98.6            | 178             | 54.5            | 24.5            | 191              | 670             |

AM = Arithmetic Mean; Cmax = maximum serum concentration; Cmin = minimum serum concentration; CV = coefficient of variation; GM = Geometric Mean; IV = intravenous; Max = maximum; Min = minimum; N = number of patients included in summary statistics; SD = standard deviation; NE = Not Evaluable; NR = Not Reported.

1 Visit is denoted by Cycle abbreviated by 'C' and Day abbreviated by 'D'.  For example, C1D1 corresponds to Cycle 1, Day 1, etc., Predose Cycle 1 is C1D1.

Data source: CSR IMpower110, Table 37.

Figure 1 Mean (±SD) Plot of Atezolizumab Concentrations versus Time Following Multiple IV Doses of Atezolizumab 1200 mg

<!-- image -->

Atezo = atezolizumab; SD = standard deviation.

Data source: CSR IMpower110, Figure 16.

## Population PK analysis

<div style=\"page-break-after: always\"></div>

Population PK analysis was performed using nonlinear mixed effect (NLME) modeling in NONMEM, V7.3. Perl-Speak-NONMEM V4.8.1 was used for model evaluation and covariate analysis. Dataset preparation; exploration and visualization of the data as well as descriptive statistics were performed using R® V3.4.3 in addition to CRAN packages.

The Phase I popPK model was subjected to an external evaluation using pharmacokinetic data collected in Phase III clinical Study GO29431 (IMpower110) to assess atezolizumab PK in NSCLC patients receiving intravenous administration of atezolizumab 1200 mg every three weeks (q3w) in monotherapy. Bayesian post-hoc estimation (MAXEVAL=0) in NONMEM with no fit of IMpower110 data.

The Phase I popPK model was built on Phase I data from 2 clinical studies: Study PCD4989g in patients with various solid tumors (including NSCLC, SCLC and mUC) and Study JO28944 in Japanese patients with advanced solid tumors. The Phase I popPK model had earlier been subject to external validations by  prediction-corrected  visual  predictive  check  (pcVPC)  for  urothelial  carcinoma,  NSCLC,  extensive stage-small cell lung cancer and triple negative breast cancer separately, using PK data collected in studies: IMvigor210 and IMvigor211 for UC; BIRCH, POPLAR, FIR, OAK, IMpower150 and IMpower130 for NSCLC; IMpower133 for ES-SCLC and IMpassion130 for TNBC.

Table 4: PK sampling for study GO29431 (IMpower110)

| StudyVisit                                      | Time                                         | Arm A                                        |
|-------------------------------------------------|----------------------------------------------|----------------------------------------------|
| Cycle 1, Day 1                                  | Pre-dose                                     | AtezolizumabADA Atezolizumabpharmacokinetics |
| Cycle 1, Day 1                                  | 30min(±10min)afterend ofatezolizumabinfusion | Atezolizumabpharmacokinetics                 |
| Cycles 2,3,4,8, and 16, Day 1                   | Pre-dose                                     | AtezolizumabADA Atezolizumabpharmacokinetics |
| Cycle 16, and every eighthcyclethereafter Day 1 | Pre-dose(samedayas treatmentadministration)  | AtezolizumabADA Atezolizumabpharmacokinetics |
| Treatment discontinuationvisita                 | At visit                                     | AtezolizumabADA Atezolizumabpharmacokinetics |
| 120+30daysafterlast doseofatezolizumab          | At visit                                     | AtezolizumabADA Atezolizumabpharmacokinetics |

ADA=anti-drugantibody

PK data in IMpower110 were sparse with a limited number of peak samples (Cycle 1) and a large number of trough levels. The Phase I popPK model was used to derive individual PK parameter estimates based on 1306 atezolizumab serum concentrations from 283 patients. A total of 37 PK samples were excluded for various reasons.

<div style=\"page-break-after: always\"></div>

Figure 2: Graphical exploration of atezolizumab concentration data in Impower110

<!-- image -->

No patient had any covariate identified in the Phase I popPK model missing in the current dataset, except for 17 patients with missing ADA status which were imputed to the most frequent category, i.e., ADA negative.

Comparison to the PK population used to inform the Phase I popPK model for the covariates retained in the model (BW, albumin, ADA, tumor burden, sex), the current population in IMpower110 had: slightly lower weight (median 70 vs. 77 kg), higher tumor burden (median 80 vs. 63 mm), similar albumin (median 40 vs. 40 g/L), higher proportion of males (69% vs. 59%), and lower proportion of patients with positive ADA (23% vs. 29%).

## Covariate effects (Phase 1 popPK model):

According to the Phase I popPK Model, the typical clearance (CL) (L/day) of atezolizumabforpatientiwas:

<!-- formula-not-decoded -->

BWT = Body weight (kg); ALBU = Albumin (g/L); Tumor burden (mm); ADA = Post-baseline status of anti-drug (ATAG) antibodies, also called anti-therapeutic antibodies;

Post-baseline Negative ADA when at all post-dose samples after baseline or ADA signal not enhancedafterbaseline(treatmentunaffected);

Post-baselinePositiveADAwhentreatment-inducedortreatmentenhanced;

Missing when all post-dose samples missing.

The typical volumes of distribution of the central compartment (V1) (L) and the peripheral compartment(V2) (L) of atezolizumabfor patientiwere:

<!-- formula-not-decoded -->

The performance of the Phase I popPK model to predict IMpower110 data was evaluated using diagnostic GoF plots and evaluated by external pcVPC based on 1000 replicates.

<div style=\"page-break-after: always\"></div>

<!-- image -->

Pl=predictioninterval;VPC=visualpredictioncheck.

Figure 3: Prediction-corrected VPC of peaks and troughs of atezolizumab (all patients, semi-log scale)

In the pcVPC (Figure 3) there is a trend toward over-prediction of atezolizumab exposure data for Cycle 1 and Cycle 2 Cmin with observations below the prediction intervals, while the Cmin at later cycles are better predicted. The GoF plots did not indicate any trends or misspecifications.

VPCs  were  performed  by  simulating  90%  PIs  of  the  concentration-time  profiles  over  50  weeks  and concentration versus time-after-dose (Cycle 5 and later) profiles, across 100 replicates and compared to observed concentrations in Appendix 9. The observed concentrations are well within the model prediction intervals including the late data collected (45 weeks after treatment start).

<div style=\"page-break-after: always\"></div>

Not all observed data are displayed; x-axis is truncated to50weeks.

<!-- image -->

Figure 4: 90% prediction interval of the PK profile using the Phase I PopPK model with IMpower110 observed concentrations

<!-- image -->

Individual  estimates  of  patient-level  random  effects  were  plotted  vs.  baseline  covariates  to  assess whether the Phase I popPK model adequately captured covariate effects in IMpower110 patients. The explorative  covariate  analysis  did  not  identify  any  unexpected  covariate  effects.  The  lack  of  trends indicated the relationships already enclosed in the model adequately described Impower100.

## Predicted exposure metrics

It  has  been  described  that  atezolizumab  CL  tended  to  decrease  over  time,  with  a  decrease  in  CL associated  with  best  overall  response,  generating  a  confounded  relationship  between  steady-state exposure and response. Therefore,  exposure  metrics  were  estimated  with  Cycle  1  PK  data  only,  to minimize the confounding due to time-varying clearance in relation with the response.

The exposure metrics for atezolizumab were derived by prediction based on the individual PK parameters. Table  5  provides  the  summary  of  the  individual  exposure  metrics  at  Cycle  1  and  at  steady-state, respectively,  based  on  Cycle  1  PK  data  and  the  Phase  I  popPK  model.  Steady-state  exposure  was assessed at 10 cycles.

<div style=\"page-break-after: always\"></div>

Table 5: Summary statistics (Geometric mean [CV%]) of atezolizumab exposure metrics at cycle 1 and steady state, half-life and accumulation ratio in IMpower110 predicted using the phase I PopPK model

| IMpower110(N=283)   | IMpower110(N=283)   | IMpower110(N=283)   | IMpower110(N=283)   |
|---------------------|---------------------|---------------------|---------------------|
| Cmax (μg/mL)        | Cmin (μg/mL)        | AUCo-21 (μg.day/mL) | t12 beta (day)      |
| 397.1 [18.8]        | 72.9 [37.8]         | 2912 [21.6]         | 21.6 [35.3]         |
| Cmax,ss (μg/mL)     | Cmin,ss (μg/mL)     | AUC,ss (μg.day/mL)  | Accumulationratio   |
| 563 [23.9]          | 153 [61.1]          | 5384 [38.2]         | 1.85 [19.8]         |

The  geometric  mean  accumulation  ratio  based  on  AUC  was  close  to  1.85-fold.  Cmin  and  Cmax accumulated 1.42 and 2.10-fold (geometric means), respectively.

All PK data from IMpower110 (not just PK data from Cycle 1) were used to assess (external validation) the  Phase  I  popPK  model.  Cycle  1  data  was  used only to  derive individual exposure  metrics.    As  a sensitivity analysis, exposure metrics were derived using all PK data with the Phase I popPK model.  The results are given below in Table 6, for comparison to those previously reported in Table 5 of the popPK Report No. 1098051, which are based on Cycle 1 data only.

Table 6: Summary statistics (Geometric mean [CV%]) of atezolizumab exposure metrics at cycle 1 and steady state, half-life and accumulation ratio in IMpower110 predicted using the phase I PopPK model and all PK data

| IMpower110 （N=283)   | IMpower110 （N=283)   | IMpower110 （N=283)   | IMpower110 （N=283)   |
|----------------------|----------------------|----------------------|----------------------|
| Cmax (μg/mL)         | Cmin（μg/mL)          | AUCo-21（μg.day/mL)   | t1/2 beta (day)      |
| 398.1 [19.5] 0.3%    | 73.1 [37.7] 0.3%     | 2928 [22.4] 0.6%     | 22.1 [40.4]          |
| Cmax,ss (μg/mL)      | Cmin,ss (μg/mL)      | AUC,ss (μg.day/mL)   | Accumulation ratio   |
| 569 [24.7] 1.1%      | 157 [61.9]2.6%       | 548639.7]1.9%        | 1.87 [23.0]          |

Both Cycle 1 and steady-state exposure metrics were similar to those estimated in other studies using atezolizumab monotherapy q3w in both second, third-line NSCLC or mUC, in combination therapy in first-line NSCLC and in small cell lung cancer. See Table 7.

<div style=\"page-break-after: always\"></div>

Table 7: Summary statistics (Geometric mean [CV%]) of atezolizumab exposure metrics at cycle 1 and steady state predicted using PopPK model in NSCLC, mUC and SCLC studies

GeometricMean(GeometricMean[CV%])

| Study(N)                                 | Cmax(μg/mL)   | Cmn (μg/mL)   | AUC (μg.day/mL)   | t2beta(day)   |
|------------------------------------------|---------------|---------------|-------------------|---------------|
| BIRCH(N=652)[3]                          | 402 [20.6]    | 77.6 [34.9]   | 3039 [22.0]       | 21.5 [7.72]   |
| FIR (N=128) [3]                          | 391[19.6]     | 68.9 [44.4]   | 2855 [23.1]       | 19.6[8.35]    |
| POPLAR（N=140)[3]                         | 355[17.9]     | 63.1[34.0]    | 2599[20.5]        | 19.8 [7.06]   |
| OAK (N=596)[4)                           | 396 [22.8]    | 74.6 [43.3]   | 2978 [26.1]       | 22.2[8.02]    |
| BiRCHcohort 1(N=138) (1L)[3]             | 412 [21.3]    | 78.8 [36.8]   | 3113 [23.7]       | 21.2 [6.65]   |
| BIRCH cohort 2 (N=263) (2L)[3]           | 395 [20]      | 75.6 [35.6]   | 2979 [21.9]       | 21.2 [6.75]a  |
| BIRCH cohort 3 (N=251) (3L)[3]           | 404 [20.7]    | 79 [33.1]     | 3061 [21]         | 21.9 [6.37] a |
| IMvigor210N=117[cohort 1] [5]            | 370 [17.8]    | 71.1 [32.9]   | 2850 [18.8]       | 22.5 [7.5]*   |
| iMvigor210 N=306 [cohort 2] [5]          | 355 [17.8]    | 69.1 [28.9]   | 2728 [19.1]       | 21.7 [6.6]a   |
| IMvigor211 (N= 455) [6]                  | 367[19.5]     | 64.6 [49.5]   | 2762[20.4]        | 19.8 [7.2]    |
| IMpower150 (N=778) [7]                   | 393 [20.7]    | 77.1 [32.6]   | 2980 [21.6]       | 22.9 [8.23]   |
| IMpower150,Atezo+CPArm (N=395)[7]        | 388[21.2]     | 75.0 [35.7]   | 2930 [22.7]       | 22.3[7.42]    |
| iMpower150,Atezo+Bev+CP Arm.(N=388).[7]. | 398 [20.2]    | 79.4 [29.0]   | 3030 [20.3]       | 23.5 [8.69]   |
| IMpower133Atezo+CEArm                    | 391[19.5]b    | 76.7 [28.0]°  | 2958 [19.6]       | 21.9 [5.0]    |
| IMpower110, (N=283)                      | 397 [18.8]    | 72.9 [37.8]6  | 2912 [21.6]       | 21.6 [35.3]6  |

<!-- image -->

|                                                 | GeometricMean(GeometricMean[CV%])   | GeometricMean(GeometricMean[CV%])   | GeometricMean(GeometricMean[CV%])    | GeometricMean(GeometricMean[CV%])   |
|-------------------------------------------------|-------------------------------------|-------------------------------------|--------------------------------------|-------------------------------------|
| Study (N)                                       | Cmax.88 (ug/mL)                     | Cmin,8s (μg/mL)                     | AUC,. (μg.day/mL)                    | Accumulation ratio                  |
| BIRCH(N=652)[3]                                 | 582 [24.9]                          | 170 [51.8]                          | 5770 [35.4]                          | 1.90 [17.9]                         |
| FIR(N=128) [3]                                  | 550[25.8]                           | 145 [64.7]                          | 5199[41.3]                           | 1.82[21.6]                          |
| POPLAR(N=140)[3]                                | 492[22.7]                           | 129[54.6]                           | 4636[35.4]                           | 1.78[19.1]                          |
| OAK(N=596)[4]                                   | 570[27.9]                           | 162[61.2]                           | 5573[38.7                            | 1.87[21.2                           |
| BIRCHcohort 1 (N=138)(1L)[3]                    | 597 [26.5]                          | 174 [57.4]                          | 5916[38.1]                           | 1.90[18.4]                          |
| BIRCHcohort 2(N=263)(2L)[3]                     | 570 [25.1]                          | 165 [55.1]                          | 5630 [37.0]                          | 1.89 [18.7]                         |
| BIRCHcohort3（N=251).3L)[3]                      | 586 [23.7]                          | 174[45.0]                           | 5840[32.1]                           | 1.91.[16.7]                         |
| IMvigor210N=117[cohort1][5]                     | 544 [22.3]                          | 165[48.4]                           | 5528[33.2]                           | 1.94[18.1]                          |
| IMvigor210N=306[cohort 2][5]                    | 513[22.5]                           | 150 [47.3]                          | 5133 [32.9]                          | 1.88[17.5]                          |
| IMvigor211(N= 455) [6]                          | 520[22.6]                           | 142[53.9]                           | 5018[34.0]                           | 1.82.[19.0]                         |
| IMpower150 (N=778) [7]                          | 578 [24.7]                          | 176 [50.1]                          | 5860 [34.8]                          | 1.97 [18.7]                         |
| IMpower150,Atezo+CPArm(N=395) 7                 | 567 [25.9]                          | 169 [54.9]                          | 5700 [37.0]                          | 1.94 [19.1]                         |
| IMpower150,Atezo+Bev+CPArm (N=388）[7]           | 590 [23.3]                          | 184 [44.4]                          | 6040 [32.0]                          | 1.99 [18.2]                         |
| IMpower133, Atezo+CE Am (N=192) 561 [23.6]6 [6] |                                     | 165[41.1]6                          | 5556 [30.6]                          | 1.87[14.1]                          |
| IMpower110, (N=283)                             | 563 [23.9]6                         |                                     | 153[61.1]***5384[38.2]6***1.85[19.8] |                                     |

CV = coefficient of variation; Cmax.ss = Cmax at steady-state; Cmin.ss = Cmn at steady-state;

AUCss=AuCatsteady-state;AccumulationratioisderivedastheratiobetweenAuCatCycle1 andAuC.ss.t1/2betaistheterminalhalf-life;

Forthesestudiesharmonicmeanandpseudo-standarddeviationarereported;

Atezo+CP=Atezolizumab+carboplatin+paclitaxel;Atezo+Bev+CP=Atezolizumab

+bevacizumab+carboplatin+paclitaxel;AtezoAtezo+CE=Atezolizumab+carboplatin+etoposide

bForIMpower133andIMpower110,individualPKparametersusedforthepredictionsof exposures,wereestimatedonCycle1PKdataonlywhilefortheotherstudies,theindividualPK parameterswereestimatedonallPkdata.

## Implications of ADA status in IMpower110

All  atezolizumab  ADA  responses  were  treatment-induced  ADA  responses.  In  the  IMpower110  PK population, 202 patients were ADA negative, 65 patients were ADA positive and 17 patients were missing ADA status. The 17 patients with missing ADA status were imputed to the most frequent category, i.e., ADA negative in the Pop PK analysis.

<div style=\"page-break-after: always\"></div>

According to the Phase 1 popPK model, patients with positive ADA, clearance was estimated to be 16% higher than in patients with negative ADA. Appendix 14 show the correlation of random effects and ADA status.

Figure 5: Exploratory correlation between random effects and covariates for the Phase I population PK model of atezolizumab - Impower110

<!-- image -->

The fit of IMpower110 data stratified by ADA status was evaluated by pc-VPC (Appendix 7). For ADA positive patients, the number of PK concentrations was limited but the model was able to describe the atezolizumab median and 95th percentile for the long-term exposure, while there was a trend to overpredict the Cmin at early timepoints (Cycle 1 and Cycle 2).

<div style=\"page-break-after: always\"></div>

<!-- image -->

Pl=predictioninterval;VPC=visual prediction check

Figure 6: Prediction-corrected VPC of peaks and troughs of atezolizumab by ADA status (Semi-log scale)

A statistical t-test showed that ADA positive patients (N=64) tend to experience lower atezolizumab exposure than ADA negative patients (N=219). Exposure by ADA status was presented in Table 8, for the geometric mean. There was a significant difference (p&lt;0.001) between atezolizumab clearance in ADA positive patients and ADA negative patients. A similar difference between ADA positive and ADA negative patients was also observed for exposure metrics Cmin and AUC0-21 with lower exposure in ADA positive patients compared to ADA negative patients, less pronounced for Cmax.

<div style=\"page-break-after: always\"></div>

Table 8 Summary Statistics (Geometric Mean [CV%]) and t-test on AtezolizumabClearanceand ExposureMetricsbyADAStatus

| Variable (unit)              | ADANegative N=219   | ADA Positive N=64   |   p-value | Ratio 95%Cl         |
|------------------------------|---------------------|---------------------|-----------|---------------------|
| Clearance (L/d)              | 0.206 [33.2]        | 0.292 [40.7]        |  4.87e-09 | 0.707 (0.635,0.786) |
| Cmax, Cycle 1 (μg/mL)        | 401 [18.7]          | 384 [18.7]          |  0.107    | 1.04 (0.991,1.1)    |
| Cmin, Cycle 1 (μg/mL)        | 78.5 [29.7]         | 56.6 [49.9]         |  1.3e-06  | 1.39 (1.22,1.57)    |
| AUCo-21, Cycle 1 (μg.day/mL) | 3016 [19.3]         | 2583 [24.4]         |  8.24e-06 | 1.17 (1.09,1.25)    |

Cmax=Individual model-predicted maximum atezolizumab concentration at Cycle 1;

AUCo-21=Area underthecurvefrom0 to21daysat Cycle1;CV=coefficientofvariation;

Cl=confidenceinterval,the95%Clfordifference/ratioand t-test.

The two-sided p-value is from a two-sample t-test. P-values for geometric mean ratios are from t-tests on log-transformedPK parameters.

N= number of patients in each ADA status group in the popPK population.

However, the distributions of exposure in ADA-negative and ADA-positive patients overlaps (Figure 7), and the vast majority of patients had Cmin above the target exposure of 6 µg/mL, regardless of ADA status.

<!-- image -->

ADA=anti-drug antibody.

Data source: CSR IMpower110, Figure 19.

Figure 7: Box plots of  Atezolizumab Concentrations versus  Time  by  Treatment-Emergent  ADA Status Following Multiple IV Doses of Atezolizumab

Examination of baseline characteristics by ADA status revealed several imbalances in known 1L NSCLC prognostic factors between the ADA-positive and ADA-negative patient subgroups. These imbalances between ADA subgroups were seen in both the ADA-evaluable population and the TC3 or IC3 WT ADA evaluable population. A greater imbalance in negative prognostic factors in the ADA-positive subgroup compared with the ADA-negative subgroup for both populations is noted, suggesting poorer prognosis for ADA-positive patients.

<div style=\"page-break-after: always\"></div>

No formal E-R analysis was conducted for IMpower110. However, in unadjusted exploratory analyses, which did not take into account the imbalances in baseline characteristics between ADA subgroups, for both  PFS  and  OS,  the  percentage  of  patients  with  events  was  numerically  higher  for  ADA-positive patients,  and  the  median  time  to  event  was  shorter  (Table  9).  The  proportion  of  responders  was numerically lower in the ADA-positive subgroup compared with ADA-negative.

Table 9: Efficacy Results by Treatment-Emergent ADA status in the TC3 or IC3-WT population

|                                        | Atezolizumab Arm   | Atezolizumab Arm   | Control          |
|----------------------------------------|--------------------|--------------------|------------------|
| Efficacy Endpoint                      | ADA- (N=75)        | ADA+ (N=23)        |                  |
| os Patientswithevent (%)               | 39 (52.0%)         | 17 (73.9%)         | 60 (65.2%)       |
| Median time to event -months (95% CI)  | 27.1 (20.2, NE)    | 13.8 (4.9, 23.1)   | 14.7 (7.4, 17.7) |
| PFS:INV-assessed Patientswithevent (%) | 42 (56.0%)         | 18 (78.3%)         | 57 (58.2%)       |
| Mediantimetoevent (95% CI) -months     | 9.6 (7.7, 17.5)    | 4.5 (2.3, 8.2)     | 5.0 (4.2, 5.7)   |
| Confirmed ORR Responders (%)           | 34 (45.3%) (33.79, | 7 (30.4%)          | 28 (28.6%)       |
| 95% CI for response rates              | 57.25)             | (13.21, 52.92)     | (19.9, 38.58)    |

Blue: OS dala is per CC0D of 4FEB2020 end ADA stetus is per CCOD of 10SEP2018.

Kaplan-Meier Plot,ADA Evaluable Atezolizumab and Control Arm, of Overall Survival, TC3 or IC3, Intent-to-TreatPatients,WildType Protocol:G029431

<!-- image -->

Program root/clinical\\_studies/RO5541267/CDPT3815/GO29431idata\\_analysis/Final\\_O5/prodiprogamg\\_ef\\_km\\_ada\\_3am.sas Ounput: root/cinical\\_stuties/R05541267/CDPT3815/G029431/data\\_analysis/Final\\_OSiprodloutputig\\_ef\\_km\\_ada\\_3arm\\_os\\_33\\_ITwT.pdf 14JAN2021 21:27

Figure 8: Kaplan-Meier plot of updated overall survival by treatment-emergent ADA status in the TC3 or IC3-WT population

Among  ADA-evaluable  patients  in  the  safety  evaluable  population,  ADA-negative  and  ADA-positive patients received atezolizumab for a median duration of 6.8 and 4.9 months, respectively. An overview of safety by ADA status is shown in Table 10. There was a difference in Grade 3-4 AE incidence by ADA status, with 28.8% ADA-negative and 40.0% ADA-positive patients reporting Grade 3-4 AEs. SAEs were

<div style=\"page-break-after: always\"></div>

observed at a higher frequency in ADA-positive compared with ADA-negative patients (Table 10). These SAEs were observed in few patients and were not driven by any specific PT.

Table 10: Safety summary profile by atezolizumab ADA status (ADA-evaluable atezolizumab patients in safety evaluable population)

<!-- image -->

## 2.3.3. Pharmacodynamics

## Dose rationale

The  following  three  dosing  regimens  are  recommended  for  atezolizumab  when  administered  as  a monotherapy:

- Atezolizumab 840 mg every 2 weeks (q2w) administered intravenously; or
- Atezolizumab 1200 mg every three weeks (q3w) administered intravenously; or
- Atezolizumab 1680 mg every 4 weeks (q4w) administered intravenously.

The rationale for the 1200 mg q3w regimen was based on data from nonclinical studies and clinical data from the Phase I Study GO27831 (PCD4989g).

The rationale for the 840 mg q2w and 1680 mg q4w dosing regimens is based on PK modeling and simulation, exposure-response assessments, and safety analyses. The two dose regimens have been approved for the 2L NSCLC and mUC monotherapy indications. Data from all evaluated dose levels using a  q3w  dosing  frequency,  showed  no  clinically  meaningful  exposure-efficacy  or  exposure-safety relationship.

IMpower110 evaluated atezolizumab administered at a fixed dose of 1200 mg by intravenous infusion q3w as monotherapy in chemotherapy-naïve patients with Stage IV NSCLC. As the pharmacokinetics of atezolizumab in IMpower110 are consistent with observations from other studies using the 1200 mg q3w regimen (IMvigor210 and IMvigor211 for UC; BIRCH, POPLAR, FIR, OAK, IMpower150 and IMpower130 for NSCLC; IMpower133 for ES-SCLC), these results are also applicable to chemotherapy-naïve patients with Stage IV NSCLC.

<div style=\"page-break-after: always\"></div>

<!-- image -->

targetconcentration

Figure 9: Superimposed simulated atezolizumab exposure profiles for 1680 mg (Geometric mean and 90%PI, 500 patients) for ADA-negative and ADA-positive patients assuming 16%, 25% or 41% increase in CL in ADA-positive patients

Table 11: Simulated atezolizumab Cmin (Geometric mean [90%PI], 500 patients) at cycle 1 and at steady-state for the 1680 mg q4w dosing regimen for ADA-negative and ADA-positive patients assuming 16%, 25% or 41% increase in CL in ADA-positive patients

|                   | Cycle 1 [ug/mL]   | Steady-State [ug/mL]   |
|-------------------|-------------------|------------------------|
| ADA negative      | 97 [58; 159]      | 182[87; 369]           |
| ADA p0sitive +16% | 83 [47; 141]      | 144 [67; 303]          |
| ADA positive +25% | 76[43; 132]       | 127 [58; 274]          |
| ADA positive +41% | 66 [35; 116]      | 103 [45; 231]          |

## 2.3.4. Discussion on clinical pharmacology

IMpower110 evaluated the pharmacokinetics of atezolizumab monotherapy administered at a fixed dose of 1200 mg q3w given intravenously in chemotherapy-naïve patients with Stage IV NSCLC. The predicted exposure metrics in IMpower110 following 1200 mg q3w at Cycle 1 and at steady-state were within the range of exposures observed in other studies with monotherapy and a similar dosing frequency. The Applicant also seeks approval for a lower and a higher dose regimen, 840 mg q2w and 1680 mg q4w. Based on PK modelling data, the 840 mg q2w or 1680 mg q4w atezolizumab monotherapy regimens are expected to have comparable efficacy and safety with the 1200 mg q3w regimen in chemotherapy-naïve patients with Stage IV NSCLC. These alternative dose regimens for monotherapy are already approved for 2L NSCLC and mUC indications based on simulation studies only.

The time-stationary Pop PK model used to predict the Impower110 metrics was based on Phase 1 data and  did  not  capture  the  confounding  effect  of  time  varying  CL  observed  for  PD-L1  inhibitors  (for atezolizumab a reduction of 22% from baseline clearance) or the Ctrough after first dose in ADA-positive patients, Exposure metrics derived using Cycle 1 data only or based on all PK data gave comparable exposure estimates. The stationary Pop PK model is capable of describing all Impower110 data, including the long-term treatment data, even though clearance decrease over time.

Without  correction  of  prognostic  factors,  post-hoc  CL  in  ADA-positive  patients  is  41%  faster  in IMpower110 compared to ADA-negative patients. A sensitivity analysis including a faster clearance of 41% indicated that all exposures within a 90% CI would fall above MEC at Cycle 1 and at steady-state. Thus indicating  that  Cmin  is  adequate  with  a  less  frequent  dosing  in  the  ADA-positive  subgroup  of patients which typically accounts for 30% of the study population across atezolizumab indications. The

<div style=\"page-break-after: always\"></div>

impact of ADAs on CL adjusted for the effects of baseline covariates in the Phase I popPK model was 18.5%.

Results of unadjusted exploratory analyses (Kaplan Meier Plot), which did not adjust for imbalances in baseline characteristics between ADA subgroups, showed that the subset of TC3/IC3 patients who were ADA positive appeared to have less efficacy (effect on overall survival) as compared to TC3/IC3 patients who tested negative for treatment emergent ADA. Moreover, comparison of the ADA positive vs. control in unadjusted analyses showed no meaningful differences between the two populations. However, the limited patient numbers in the TC3/IC3 subgroup is acknowledged. The incidences of ADAs and the impact  on  efficacy  have  been  adequately  reflected  in  the  SmPC  in  the  context  of  variation EMEA/H/C/004143/II/0030.

## 2.3.5. Conclusions on clinical pharmacology

Overall atezolizumab PK is sufficiently described. Based on PK modelling data, the 840 mg q2w or 1680 mg q4w atezolizumab monotherapy regimens are expected to have comparable efficacy and safety with the 1200 mg q3w regimen in chemotherapy-naïve patients with Stage IV NSCLC.

Exploratory analyses did not exclude possible attenuation of efficacy benefit in patients who developed ADA compared to patients who did not develop ADA.

## 2.4. Clinical efficacy

## 2.4.1. Dose response study

Please see section 2.3.3 Pharmacodynamics.

## 2.4.2. Main study

IMpower110: A phase III, open-label, randomized study of atezolizumab (anti-PD-L1 antibody) compared with platinum agent (cisplatin or carboplatin) in combination with either pemetrexed or gemcitabine for PDL1-selected, chemotherapy-naive patients with stage IV non-squamous or squamous non-small cell lung cancer.

IMpower110 is a randomized, phase III, global, multicenter, open-label study designed to evaluate the safety  and  efficacy  of  atezolizumab  compared  with  chemotherapy  consisting  of  a  platinum  agent (cisplatin or carboplatin per investigator discretion) combined with either pemetrexed (non-squamous disease)  or  gemcitabine  (squamous  disease),  chemotherapy-naïve  patients  with  Stage IV  NSCLC. Patients had PD-L1 expression ≥ 1% TC (PD-L1 stained ≥ 1% of tumour cells) or ≥ 1% IC (PD-L1 stained tumour-infiltrating  immune  cells  covering ≥ 1%  of  the  tumour  area)  based  on  the  VENTANA  PD-L1 (SP142) Assay.

<div style=\"page-break-after: always\"></div>

Table 12: Summary of studies contributing to efficacy evaluation

<!-- image -->

| Study Number         | Study Design                                    | Population                                                                                                                                                                                                                                                                                                                                                                                   | Number of Patients Enrolled                          | Dose,Route, and Regimen                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Primary Efficacy Endpoint   | Timing of Primary/lnterim Analysis (Clinical Cutoff Date)                                                                                                                          |
|----------------------|-------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Pivotal Study        | Pivotal Study                                   | Pivotal Study                                                                                                                                                                                                                                                                                                                                                                                | Pivotal Study                                        | Pivotal Study                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Pivotal Study               | Pivotal Study                                                                                                                                                                      |
| GO29431 (IMpower110) | Phase Ill, global, randomized, open-label study | PD-L1-selected (TC1/2/3 or IC1/2/3), chemotherapy-naive patients with Stage IV squamous or non- squamous NSCLC excluding patients with a sensitizing EGFR mutation or ALK translocation Patients were stratified by sex(male vs. female),ECOG PerformanceStatus(0 vs. 1), histology (non- squamous vs. squamous), and PD-L1 tumor expression by IHC (TC1/2/3 and any IC vs. TC0 and IC1/2/3) | Total: N=572 Atezolizumab: n=285 Chemotherapy: n=287 | Atezolizumab: 1200mg IV q3w Chemotherapy: Induction Period: Non-squamous:Pemetrexed (500mg/m² Iv) in combination with cisplatin (75 mg/m² IV) or carboplatin (AUC 6 IV] q3w for 4-6 cycles Squamous: gemcitabine (1250 mg/m²IV)on day 1and 8+cisplatin on day 1 (75 mg/m2 IV)or gemcitabine (1000 mg/m² IV) on day 1and8+carboplatinon day1 (AUC 5IV)q3w for4-6 cycles MaintenancePeriod: Non-squamous:Pemetrexed (500mg/m²IV q3w) until PD Squamous: Best supportive care | SO                          | The interim analysis of OS was planned for approximately 45% when an event-patient ratio and approximately 96deathswere observed inthe TC3or IC3-WT population (10 September 2018) |

<!-- image -->

AUC = area under the concentration -time curve; ECOG PS = Eastern Cooperative Oncology Group Performance Status; IV = intravenous; NSCLC = non -small cell lung cancer; PD-L1 = programmed death -ligand 1; q21d = every 21 days; RECIST = Response Evaluation Criteria in Solid Tumors. Note:  Gemcitabine is given on Days 1 and 8.

Figure 10 : Overview of Study Design for IMpower110

<div style=\"page-break-after: always\"></div>

## Methods

## Study participants

## Key study eligibility criteria

Patients were enrolled in the study if the following key inclusion criteria were met:

- Age ≥ 18 years
- ECOG Performance Status of 0 or 1
- Histologically or cytologically confirmed, Stage IV non-squamous or squamous NSCLC (per the Union Internationale contre le Cancer/American Joint Committee on Cancer staging system, 7th edition)
- o Patients  with  tumors  of  mixed  histology  had  to  be  classified  as  non-squamous  or squamous based on the major histological component.
- No prior treatment for Stage IV non-squamous or squamous NSCLC
- o Patients  known  to  have  a  sensitizing  mutation  in  the  EGFR  gene  or  an  ALK  fusion oncogene are excluded from the study.
- o Patients  with  non-squamous  NSCLC  who  had  an  unknown  EGFR  or  ALK  status  were required to be tested at prescreening/screening. Patients with squamous NSCLC who had an unknown EGFR or ALK status were not required to be tested at prescreening/screening.
- o EGFR and/or ALK could be assessed locally or at a central lab. Additional tissue was required for central testing of EGFR and/or ALK.
- Patients who had received prior neo-adjuvant, adjuvant chemotherapy, radiotherapy, or chemoradiotherapy  with  curative  intent  for  non-metastatic  disease  must  have  experienced  a treatment-free  interval  of  at  least  6  months  from  randomization  since  the  last  chemotherapy, radiotherapy, or chemoradiotherapy cycle.
- Patients with a history of treated asymptomatic central nervous system (CNS) metastases were eligible, provided they met all of the following criteria:
- o Only supratentorial and cerebellar metastases allowed (i.e., no metastases to midbrain, pons, medulla, or spinal cord)
- o No ongoing requirement for corticosteroids as therapy for CNS disease
- o No stereotactic radiation within 7 days or whole-brain radiation within 14 days prior to randomization
- o No evidence of interim progression between the completion of CNS-directed therapy and the screening radiographic study

Patients with new asymptomatic CNS metastases detected at the screening scan must have  received  radiation  therapy  and/or  surgery  for  CNS  metastases.    Following treatment, these patients could then be eligible without the need for an additional brain scan prior to randomization, if all other criteria were met.

<div style=\"page-break-after: always\"></div>

- Tumor PD-L1 expression (TC1/2/3 or IC1/2/3; corresponding to ≥ 1% PD-L1 expressing TCs and ≥ 1% of tumor area occupied by PD-L1 expressing ICs), as determined by an IHC assay performed by a central laboratory on previously obtained archival tumor tissue or tissue obtained from a biopsy at screening.
- Measurable disease, as defined by RECIST v1.1
- o Previously  irradiated  lesions  could  only  be  considered  measurable  disease  if  disease progression  had  been  unequivocally  documented  at  that  site  since  radiation  and  the previously irradiated lesion was not the only site of measurable disease

Key exclusion criteria are shown below:

- Known sensitizing mutation in the EGFR gene or ALK fusion oncogene
- Active or untreated CNS metastases as determined by computed tomography (CT) or MRI evaluation during screening and prior radiographic assessments
- Spinal  cord  compression  not  definitively  treated  with  surgery  and/or  radiation,  or  previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for ≥ 2 weeks prior to randomization
- Leptomeningeal disease
- Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death (e.g., expected 5-year OS &gt; 90%) treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated surgically with curative intent, ductal carcinoma in situ treated surgically with curative intent)

## Treatments

Atezolizumab treatment:  atezolizumab 1200 mg iv (21-day cycles)

Chemotherapy treatment:

- o Non-Squamous  disease:  pemetrexed  500  mg/m2  +  platinum-based  chemotherapy (cisplatin  75  mg/m2  or  carboplatin  AUC  6)  (induction:  four  to  six  21-day  cycles); followed by pemetrexed 500 mg/m2 (maintenance: 21-day cycles)
- o Squamous  disease: gemcitabine 1250 mg/m2  +  platinum-based chemotherapy (cisplatin  75  mg/m2  or  carboplatin  AUC  6)  (induction:  four  to  six  21-day  cycles); followed by best supportive care

The intended number of cycles planned for the platinum-based induction chemotherapy (i.e., four or six cycles)  was  specified  by  the  investigator  prior  to  study  randomization.  Chemotherapy  treatment continued until disease progression, unacceptable toxicity, or death. Given the toxicities associated with platinum-based chemotherapies (e.g., neutropenia, anemia) and the requirement for pre-medications, this  was  an  open-label  study.  No  crossover  was  allowed  from  the  control  arm  (platinum-based chemotherapy) to the experimental arm (atezolizumab).

Patients who were treated with atezolizumab and who demonstrated evidence of clinical benefit were permitted  to  continue  atezolizumab  treatment  after  evidence  of  PD  based  on  RECIST v1.1  criteria. Atezolizumab treatment continued as long as patients were experiencing clinical benefit as assessed by the investigator (i.e., in the absence of unacceptable toxicity or symptomatic deterioration attributed to

<div style=\"page-break-after: always\"></div>

disease progression as determined by the investigator after an integrated assessment of radiographic data, biopsy results [if available], and clinical status) or until unacceptable toxicity or death.

```
Study Drug_Exposure After Disease Progression, Overall, Atezolizumab, Reported Disease Progression, Intent-to-Treat Patients Prot0co1: G029431
```

Table 4: Summary of exposure to atezolizumab for patients in the atezolizumab arm treated beyond PD (safety-evaluable population)

```
Atezo Treated on or after First PD (N=77) Treatment duration (months) n 77 Mean (SD) 2.8 (3.7) Medlian 1.4 Min - Max - 17 Treatment duration  (months) n 77 0 to<= 3 months 58 (75.38) 02 6 months 8 (10.48) > 6to<=12 months 8 (10.4) 12 months 3 (3.9号] Total cumulative dose (mg) n 77 Mean (SD) 5797.4.(6218.4) Median 3600.0 Min - Max 1200 - 28800 Dose intensity (e) n 77 Mean (SD) 97.6.(6.0) Median 100.0 Min - Max 71 - 105 Number of doses/cycles n 77 Mean (SD) 4.8 (5.2) Median 3.0 Min - Max 一 24 Number of doses/cycles n 77 0 to = 3 42 (54.58) 3 to = 6 18 (23.4) 6 to = 12 10 (13.0号) 12 7 9.18) Treatment duration is the date of the last dose of study medication minus the date of the first Dose intensity is the number of doses actually I received divided by the expected number of doses.
```

```
dose plus one day. Data Extraction Date - 3lAuG2ol9 : Data Cutoff Date -10SEP2018.
```

## Objectives

## Primary Efficacy Objective

The primary efficacy objective for this study was to evaluate the efficacy of atezolizumab compared with platinum-based chemotherapy consisting of a platinum agent (cisplatin or carboplatin) in combination with either pemetrexed (non-squamous disease) or gemcitabine (squamous disease) in chemotherapy-naïve patients with Stage IV NSCLC, as measured by OS.

## Secondary Efficacy Objectives

The secondary objectives for this study were as follows:

- To evaluate the efficacy of atezolizumab compared with platinum-based chemotherapy as measured by investigator-assessed PFS according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
- To evaluate the efficacy of atezolizumab compared with platinum-based chemotherapy as measured by objective response rate (ORR) according to RECIST v1.1 assessed by investigator

<div style=\"page-break-after: always\"></div>

- To evaluate the efficacy of atezolizumab as measured by investigator-assessed duration of response (DOR) according to RECIST v1.1
- To evaluate the efficacy of atezolizumab compared with platinum-based chemotherapy as measured by OS and investigator-assessed PFS according to RECIST v1.1 in patients with PDL1 expression defined by the SP263 IHC assay
- To evaluate the efficacy of atezolizumab compared with platinum-based chemotherapy as measured by OS and investigator-assessed PFS according to RECIST v1.1 in patients with blood tumor mutational burden (bTMB)
- To evaluate the OS rate at 1- and 2-year landmark timepoints in each treatment arm
- To determine the impact of atezolizumab compared with platinum-based chemotherapy as measured by time to deterioration (TTD) and change from baseline (i.e., improvement or deterioration based on presenting symptomatology) in each of the patient-reported lung cancer symptom (cough, dyspnea, chest pain) score as assessed by the Symptoms in Lung Cancer (SILC) scale
- To determine the impact of atezolizumab compared with platinum-based chemotherapy as measured by TTD in patient-reported lung cancer symptoms of cough, dyspnea (multi-item subscale), and chest pain as measured by the European Organisation for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire Core (QLQ-C30) and supplementary Quality-of-Life Questionnaire Lung Cancer Module (QLQ-LC13)

## Outcomes/endpoints

The primary efficacy outcome measure was OS and was analyzed in three PD-L1-selected populations: the TC3 or IC3-WT subpopulation, the TC2/3 or IC2/3-WT subpopulation and the TC1/2/3 or IC1/2/3WT population.

As per the pre-specified analysis hierarchy and α spending algorithm, OS in the TC3 or IC3-WT population was  tested  first  and,  if  this  test  was  significant,  the  testing  continued  to  the  TC2/3  or  IC2/3-WT population and then to the TC1/2/3 or IC1/2/3-WT population.

Table 14 Key Efficacy Endpoint Definitions in IMpower110

| Endpoint   | Definition                                                                                                                                                                        |
|------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| OS         | Time from randomization to death from any cause                                                                                                                                   |
| PFS-INV    | Time from randomization to first documented PD, as determined by the investigator using RECIST v1.1, or death from any cause, whichever occurred first                            |
| ORR        | Proportion of patients with an objective response (either CR or PR), as determined by the investigator using RECIST v1.1                                                          |
| DOR        | Time from first documented objective response (CR or PR) to documented PD, as determined by the investigator using RECIST v1.1, or death from any cause, whichever occurred first |

CR = complete response; DOR = duration of response; ORR = objective response rate; OS = overall survival; PD = progressive disease; PFS-INV = investigator-assessed progression-free survival;  PR = partial response;  RECIST = Response Evaluation Criteria in Solid Tumors

<div style=\"page-break-after: always\"></div>

## Sample size

A total enrolment of approximately 555 patients was planned for this study such that approximately 64% of those enrolled would be PD-L1 TC2/3 or IC2/3 patients.

Comparisons with respect to the primary endpoint of OS between treatment arms will be tested in a hierarchical fashion for the following populations: TC3 or IC3-wild type (WT), TC2/3 or IC2/3-WT, and TC1/2/3 or IC1/2/3-WT. Estimates of the number of events required to demonstrate efficacy in terms of OS are based on the following assumptions:

- 1:1 randomization ratio
- One interim analysis of OS in the TC3 or IC3-WT, TC2/3 or IC2/3-WT, and TC1/2/3 or IC1/2/3WT populations
- Two-sided significance level of 0.05
- 99% power to detect a HR of 0.45 for OS in the TC3 or IC3-WT subpopulation
- 85% power to detect a HR of 0.65 for OS in the TC2/3 or IC2/3-WT subpopulation, and
- 77% power to detect a HR of 0.75 for OS in the TC1/2/3 or IC1/2/3-WT population
- Median survival of 14 months in the control arm (platinum-based chemotherapy)
- Event times exponentially distributed
- Dropout rate assumed for all treatment arms of 5% per 24 months
- 37% prevalence rate for TC3 or IC3 and 59% prevalence rate for TC2/3 or IC2/3 within the TC1/2/3 or IC1/2/3 population

## Randomisation

Patients with non-squamous disease were to be randomized 1:1 to receive either atezolizumab alone or pemetrexed in combination with cisplatin or carboplatin. Patients with squamous disease were to be randomized 1:1 to receive either atezolizumab alone or gemcitabine in combination with cisplatin or carboplatin.  A  permuted-block  randomization  was  applied  to  ensure  a  balanced  assignment  to  each treatment arm for the following stratification factors: Sex (male vs. female), ECOG performance status (0 vs. 1), Histology (non-squamous vs. squamous), and PD-L1 tumour expression status (TC1/2/3 and any IC vs. TC0 and IC1/2/3).

## Blinding (masking)

This was an open-label study.

## Statistical methods

## Efficacy Analysis Populations

The randomized population or intent-to-treat (ITT) population is defined as all randomized patients, regardless of receipt of the assigned treatment. The primary efficacy endpoint, OS, will be analyzed in three  PD-L1  selected  populations,  the  TC3  or  IC3-WT  subpopulation,  the  TC2/3  or  IC2/3-WT subpopulation and the TC1/2/3 or IC1/2/3-WT population. Unless otherwise indicated, the secondary efficacy endpoints will be analyzed in TC1/2/3 or IC1/2/3-WT, TC2/3 or IC2/3-WT, and/or TC3 or IC3WT.

<div style=\"page-break-after: always\"></div>

For  efficacy  analyses,  patients  will  be  grouped  per  the  treatment  that  was  assigned  at  the  time  of randomization regardless whether they received any assigned study drug.

## PD-L1 testing used to select the target population

PD-L1 expression on TC (tumour cells) or IC (immune cells) were assessed using prospectively stained tumour specimens evaluated by external central laboratories using the VENTANA PD-L1 (SP142) IHC assay, according to a scoring algorithm measuring PD-L1 on TCs and ICs. On 19 December 2017 and 2 August 2018, Ventana Medical Systems globally recalled multiple detection kits used for ICH laboratory testing  due  to  the  leaking  and  sticking  of  reagent  dispensers,  which  could  impact  staining  results. Impacted  lots  were  deployed  during  the  course  of  the  IMpower110  study  (as  a  component  of  the investigational PD-L1 [SP142] assay) and were used to determine the PD-L1 status of a total of 103 enrolled patients (18% of all randomized patients). Available samples from enrolled patients impacted by recalled dispensers from IMpower110 were re-tested. The primary analysis populations were defined by the original PD-L1 results derived from the PD-L1 tissue slide stained at enrolment.

Table 5: Concordance - cross tabulation of PD-L1 expression: retest results compared with original testing result

|                               |                                          | Number(%)of Patients     | Number(%)of Patients                   | Number(%)of Patients                            | Number(%)of Patients     | Number(%)of Patients     | Number(%)of Patients     | Number(%)of Patients     |
|-------------------------------|------------------------------------------|--------------------------|----------------------------------------|-------------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                               |                                          | Re-TestPD-L1StatusResult | Re-TestPD-L1StatusResult               | Re-TestPD-L1StatusResult                        | Re-TestPD-L1StatusResult | Re-TestPD-L1StatusResult | Re-TestPD-L1StatusResult | Re-TestPD-L1StatusResult |
|                               |                                          | TC3orIC3 (N=20)          | TC2/3orIC2/3 excluding TC3orIC3 (N=12) | TC1/2/3or IC1/2/3 excluding TC2/3orIC2/3 (N=25) | TCOandICO (N=14)         | NotEvaluable (N=10)      | NotTested (N=22)         | Total (N=103)            |
| Original PD- L1 Status Result | TC3orIC3                                 | 16 (80.0%)               | 3 (25.0%)                              | 0                                               | 0                        | 1 (10.0%)                | 2 (9.1%)                 | 22 (21.4%)               |
| Original PD- L1 Status Result | TC2/3orIC2/3 excluding TC3orIC3          | 4 (20.0%)                | 5 (41.7%)                              | 1 (4.0%)                                        | 2 (14.3%)                | 2 (20.0%)                | 3 (13.6%)                | 17 (16.5%)               |
| Original PD- L1 Status Result | TC1/2/3or IC1/2/3 excluding TC2/3orIC2/3 | 0                        | 4 (33.3%)                              | 24 (96.0%)                                      | 12 (85.7%)               | 7 (70.0%)                | 17 (77.3%)               | 64 (62.1%)               |
| Original PD- L1 Status Result | Total                                    | 20                       | 12                                     | 25                                              | 14                       | 10                       | 22                       | 103                      |

IC=immune cell;PD-L1=programmed-dealthligand 1;TC=tumor cell

Source:t\\_pdl1\\_rt\\_cat\\_IMP\\_10Sep2018\\_29431

## Primary endpoint

## Overall survival (OS)

The primary efficacy analysis is the comparison of OS between the two treatment arms (atezolizumab arm and chemotherapy control arm). Treatment comparisons will be based on the stratified log-rank test.

For the TC3 or IC3-WT subpopulation and the TC2/3 or IC2/3-WT subpopulation, the stratification factors will  be  those  that  were  used  during  randomization.  For  the  TC1/2/3  or  IC1/2/3-WT  population,  the stratification factors will be those that were used during randomization and PD-L1 tumor expression status [TC1/2/3 and any IC vs. TC0 and IC1/2/3]).

Due to the potential risk of over-stratification, if at least 1 stratum has less than 10 OS events, the stratification factor which contains the level with the smallest number of patients will be removed from the stratified analyses. The removal of the stratification factor will continue until there is no stratum with less than 10 OS events in the analysis population. Results from an unstratified analysis will also be provided.

The HR will be estimated with a stratified Cox regression model with the same stratification variables that are used in the stratified log-rank test at the interim and final analyses. The unstratified HR will also be presented.

<div style=\"page-break-after: always\"></div>

The Kaplan-Meier methodology will be used to estimate the median OS for each treatment arm and construct survival curves for the visual description of the difference between the treatment arms. The Brookmeyer-Crowley methodology will be used to construct the 95%CI for the median OS for each treatment arm.

Censoring rules: Data for patients, who are not reported as having died at the time of the analysis, will be censored at the date when they were last known to be alive. Patients who do not have any postbaseline information will be censored at the date of randomization plus 1 day.

Sensitivity analysis of OS for NPT was based on the time interval during, which patients received NPT until the event or censoring time was discounted at 10%, 20%, and 30% for both arms to investigate how the OS results would have looked if the NPT was not available.

## Secondary endpoints

## Progression free survival based on the investigators' assessment (PFS-INV)

PFS-INV will be analyzed through use of the same methods described for the OS analysis.

Censoring rules: Patients who have not experienced disease progression or death at the time of analysis will be censored at the time of last tumor assessment. Patients with no post-baseline tumor assessment will be censored at the date of randomization plus 1 day.

Objective  response  (partial  response  [PR]  plus  complete  response  [CR])  as  determined  by  the investigator (ORR)

ORR is defined as the proportion of patients who had an objective response (CR or PR). Patients not meeting  these  criteria,  including  patients  without  any  post-baseline  tumor  assessments,  will  be considered non-responders.

The analysis of ORR will be performed for patients in the secondary efficacy analysis populations who have measurable disease at baseline.

The confirmation of response in accordance with RECIST v.1.1 is not required, but for the exploratory purpose, rate of confirmed response may be reported as needed.

An  estimate  of  ORR  and  its  95%CI  will  be  calculated  using  the  Clopper-Pearson  method  for  each treatment arm. The 95%CIs for the difference in ORRs between the two arms will be computed using the normal approximation to the binomial distribution.

The ORR will be compared between the two arms using the stratified Cochran-Mantel-Haenszel test, stratified by the same factors used in the primary OS analysis.

## Type I error control and interim analyses

The hierarchy of alpha spending is specified in Figure 11.

<!-- image -->

IC =tumor-infiltrating immune cell; OS=overall survival; TC =tumor cell; WT=wild type (i.e., excludingpatientswithasensitizingepidermalgrowthfactorreceptor[EGFR] mutation or anaplastic lymphomakinase[ALK] translocation).

<div style=\"page-break-after: always\"></div>

## Figure 11: Type I error control plan

The Sponsor plans to conduct one interim efficacy analysis for the primary endpoint of OS in the TC3 or IC3-WT, the TC2/3 or IC2/3-WT, and the TC1/2/3 or IC1/2/3-WT populations, respectively. With a lack of the final PD-L1 prevalence, to ensure the data maturity and have sufficient event-patient ratio for the evaluation of the OS benefit, an interim analysis of OS in the TC3 or IC3-WT population will be conducted when both of the following criteria have been met:

- An  approximately  45%  event-patient  ratio  has  been  observed  in  the  TC3  or  IC3-WT subpopulation
- Approximately 96 deaths have occurred in the TC3 or IC3-WTsubpopulation

It  is  expected  that  approximately  154  OS  events  would  have  occurred  in  the  TC2/3  or  IC2/3-WT population at the time of the interim analysis of OS in the TC3 or IC3-WT subpopulation. If the OS interim analysis in the TC3 or IC3-WT population is claimed as statistically significant, the OS analysis in the TC2/3 or IC2/3-WT population will be tested under the overall type I error of 0.05.

If  there  are  significantly  fewer  than  154  OS  events  (i.e.,  &lt;135  events)  in  the  TC2/3  or  IC2/3-WT population at the time of TC3 or IC3-WT OS interim analysis, a nominal two-sided alpha of 0.0001 (negligible impact on overall type I error rate) will be spent on the OS interim analysis in the TC2/3 or IC2/3-WT population. The next interim and final OS analysis in the TC2/3 or IC2/3-WT population will be conducted when approximately 154 and 216 events are observed, respectively. The interim and final analyses of OS in TC1/2/3 or IC1/2/3-WT would be conducted at the same time as those for the TC2/3 or IC2/3-WT population.

Boundaries will be adjusted based on observed number of OS events by using the Lan-DeMets approximation to the Pocock boundary.

## Changes to the SAP

The first version (v1) of the SAP was issued on 18 April 2017 and was amended two times (v2 and v3). The key changes to the SAP are summarized below.

## SAP Amendment 1, Version 2 (19 December 2018)

The following main changes were made in the SAP:

- Earlier interim analysis
- Crossing  boundaries  of  interim  and  final  analyses  was  determined  by  the  Lan-DeMets approximation to the Pocock boundaries
- Potentially merged stratification factors in stratified analyses based on number of events in strata

In addition, exploratory analyses of tissue Tumor Mutational Burden and T-effector gene expression were removed given the correlation between blood TMB (already a secondary endpoint) and tissue TMB, and the limited biomarker value of T-effector gene expression observed in other 1L NSCLC studies in the atezolizumab clinical program.

## SAP Amendment 2, Version 3 (2 April 2019)

The following major changes were made in the SAP:

- The  TC3  or  IC3  population,  excluding  patients  with  a  sensitizing  EGFR  mutation  or  ALK translocation (i.e., TC3 or IC3-WT), have been added as the first test in the hierarchy
- The timing of the efficacy analysis was updated to be when the pre-specified criteria were met for the TC3 or IC3-WT population

<div style=\"page-break-after: always\"></div>

In addition, the cutoffs were clarified to include ≥1%, ≥25%, and ≥ 50% of tumor cells for the PD-L1 SP263 IHC assay and include ≥10, ≥16, and ≥20 mutations for the bTMB assay.

## Results

## Participant flow

<!-- image -->

- a Pre-screening for PD-L1 status was not required prior to patients entering screening. Therefore, total number of screened patients includes patients that were not pre-screened for PD-L1 status or that were re-screened.
- Includes 5 patients who did not receive treatment.
- Includes 18 patients who did not receive treatment.
- Includes one patient that at the time of CCOD had survival follow up status lost to follow-up.
- Includes two patients that at the time of CCOD had survival follow up status lost to follow-up.

Figure 1: Patient disposition

<div style=\"page-break-after: always\"></div>

Table 6: Patient disposition from study, ITT patients

Protoco1:G029431

|                                                                                  | Chemotherapy (N=287)   | Atezolizumab (N=285)   | Atezolizumab (N=285)   | All Patients (N=572)   | All Patients (N=572)   |
|----------------------------------------------------------------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|
| ReceivedTreatment                                                                | 264                    | (92.0%)                | 285 (100.0%)           | 549                    | (96.0%)                |
| On-StudyStatus Alive:OnTreatment Alive:In_Follow-Up SurvivalStatus\"UnknownatCcoD |                        | (48.48） (38:383 8.7%   | 54.0%) 31.6%           |                        |                        |
| Discontinued Study Death WithdirawalBySubject                                    | 24                     | :8} 8.4%               | : 13 4.6%              |                        | 6.5%                   |

<!-- image -->

## Recruitment

The IMpower110 study was fully recruited in approximately 31 months from 21 July 2015 to 21 February 2018.  Median  follow-up  time  for  the  targeted  population  (TC3/IC3-WT)  was  16.5  months  with atezolizumab monotherapy and 15.5 months with chemotherapy at data cut-off 10 September 2018.

Patients were recruited from 144 centers across 19 countries. The majority of centers each recruited between 1-4 patients; the 5 highest enrolling sites each recruited between 16-19 patients. The number of  patients  randomized  per  region  and  country,  followed  by the  number of centers  (in  brackets),  is summarized below in descending order.

- Europe and Middle East: Romania 54 (7), Poland 51 (5), Russia 50 (11), Italy 46 (12), Serbia 42 (5), Turkey 36 (6), Spain 35 (15), Greece 32 (12), France 27 (10), Ukraine 26 (8), Hungary 26 (4), Great Britain 13 (3), Germany 8 (2)
- Asia-Pacific: Japan 51 (16), Thailand 14 (4), Republic of Korea 11 (3), China 3 (1)

- South America: Brazil 31 (11)

- North America: United States of America 16 (9)

## Conduct of the study

## Protocol changes

The first version of the protocol was issued on 23 December 2014. There were also country specific protocol amendments issued for South Korea, Brazil, and China.

The key changes made to the protocol deemed important for the study conduct are summarized below:

Protocol Amendment 1, Version 2 (24 April 2015)

- Reporting for serious AEs and AESIs was extended to 90 days after last dose of study treatment or until initiation of a new anti-cancer therapy, whichever occurred first.

Protocol Amendment 2, Version 3 (5 October 2015; key changes listed)

- The study inclusion criteria were modified to allow for patients with treated, asymptomatic cerebellar metastases to be enrolled provided specific criteria were met.

<div style=\"page-break-after: always\"></div>

-  The exclusion criteria for history of autoimmune disease was broadened to allow for patients with eczema,  psoriasis,  lichen  simplex  chronicus,  or  vitiligo  with  dermatologic  manifestations  only  (e.g., patients with psoriatic arthritis would be excluded) to be permitted provided that they met the specific conditions.

- The exclusion criterion specifying that patients with a history of allergic reaction to IV contrast that requires steroid pretreatment should have baseline and subsequent tumor assessments performed via MRI was removed because this was in conflict with Section 4.5.5. Patients with contraindications to contrast could have assessments done with non-contrast CT or MRI.

- Systemic immune activation (SIA) was identified as a potential risk of atezolizumab when given in combination with other immunomodulating agents. The management recommendations regarding early identification and management of SIA were added.

## Protocol Amendment 3, Version 4 (16 December 2015)

- Clarified that a wash-out period of at least 4 weeks or five half-lives, whichever was longer, of any systemic immunostimulatory agent was required prior to randomization.

Protocol Amendment 4, Version 5 (29 June 2016; key changes listed)

- Expanded the patient population to include patients with squamous NSCLC, who was randomized to receive either atezolizumab or chemotherapy consisting of a platinum agent (carboplatin or cisplatin per investigator discretion) combined with gemcitabine (in contrast to patients with non-squamous NSCLC, who  received  either  atezolizumab  or  chemotherapy  consisting  of  a  platinum  agent  combined  with pemetrexed).

- Revised the cutoff for PD-L1 expression in TCs and ICs to allow for inclusion of patients with TC1/2/3 or IC1/2/3 instead of TC3 of IC3.

- Added a co-primary endpoint of OS in addition to PFS endpoint.

- Made modifications to the statistical testing procedures.

- Stratification factors were modified to include sex (male vs. female), ECOG Performance Status (0 vs. 1), histology (non-squamous vs. squamous), and tumor tissue PD-L1 expression by IHC (TC1/2/3 and any IC vs. TC0 and IC1/2/3).

- The timing of the primary PFS analysis and the definition of end of study were updated. The primary efficacy  analysis  was  performed  when  approximately  368  investigator-assessed  PFS  events  have occurred  in  patients  enrolled  during  the  global  enrollment  phase  or  after  the  last  patient  has  been enrolled, whichever occurred later. The study ended when approximately 425 deaths have occurred among patients enrolled during the global enrollment phase or when approximately 112 OS events have occurred in the China subpopulation, whichever occurred later.

Protocol Amendment 5, Version 6 (14 March 2017; key changes listed)

- Excluded patients with a known sensitizing EGFR mutation or ALK translocation from the study.

This change in eligibility was made to further identify patients with NSCLC who may derive the most benefit from treatment with atezolizumab. In Study GO28915 (OAK), which investigated atezolizumab  versus  docetaxel  as  second-  or  third-line  treatment  in  patients  with  advanced NSCLC, there was no difference in the magnitude of benefit observed in OS for atezolizumab versus docetaxel among patients with an EGFR mutation. Consistent results were observed with two PD-1 inhibitors, nivolumab and pembrolizumab in the CheckMate057 (Borghaei et al. 2015) and KEYNOTE-010 (Herbst et al. 2016) studies, respectively.

<div style=\"page-break-after: always\"></div>

-  Changed  investigator-assessed  PFS  to  a  secondary  endpoint  and  maintained  OS  as  the  primary endpoint.

OS  remains  the  primary  endpoint  since  it  is  a  well-established  and  robust  endpoint  that  is generally accepted as the most objective measure of clinical benefit, and available data suggest that OS may be a more sensitive endpoint for cancer immunotherapy than PFS. For example, in Studies  GO28753  (POPLAR)  and  GO28915  (OAK),  OS  in  the  TC1/2/3  or  IC1/2/3  subgroup (subgroups based on TC and IC PD-L1 expression), was significantly improved with atezolizumab compared with docetaxel, whereas PFS was similar in the two arms. In Study GO28754 (BIRCH), the median OS observed in PD-L1-selected patients (TC2/3 or IC2/3) with advanced NSCLC who received 1L treatment with atezolizumab was favorable compared with data from platinum-based chemotherapy regimens, whereas PFS was consistent with data from platinum-based chemotherapy regimens. Because of this change, the additional  PFS  censoring  rule  for  U.S. registrational purposes was removed.

- The secondary objective and outcome measure regarding independent review facility (IRF)-assessed PFS according to RECIST v1.1 have been removed.

- Made modifications to the statistical testing procedure for the primary efficacy endpoint (OS)

The OS analysis was amended to test hierarchically in the TC2/3 or IC2/3 subpopulation and the TC1/2/3 or IC1/2/3 population, with both populations excluding patients with a sensitizing EGFR mutation or ALK translocation, at both the interim and final analysis. Evolving evidence indicates a strong treatment effect on OS in both the TC2/3 or IC2/3 subgroup and the TC1/2/3 or IC1/2/3 subgroup, with a stronger effect on the TC2/3 or IC2/3 subgroup compared with the TC1/2/3 or IC1/2/3  subgroup.  In  Study  GO28915  (OAK),  an  improvement  in  OS  was  observed  in  the atezolizumab arm compared with the docetaxel arm in the TC2/3 or IC2/3 subgroup (HR=0.67; median OS, 16.3 vs. 10.8 months). In the TC1/2/3 or IC1/2/3 population, median OS was 15.7 months for atezolizumab versus 10.3 months for docetaxel (HR=0.74) (Barlesi et al. 2016). The total sample size and the timing of the interim and final OS analyses have been adjusted to account for the updated statistical testing procedure.

- Modified the OS interim analysis to be evaluated by the iDMC to minimize the Sponsor's access to population-level  efficacy  data  summaries  in  this  open-label  study  and  ensured  that  any  future modifications to the trial were not based on the OS interim analysis.

- The sample size was changed from 570 to 555 patients.

- The sensitivity analyses that accounted for missing data and evaluated the impact of discontinuation caused by toxicity was removed.

- Sensitivity analyses on the impact of non-protocol-specified anti-cancer therapy and the proportional hazards assumption on OS were added.

Protocol Amendment 6, Version 7 (16 April 2018; key changes listed)

- Modified the number of OS events required in the TC2/3 or tumor-infiltrating IC2/3-WT subgroup due to lower PD-L1 prevalence of TC2/3 or IC2/3-WT than the previous protocol assumption.

- Secondary endpoints to evaluate OS and PFS in patients with PD-L1 expression defined by the SP263 IHC assay and in patients with bTMB, including bTMB ≥10, and bTMB ≥16 were added. Exploratory endpoints of OS and PFS in patients with PD-L1 expression defined by the 22C3 PD-L1 IHC assay, Teffector gene expression, and/or high tumor mutational burden were specified.

Protocol Amendment 7, Version 8 (29 August 2018; key changes listed)

<div style=\"page-break-after: always\"></div>

- Modified the timing of the interim efficacy analysis, as data external to this trial suggest that an earlier analysis can demonstrate OS benefit.

- Included the newly identified risk and associated management guidelines of immune-related nephritis for atezolizumab.

Protocol Amendment 8, Version 9 (14 March 2019; key changes listed)

-The TC3 or IC3 population excluding patients with a sensitizing EGFR mutation or ALK translocation (i.e.; TC3 or IC3-WT) was added as the first testing hierarchy. The ongoing blinded tracking of PD-L1 prevalence indicated that the prevalence of the TC3 or IC3 subgroup was higher than expected. Data from the atezolizumab 1L NSCLC Phase III Studies GO29436 and GO29437 and the second-line NSCLC Phase III Study GO28915 had shown that the TC3 or IC3 subgroup appears to derive the biggest clinical benefit. With these emerging data, this study could have adequate power for testing OS in the TC3 or IC3-WT population.

- The timing of the interim efficacy analysis was changed to be conducted when the prespecified criteria was met for the TC3 or IC3-WT population. This change was based on two factors: 1) the TC3 or IC3WT  was  now  the  first  primary  patient  population  (see  above),  and  2)  data  external  to  this  study suggested that the proposed event-patient ratio may be sufficient to evaluate OS benefit in this patient population,  which  could  minimize  the  potential  confounding  effect  due  to  the  use  of  subsequent therapies.

- It was clarified that the Lan-DeMets approximation to the Pocock boundaries was used to determine the stopping boundaries.

- The secondary endpoints for OS and investigator-assessed PFS in patients defined by the SP263 IHC assay were being updated to include the validated PDL1 tumor expression cutoff of ≥25% (in addition to ≥1% and ≥50%) in order to evaluate this additional PD -L1 expression level with respect to efficacy.

- The secondary endpoints for OS and investigator-assessed PFS in patients defined by the bTMB assay were being updated to include the 20 mutations cutoff (in addition to 10 and 16 mutations), in order to evaluate this additional TMB level with respect to efficacy.

- The exploratory analysis of T-effector gene expression was removed given the limited biomarker value of T-effector gene expression observed in other 1L NSCLC studies in the atezolizumab clinical program.

- The exploratory analysis of tissue tumor mutational burden (tTMB) was removed, as evolving data indicated that tTMB and bTMB (secondary endpoint) results are correlated (Gandara et al. 2018), and the missing data rate is expected to be high since tTMB testing requires a significant amount of tissue.

- It was clarified that the primary safety analyses included all treated patients, defined as randomized patients who received any amount of study treatment, regardless of EGFR/ALK and PD-L1 status.

## Baseline data

Table 7: Summary of baseline demographic characteristics (TC3 or IC3-WT population)

<div style=\"page-break-after: always\"></div>

Protoc01: G029431

|                                                                | Chemotherapy (N=98)                                        | Atezolizumab (N=107)                  | All Patients (N=205)                                                        |
|----------------------------------------------------------------|------------------------------------------------------------|---------------------------------------|-----------------------------------------------------------------------------|
| Age (years)                                                    |                                                            |                                       |                                                                             |
| n. Mean (SD) Median Min - Max                                  | 98 64.2. (9.0) 66.0 33-87                                  | 107 63.3 (9.1) 63.0 33 - 79           | 205 63.7_ (9.0) 65.0 33-87                                                  |
| n <65 >= 65                                                    | 98 43(43.98) 55 (56.18)                                    | 107 59 (55.18) 48 (44.98)             | 205 102 (49.88) 103 (50.28)                                                 |
| Age group (years)                                              |                                                            |                                       |                                                                             |
| 65 to74 75 to 84 >= 85 Sex n Male Female Race n                | 47 (48.08) 7 7.18) 1.0%) 98 64 (65.38) 34 (34.7%) 98       | 33 15 0 107 79 (73.8%) 28 (26.28) 107 | 1 (0.5%) 205 143 (69.88) 62 (30.28) 205 35 (17.18)                          |
| White Unkmown                                                  | (15.3号) 82 (83.78) 1 (1.0%)                                |                                       | 205 (55.18) 102 (49.8%) (30.88) 80 (39.0%) (14.0%) 22 (10.78) 169 (82.4号) 1 |
| Asian n Hispanic or Latino Not Hispanic or Latino Not reported | 15 98 5 (5.18) 91 (92.98) 2 ( 2.0%)                        | 20 (18.78) 87 (81.38) 0 107           | (0.5%) 205 14(6.88)                                                         |
| Ethnicity                                                      |                                                            |                                       |                                                                             |
| n Mean (SD) Median                                             |                                                            | 86 (91.68) 0 107                      | 189(92.28) 2 (1.08)                                                         |
|                                                                |                                                            | 6 (8.48)                              |                                                                             |
|                                                                | 92 67.93 (14.33)                                           | 69.43 (14.99) 00.69 39.4 -111.0       | 199                                                                         |
| Weight (kg) at baseline                                        |                                                            |                                       |                                                                             |
| Min - Max Baseline ECoG per eCRF n                             | 66.73 32.9-98.4                                            | 107 35 (32.7%)                        | 68.74 (14.67) 68.00 32.9-111.0 205 73 (35.6%)                               |
| 0 1 ECOG PS from IxRS n                                        | 98 38 (38.8%) 60 (61.2%)                                   | 72 (67.3%) 107 9 (8.48) 20            | 132 (64.4%) 24 49                                                           |
| 1                                                              | 54 (55.18)                                                 | 78 (72.98)                            | 132                                                                         |
|                                                                | 15                                                         |                                       |                                                                             |
|                                                                | 60                                                         |                                       |                                                                             |
|                                                                |                                                            |                                       | 134                                                                         |
|                                                                | 38                                                         |                                       | 71                                                                          |
|                                                                |                                                            | 33 74                                 | 205                                                                         |
|                                                                | 98 (38.88)                                                 | 107                                   |                                                                             |
|                                                                |                                                            | (30.8%) (69.28)                       |                                                                             |
|                                                                | (61.28)                                                    |                                       |                                                                             |
| Tobacco Use History                                            |                                                            |                                       |                                                                             |
|                                                                |                                                            |                                       | (34.6%) (65.48)                                                             |
|                                                                |                                                            |                                       | 205                                                                         |
| n                                                              |                                                            |                                       | (11.78)                                                                     |
| Never                                                          | 98 (15.38) 29 (29.68)                                      | (18.78)                               |                                                                             |
|                                                                |                                                            |                                       | (23.98) (64.48)                                                             |
| Current Previous                                               |                                                            |                                       |                                                                             |
| mutation or ALK translocation.                                 | Data Extraction Date-3lAUG2019;Data Cutoff Date-10SEP2018. |                                       |                                                                             |

Demographic characteristics for the IC2/3 or TC2/3-WT population were consistent with those presented here for the TC1/2/3 or IC1/2/3-WT and the TC3 or IC3-WT populations.

<div style=\"page-break-after: always\"></div>

Table 8: Summary of baseline disease characteristics (TC3 or IC3-WT population)

Baseline Disease Characteristics，TC3 or IC3，Intent-to-Treat Patients,Wild Type Protocol:G029431

|                                                                                                | Chemotherapy (N=98)   | Atezolizumab (N=107)         | All Patients (N=205)     |
|------------------------------------------------------------------------------------------------|-----------------------|------------------------------|--------------------------|
| Staging at Initial Diagnosis                                                                   |                       |                              |                          |
| n                                                                                              | 98                    | 107                          | 205                      |
| STAGE IA                                                                                       | 2 2.0%)               | 3 2.8)                       | 5 （ 2.4%)                |
| STAGE IB                                                                                       | 5 5.1$)               | 7 6.5)                       | 12 5.9%)                 |
| STAGE IIA                                                                                      | 4 4.1$)               | 10 9.3)                      | 14 6.8$)                 |
| STAGE IIB                                                                                      | 6 6.1$)               | 2 1.9)                       | 8 3.9$)                  |
| STAGE IIIA                                                                                     | 4 4.1$)               | 8 7.5$)                      | 12 5.9$)                 |
| STAGE IIIB                                                                                     | 2 2.0$)               | 2 1.9$) 73                   | 4 2.0$) 148              |
| STAGE IV Unknown                                                                               | 75 76.5$) 0           | 68.2) 2 1.9)                 | 72,2$) 2( 1.0%)          |
| Histology at Initial Diagnosis (eCRF)                                                          |                       |                              |                          |
| n Squamous Non-squamous                                                                        | 98 23（23.5) 75(76.5)  | 107 27 （25.2） 80(74.8%)      | 205 50（24.4%) 155 (75.6) |
| Histology in Non-Squamous                                                                      |                       |                              |                          |
| n                                                                                              | 74                    | 79                           | 153                      |
| Adenocarcinoma                                                                                 | 69 93.2$）             | 74 (93.7)                    | 143 93.5$)               |
| Adenocarcinoma with Neuroendocrine Features                                                    | 1 1.4)                | 1 1 1.3)                     | 2 1.3$)                  |
| Adenosquamous Large Cell                                                                       | 2 2.7$) 1.4)          | 1.3) 2 2.5$)                 | 3 2.0$) 3 2.0$)          |
| Undifferentiated                                                                               | 1,4$)                 | 1.3$)                        | 1.3$)                    |
| Histology in Squamous                                                                          |                       |                              |                          |
| n                                                                                              | 22                    | 26                           | 44 （91.7$) 48            |
| Squamous Other Mixed Histology (Predominantly Squamous) Adenosquamous (Predominantly Squamous) | 21 95.5$) 1 0 4.5$)   | 23 （88.5) 1 2 3.8$) 7.7%)    | 2 【 ( 4.2%) 4.2$)        |
| Metastatic Disease Status                                                                      |                       |                              |                          |
| n Locally Advanced Disease Metastatic Disease                                                  | 98 0 98 (100.0%)      | 107 1 0.9$) 106(99.1)        | 205 1（0.5） 204（99.5)     |
| n                                                                                              | 98                    |                              | 205                      |
| No.of Metastatic Sites at Enrollment                                                           |                       |                              |                          |
| Mean (SD) Median xw-U                                                                          | 3.28(1.42) 3.00       | 107 2.93 (1.27) 3.00 1.0-7.0 | 3.09(1.35) 3.00 1.0-9.0  |
|                                                                                                | 1.0-9.0               |                              |                          |
| Date of 1st Diag.of Metastatic Disease to InitialDoseAdmin.                                    |                       | (Months)                     |                          |
| n Mean (SD)                                                                                    | 98 1.73 (1.25) 1.48   | 105 2.93 (6.19) 1.64         | 203 2.35(4.57) 1.54      |
| Median Min - Max                                                                               | 0.1-9.9               | 0.1-50.8                     | 0.1-50.8                 |
| n                                                                                              | 98 7.1$）              | 3 107 2.8%）                  | 10（ 205                  |
| Positive                                                                                       |                       |                              |                          |
| KRAS Mutation Status                                                                           |                       |                              |                          |
| Unknown                                                                                        | 85(86.7%) 75          | 13 （12.1$) 91(85.0)          | 4.9%) 19 9.3) 176 (85.9) |
| Negative                                                                                       | 6 6.1$)               |                              |                          |
| EML4-ALK Rearrangement Status in Non-Squamous n No                                             | 75 (100.0$) 109.50    | 80 80 (100.0%) 82.00         | 155 155 (100.0$) 92.00   |
| BLTarget Tumor Sum Longest Diameter                                                            | 98                    |                              |                          |
| n                                                                                              | 110.84 (60.37)        | 107 97.99(67.54)             | 205 104.13 (64.38)       |
| Mean (SD)                                                                                      |                       |                              |                          |
| Median Min -Max                                                                                | 15.0-265.0            | 11.0-390.0                   | 11.0-390.0               |
| PD-L1Tumor Expression by IHC (Strat Factor from IxRS)                                          |                       |                              |                          |
| n TC1/2/3and any IC TC0 and IC1/2/3                                                            | 98 73 （74.5%)         | 107 82(76.6%)                | 205 155(75.6)            |
|                                                                                                | 25(25.5)              | 25(23.4%)                    | 50(24.4%)                |
| Yes                                                                                            |                       | 89(83.2)                     |                          |
|                                                                                                | (17.3$)               |                              |                          |
| Liver Metastases at Baseline n                                                                 | 17 98 81 （82.7$)      | 18(16.8) 107                 | 35(17.1$) 205            |
|                                                                                                |                       |                              | 170 (82.9)               |
| Intended Cycles at Induction TxPeriod                                                          |                       | 0                            |                          |
| No                                                                                             | 98 45 （ 45.9$)        |                              | 45 （ 45.9%) 53 （54.1)    |
| n 4 Cycles                                                                                     |                       |                              | 98                       |
| 6Cycles                                                                                        | 53 （54.1)             | 0 0                          |                          |

ALK positive = ALK translocation,

Table 19 Baseline Disease Characteristics

|                                 | TC3 or IC3 WT   | TC3 or IC3 WT   | TC1/2/3 or IC1/2/3-WT   | TC1/2/3 or IC1/2/3-WT   |
|---------------------------------|-----------------|-----------------|-------------------------|-------------------------|
|                                 | Chemotherapy    | Atezolizumab    | Chemotherapy            | Atezolizumab            |
| Liver metastases at enrollment  | 98              | 107             | 277                     | 277                     |
| Yes                             | 17 (17.3%)      | 18 (16.8%)      | 40 (14.4%)              | 47 (17.0%)              |
| No                              | 81 (82.7%)      | 89 (83.2%)      | 237 (85.6%)             | 230 (83.0%)             |
| Brain metastases at enrollment* | 98              | 107             | 277                     | 277                     |
| Yes                             | 11 (11.2%)      | 11 (10.3%)      | 26 (9.4%)               | 27 (9.7%)               |

<div style=\"page-break-after: always\"></div>

| No                                    | 87 (88.8%)   | 96 (89.7%)   | 251 (90.6%)   | 250 (90.3%)   |
|---------------------------------------|--------------|--------------|---------------|---------------|
| Histology at Initial Diagnosis (eCRF) | 98           | 107          | 277           | 277           |
| Squamous                              | 23 (23.5%)   | 27 (25.2%)   | 84 (30.3%)    | 85 (30.7%)    |
| Non-squamous                          | 75 (76.5%)   | 80 (74.8%)   | 193 (69.7%)   | 192 (69.3%)   |

*% is calculated manually.

```
Patients receiving Femetrewed, Tc3 or Ic3, Intent-to-Treat Patients, Wild Iype Prot0c6l:G029431 PemetremedPatients (N=70) Pemetrewedl Es Neintenence n 70 Yes 39(55.71) No 31(44.38] H39g butar4Toue6 8 4a74 6quegaed 6ugpnlowe 6uorelndod ane 6quegaea 2dlg PtrM qes1 o9 queau1 mtation or Alk translocation. Data Entraction Date - 31AuG20l9 : Data Cutoff Date - 10sEP2018.
```

Table 20: Summary of patients who received pemetrexed (TC3 or IC3-WT population)

## Numbers analysed

The ITT population consisted of 572 patients with Stage IV non-squamous or squamous NSCLC randomized into the study (287 chemotherapy vs. 285 atezolizumab). The TC1/2/3 or IC1/2/3-WT population (n = 554) excluded patients whose tumours harboured sensitizing EGFR mutations (14 patients) or ALK translocations (4 patients). The targeted population for the applied indication i.e. the TC3 or IC3-WT population comprised 205 randomized patients (98 chemotherapy vs. 107 atezolizumab).

## Outcomes and estimation

Primary endpoint: Overall survival

Table 9: Overall survival (TC3 or IC3-WT population)

|                                               | Interim Analysis (CCOD 10 September 2018)   | Interim Analysis (CCOD 10 September 2018)   | Updated Analysis** (CCOD 4 February 2020)   | Updated Analysis** (CCOD 4 February 2020)   |
|-----------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|
| Parameter                                     | Chemotherapy                                | Atezolizumab                                | Chemotherapy                                | Atezolizumab                                |
| Primary Endpoint: Overall Survival            | Primary Endpoint: Overall Survival          | Primary Endpoint: Overall Survival          | Primary Endpoint: Overall Survival          | Primary Endpoint: Overall Survival          |
|                                               | n = 98                                      | n = 107                                     | n = 98                                      | n = 107                                     |
| Patients with event (%)                       | 57 (58.2%)                                  | 44 (41.1%)                                  | 64 (65.3%)                                  | 64 (59.8%)                                  |
| Median duration of survival (95% CI) (months) | 13.1 (7.4, 16.5)                            | 20.2 (16.5, NE)                             | 14.7 (7.4, 17.7)                            | 20.2 (17.2, 27.9)                           |
| Stratified Hazard Ratio (95% CI)              | 0.595 (0.398, 0.890)                        |                                             | 0.764 (0.536, 1.087)                        | 0.764 (0.536, 1.087)                        |
| p-value (Stratified log-rank)                 | 0.0106                                      |                                             | 0.1338*                                     |                                             |
| 12-month OS rate                              | 50.6%                                       | 64.9%                                       | 52.3%                                       | 66.1%                                       |
| 24-month OS rate                              | 24.8%                                       | 45.5%                                       | 34.1%                                       | 47.1%                                       |

<div style=\"page-break-after: always\"></div>

<!-- image -->

DataExtractionDate-31AUG2019:DataCutoffDate-10SEP2018.

Figure 2: KM Plot of OS with Stratified Analysis (TC3 or IC3-WT Population) CCOD: 10 September 2018

Figure 3: KM Plot of OS with Stratified Analysis (TC3 or IC3-WT Population) CCOD: 4 February 2020

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Secondary endpoints

## - Progression free survival

Table 10: Progression free survival (TC3 or IC3-WT Population)

|                                              | Interim Analysis (CCOD 10 September 2018)   | Interim Analysis (CCOD 10 September 2018)   | Updated Analysis* (CCOD 4 February 2020)   | Updated Analysis* (CCOD 4 February 2020)   |
|----------------------------------------------|---------------------------------------------|---------------------------------------------|--------------------------------------------|--------------------------------------------|
| Parameter                                    | Chemotherapy                                | Atezolizumab                                | Chemotherapy                               | Atezolizumab                               |
| Secondary Endpoints                          |                                             |                                             |                                            |                                            |
| Progression-Free Survival                    |                                             |                                             |                                            |                                            |
|                                              | n = 98                                      | n = 107                                     | n = 98                                     | n = 107                                    |
| Patients with event (%)                      | 79 (80.6%)                                  | 67 (62.6%)                                  | 87 (88.8%)                                 | 82 (76.6%)                                 |
| Median duration of INV-PFS (95% CI) (months) | 5.0 (4.2, 5.7)                              | 8.1 (6.8, 11.0)                             | 5.0 (4.2, 5.7)                             | 8.2 (6.8, 11.4)                            |
| Stratified Hazard Ratio (95% CI)             | 0.630 (0.449, 0.884)                        | 0.630 (0.449, 0.884)                        | 0.592 (0.432, 0.812)                       | 0.592 (0.432, 0.812)                       |
| 12-month PFS rate                            | 21.6%                                       | 36.9%                                       | 19.2%                                      | 39.2%                                      |

CCOD = clinical cutoff date; CI = confidence interval; NE = Not estimable; INV-PFS = investigator assessed-progression free survival; WT = wild-type.

* exploratory analysis for the TC3 or IC3-WT Population at this cut-off date.

Figure 4: KM Plot for PFS in the TC3 or IC3-WT Population - CCOD: 10 September 2018

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 5: KM Plot of PFS in the TC3 or IC3-WT Population - CCOD: 4 February 2020

<!-- image -->

Table 11: Landmark PFS-INV analysis at 6 and 12 months (TC3 or IC3-WT population) - CCOD: 10 September 2018

<!-- image -->

<div style=\"page-break-after: always\"></div>

## - Objective response rate/Duration of response

Table 12: Objective response rate/Duration of response (TC3 or IC3-WT Population)

|                                     | Interim Analysis (CCOD 10 September 2018)   | Interim Analysis (CCOD 10 September 2018)   | Updated Analysis* (CCOD 4 February 2020)   | Updated Analysis* (CCOD 4 February 2020)   |
|-------------------------------------|---------------------------------------------|---------------------------------------------|--------------------------------------------|--------------------------------------------|
| Parameter                           | Chemotherapy                                | Atezolizumab                                | Chemotherapy                               | Atezolizumab                               |
| Secondary Endpoints                 |                                             |                                             |                                            |                                            |
| Objective Response Rate (confirmed) |                                             |                                             |                                            |                                            |
|                                     | n = 98                                      | n = 107                                     | n = 98                                     | n = 107                                    |
| ORR (%)                             | 28 (28.6%)                                  | 41 (38.3%)                                  | 28 (28.6%)                                 | 43 (40.2%)                                 |
| (95% CI)                            | (19.90, 38.58)                              | (29.08, 48.22)                              | (19.90, 38.58)                             | (30.82, 50.11)                             |
| Duration of Response (confirmed)    |                                             |                                             |                                            |                                            |
|                                     | n = 28                                      | n = 41                                      | n = 28                                     | n = 43                                     |
| Median DOR (months)                 | 6.7                                         | NE                                          | 8.3                                        | 38.9                                       |
| (95% CI)                            | (5.5, 17.3)                                 | (11.8, NE)                                  | (5.6, 11.0)                                | (16.1, NE)                                 |

CCOD = clinical cutoff date; CI = confidence interval; DOR = duration of response; NE = Not estimable; OS = overall survival; INVPFS = investigator assessed-progression free survival; WT = wild-type.

* exploratory analysis for the TC3 or IC3-WT Population at this cut-off date.

Table 13: Best overall confirmed response rate (TC3 or IC3-WT population) - CCOD: 10 September 2018

BL-Investigator,Intent-to-Treat Patients, Wild Type Protoco1:G029431

|                                                                                                             | Chemotherapy (N=98)         | Atezolizumab (N=107)           |
|-------------------------------------------------------------------------------------------------------------|-----------------------------|--------------------------------|
| Responders Non-Responders                                                                                   | 8 9:8                       | 器结 :瘤                          |
| 95& CI for Response Rate (Clopper-Pearson) Difference in Response Rates                                     | (19.90, 38.58)              | (29.08, 48.22) 9.75            |
| 95& CI for Difference in Response Rates (Wald with Continuity Correction) p-Value*(Cochran-Mantel-Haenszel) |                             | (-4.07,23.56) 0.1458           |
| Odds Ratio* 958CIfor OddsRatio*                                                                             |                             | 1.55 (0.86, 2.79)              |
| Complete Response (CR) 958CI Partial Response (PR)                                                          |                             | 1(0.98) (0.02, 5.10) 40(37.48) |
| 958CI                                                                                                       | 27.(27.68) (19.01, 37.50)   | (28.22,47.26)                  |
| Stable Disease (SD) 958 CI                                                                                  | 34 (34.7%) (25.36, 44.98)   | 37(34.68) (25.65, 44.39)       |
| Progressive Disease (PD) 958 CI                                                                             | 17. (17.38) (10.44,26.31) 0 | 15 (14.0%) (8.06, 22.07) 0     |
| Non-CR / Non-PD 958CI                                                                                       | (0.00, 3.69)                | (0.00, 3.39)                   |
| Missing or unevaluable                                                                                      | 19 (19.48)                  | 14 (13.18)                     |

Table 14: Summary of DOR (TC3 or IC3-WT patients with a  confirmed response per RECIST v1.1) CCOD: 10 September 2018

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Patient-Reported Outcomes (PRO)

PRO  questionnaire  completion  rates  were  high  at  baseline  for  the  EORTC  QLQ-LC13  and  QLQ-C30 (&gt;80%), but low for the SILC (50-60%) for both arms.

Table 15: Baseline patient-reported outcome scores for TC3 or IC3-WT population - CCOD: 10 September 2018

|                             | Chemotherapy (86 = N)   | Atezolizumab (N = 107)   |
|-----------------------------|-------------------------|--------------------------|
|                             | Mean scores (SD)        | Mean scores (SD)         |
|                             | n =52                   | n =61                    |
| SILC scales                 |                         |                          |
| Cough                       | 1.15 (1.00)             | 1.44 (1.03)              |
| Dyspnoea                    | 1.12 (1.01)             | 1.08 (1.00)              |
| Chest Pain                  | 0.78 (1.02)             | 0.82 (0.93)              |
| SelectEORTCQLQ-LC13scales   | n=83                    | n=95                     |
| Coughing                    | 29.32 (25.18)           | 36.14 (24.63)            |
| Pain in chest               | 15.26 (25.13)           | 20.00 (23.52)            |
| Dyspnoea                    | 25.03 (23.46)           | 23.98 (24.27)            |
| Pain in arm or shoulder     | 16.87 (29.62)           | 18.25 (27.40)            |
| Select EORTC QLQ-C30 scales | n=84                    | n=96                     |
| Fatigue                     | 32.67 (23.16)           | 36.81 (25.30)            |
| Appetite loss               | 22.62 (29.80)           | 25.69 (30.77)            |
| Physical functioning        | 75.08 (19.45)           | 74.24 (21.88)            |
| Role functioning            | 70.83 (28.79)           | 72.05 (29.76)            |
| Social functioning          | 79.56 (23.62)           | 76.91 (25.63)            |
| Emotional functioning       | 77.98 (17.72)           | 73.52 (24.18)            |
| Cognitive functioning       | 85.71 (18.32)           | 86.11 (17.72)            |
| Global healthstatusorHRQoL  | 59.92 (21.51)           | 62.76 (20.09)            |

<div style=\"page-break-after: always\"></div>

## Ancillary analyses

## Sensitivity analyses for OS

Table 16: Analysis of OS discounting for NPT with 10, 20, or 30% benefit reduction (TC3 or IC3-WT population) - CCOD: 10 September 2018

<!-- image -->

Cl=confidence interval; HR=hazard ratio; NE=not estimable; OS=overall survival; WT=wild-type

p-value is descriptive only

Table 17: Sensitivity Analyses for Overall Survival Based on 'Replacement Approach' to Define PD-L1 Status - CCOD: 10 September 2018

| Key Analysis Population Stratified HR (95%CI) p-value   | Primary Analysis for OS                       | Sensitivity Analysis based on 'Replacement Approach'   |
|---------------------------------------------------------|-----------------------------------------------|--------------------------------------------------------|
| N TC3 or IC3-WT IA boundary**: α = 0.0413               | n = 205 0.595 (0.398, 0.890) p-value = 0.0106 | n = 206 0.606 (0.407, 0.902) p-value = 0.0128*         |
| N TC2/3 or IC2/3-WT                                     | n = 328 0.717 (0.520,                         | n = 329 0.714 (0.517, 0.986)                           |
| IA boundary**: α = 0.0400                               | p-value = 0.0416                              | p-value = 0.0400* n = 540 0.836 (0.650, 1.074)         |
|                                                         | 0.989)                                        |                                                        |
| N                                                       | n = 554                                       |                                                        |
| TC1/2/3 or IC1/2/3-WT                                   | 0.832 (0.649, 1.067)                          |                                                        |
| IA boundary**: α = 0.0374                               | p-value = 0.1481*                             | p-value = 0.1605*                                      |

Table 18: Sensitivity Analyses for Overall Survival Based on 'Exclusion Approach' to Define PD-L1 Status - CCOD: 10 September 2018

| Key Analysis Population Stratified HR (95%CI) p-value   | Primary Analysis for OS                        | Sensitivity Analysis Based on 'Exclusion Approach'   |
|---------------------------------------------------------|------------------------------------------------|------------------------------------------------------|
| N TC3 or IC3-WT IA boundary**: α= 0.0413                | n = 205 0.595 (0.398, 0.890) p-value = 0.0106  | n = 183 0.596 (0.391, 0.908) p-value = 0.0149*       |
| N TC2/3 or IC2/3-WT IA boundary**: α= 0.0400            | n = 328 0.717 (0.520, 0.989) p-value = 0.0416  | n = 289 0.736 (0.524, 1.035) p-value = 0.0773*       |
| N TC1/2/3 or IC1/2/3-WT IA boundary**: α= 0.0374        | n = 554 0.832 (0.649, 1.067) p-value = 0.1481* | n = 452 0.824 (0.628, 1.081) p-value = 0.1623*       |

<div style=\"page-break-after: always\"></div>

## Subgroup analyses of OS and PFS

|                      |         | Chemotherapy (86=N)   | Chemotherapy (86=N)   | Chemotherapy (86=N)   | Atezolizumab (N=107)   | Atezolizumab (N=107)   | Atezolizumab (N=107)   |              |             |                     |                     |
|----------------------|---------|-----------------------|-----------------------|-----------------------|------------------------|------------------------|------------------------|--------------|-------------|---------------------|---------------------|
| Subgroups            | Total n | n                     | Events                | Median (Months)       | n                      | Events                 | Median (Months)        | Hazard Ratio | 95%Wald CI  | Atezolizumab better | Chemotherapy better |
| AllPatients          | 205     | 98                    | 57                    | 13.1                  | 107                    | 44                     | 20.2                   | 0.60         | (0.40.0.89) |                     |                     |
| AgeGroup4Categories  |         |                       |                       |                       |                        |                        |                        |              |             |                     |                     |
| <65                  | 102     | 43                    | 26                    | 13.1                  | 59                     |                        | NE                     | 0.59         | (0.34.1.04) |                     |                     |
| 65to74               |         | 47                    |                       | 10.4                  | 3                      | 25                     | 17.8                   | 0.63         | (0.34.1.19) |                     |                     |
| 75to84               |         | 7                     |                       | 16.2                  |                        | 4                      | NE                     | 1.04         | (0.19.5.70) |                     |                     |
| S8=<                 | 1       | 1                     |                       | 8.8                   |                        |                        |                        | NE           | (NE,NE)     |                     |                     |
| SexfromeCRF          |         |                       |                       |                       |                        |                        |                        |              |             |                     |                     |
| Male                 | 143     |                       |                       | 13.1                  |                        |                        | 23.8                   | 0.57         | (0.35.0.93) |                     |                     |
| Female               | 62      | S4                    | 38                    | 14.1                  | 728                    | 33                     |                        | 0.69         | (0.34.1.39) |                     |                     |
| SexfromIxRS          |         |                       |                       |                       |                        |                        |                        |              |             |                     |                     |
| Male                 | 143     | S4                    | 38                    | 13.1                  | Z                      | 33                     |                        | 0.57         | (0.35.0.93) |                     |                     |
| Female               | 62      |                       |                       | 14.1                  |                        |                        |                        | 0.69         | (0.34.1.39) |                     |                     |
| Race                 |         |                       |                       |                       |                        |                        |                        |              |             |                     |                     |
| Asian                | 35      |                       | 9                     | 14.1                  |                        |                        | NE                     | 0.38         | (0.13.1.13) |                     |                     |
| White                | 169     | 1581                  | 47                    | 13.1                  |                        |                        | 17.8                   | 0.67         | (0.44.1.03) |                     |                     |
| Unknown              | 1       |                       | 1                     | 4.6                   |                        |                        |                        | NE           | (NE.NE)     |                     |                     |
| Ethnicity            |         |                       |                       |                       |                        |                        |                        |              |             |                     |                     |
| Hispanic or Latino   | 14      | 5                     | 4                     | 16.5                  | 9                      | 42                     | NE                     | 0.39         | (0.06.2.39) |                     |                     |
| NotHispanic orLatino | 189     | 91                    | 52                    | 13.1                  | 98                     |                        | 20.2                   | 0.61         | (0.41,0.93) |                     |                     |
| Notreported          | 2       | 2                     | 1                     | NE                    |                        |                        |                        | NE           | (NE,NE)     |                     |                     |
| TobaccoUseHistory    |         |                       |                       |                       |                        |                        |                        |              |             |                     |                     |
| Never                |         |                       |                       | 182                   |                        |                        |                        |              | (0.63.5.31) |                     |                     |
| Current              | 2#      |                       | 988                   |                       |                        | 66                     |                        |              | (0.14.0.88) |                     |                     |
| Previous             | 132     |                       | 30                    | 13.1                  | 92018                  | 32                     | 23.1                   | 0.60         | (0.36.1.00) |                     |                     |

|                             |       | Chemotherapy (N=98)   | Chemotherapy (N=98)   | Chemotherapy (N=98)   | Atezolizumab (N=107)   | Atezolizumab (N=107)   | Atezolizumab (N=107)   |              |             |                     |                     |
|-----------------------------|-------|-----------------------|-----------------------|-----------------------|------------------------|------------------------|------------------------|--------------|-------------|---------------------|---------------------|
| Subgroups                   | Total | n                     | Events                | Median (Months)       | n                      | Events                 | Median (Months)        | Hazard Ratio | PIPM%S6 CI  | Atezolizumab better | Chemotherapy better |
| AllPatients                 | 205   | 98                    | 57                    | 13.1                  | 107                    | 44                     | 20.2                   | 0.60         | (0.40,0.89) |                     |                     |
| BaselineECoGfromeCRF        |       |                       |                       |                       |                        |                        |                        |              |             |                     |                     |
| 0                           | 73    | 38                    | 19                    | 15.7                  | 35                     | 10                     | NE                     | 0.42         | (0.20,0.92) |                     |                     |
| 1                           | 132   | 60                    | 38                    | 13.1                  | 72                     | 34                     | 16.5                   | 0.69         | (0.43.1.10) |                     |                     |
| ECOGPSfromlxRS              |       |                       |                       |                       |                        |                        |                        |              |             |                     |                     |
| 01                          | 71    |                       | 19                    | 15.7                  |                        | 37                     |                        | 0.31         | (0.13.0.73) |                     |                     |
|                             | 134   |                       |                       | 13.1                  | 34                     |                        | 16.5                   | 0.73         | (0.46,1.15) |                     |                     |
| Pathology/HistologyfromeCRF |       |                       |                       |                       |                        |                        |                        |              |             |                     |                     |
| Squamous                    |       | 2号                    | 143                   | 15.3                  | 20                     | 8                      | NE                     | 0.56         | (0.23.1.37) |                     |                     |
| Non-squamous                | 155   |                       |                       | 10.5                  |                        | 36                     | 20.2                   | 0.62         | (0.40,0.96) |                     |                     |
| Pathology/HistologyfromxRS  |       |                       |                       |                       |                        |                        |                        |              |             |                     |                     |
| Squamous                    | 49    |                       |                       | 15.3                  |                        | 8                      | NE                     | 0.60         | (0.24,1.47) |                     |                     |
| Non-squamous                | 156   | 2号                    |                       | 10.5                  | 26                     | 36                     | 20.2                   | 0.61         | (0.39.0.94) |                     |                     |

NE=Notestimable;MedianSurvivalwasestimatedfromKaplan-Meiermethod.Unstratifiedhazardratiorelativeto Chemotherapyand95%ClforthehazardratiowereestimatedusingCoxregression.Theverticaldashedlineindicates thehazardratioforallpatients.Thediameterofthecircleisproportionaltothesquarerootofthetotalnumberofevents. Randomizedtreatmentsaredisplayed.

IntenttoTreatWildTypePatientsarepopulationsexcludingpatientswithasensitizingEGFRmutationorALKtranslocation. DataExtractionDate-31AUG2019:DataCutoffDate-10SEP2018.

## Figure 6: Subgroup analysis of OS by selected demographics and baseline disease characteristics (TC3 or IC3-WT population) - CCOD: 10 September 2018

<div style=\"page-break-after: always\"></div>

|                       |         | Chemotherapy (N=98)   | Chemotherapy (N=98)   | Chemotherapy (N=98)   | Atezolizumab (N=107)   | Atezolizumab (N=107)   | Atezolizumab (N=107)   |              |             |     |                     |                     |
|-----------------------|---------|-----------------------|-----------------------|-----------------------|------------------------|------------------------|------------------------|--------------|-------------|-----|---------------------|---------------------|
| Subgroups             | Total n | n                     | Events                | Median (Months)       | n                      | Events                 | Median (Months)        | Hazard Ratio | 95%Wald CI  |     | Atezolizumab better | Chemotherapy better |
| AllPatients           | 205     | 98                    | 79                    | 5.0                   | 107                    | 67                     | 8.1                    | 0.59         | (0.43.0.82) |     |                     |                     |
| AgeGroup4Categories   |         |                       |                       |                       |                        |                        |                        |              |             |     |                     |                     |
| <65                   | 102     |                       | 3                     |                       | 9315                   |                        | 7.3                    | 0.68         | (0.42.1.10) |     |                     |                     |
| 65to74                |         | #                     |                       |                       |                        | 7210                   | 8.1                    |              | (0.29.0.06) |     |                     |                     |
| 75to84                |         | 7                     | 4                     |                       |                        |                        | 8.2                    | 0.97         | (0.30,3.10) |     |                     |                     |
| >=85                  | 1       | 1                     | 1                     | 8.2                   |                        |                        |                        | NE           | (NE.NE)     |     |                     |                     |
| SexfromeCRF           |         |                       |                       |                       |                        |                        |                        |              |             |     |                     |                     |
| Male                  | 143     |                       | 5.28                  | 4.7                   |                        |                        | 7.3                    | 0.55         | (0.37.0.83) |     |                     |                     |
| Female                | 62      | 34                    |                       | 5.6                   | 78                     | 46                     |                        | 0.78         | (0.44.1.40) |     |                     |                     |
| SexfromIxRS           |         |                       |                       |                       |                        |                        |                        |              |             |     |                     |                     |
| Male                  | 143     | 64                    |                       | 4.7                   | 28                     | 46                     | 3                      | 0.55         | (0.37,0.83) |     |                     |                     |
| Female                | 62      | 34                    |                       | 5.6                   |                        | 21                     |                        | 0.78         | (0.44.1.40) |     |                     |                     |
| Race                  |         |                       |                       |                       |                        |                        |                        |              |             |     |                     |                     |
| Asian                 | 35      |                       | 14                    | 5.5                   |                        | 7                      | NE                     | 0.27         | (0.11.0.66) |     |                     |                     |
| White                 | 169     | 1                     |                       | 4.9                   |                        | 60                     | 7.2                    | 0.71         | (0.50.1.01) |     |                     |                     |
| Unknown               |         | 1                     | 1                     | 4.6                   |                        |                        |                        | NE           | (NE.NE)     |     |                     |                     |
| Ethnicity             |         |                       |                       |                       |                        |                        |                        |              |             |     |                     |                     |
| Hispanicor Latino     | 14      |                       | 4                     | 5.7                   | 9                      | 4                      | 8.7                    | 0.46         | (0.10.2.06) |     |                     |                     |
| Not Hispanicor Latino | 189     |                       | 74                    | 4.9                   | 98                     | 63                     | 7.7                    | 0.59         | (0.42.0.83) |     |                     |                     |
| Notreported           | 2       | 2                     | 1                     | NE                    |                        |                        |                        | NE           | (NE.NE)     |     |                     |                     |
| Tobacco Use History   |         |                       |                       |                       |                        |                        |                        |              |             |     |                     |                     |
| Never                 |         |                       |                       |                       |                        |                        |                        | 1.80         | (0.69.4.71) |     |                     |                     |
| Current               | 2       |                       |                       |                       | 92018                  | 12                     |                        | 850          | (0.28.1.18) |     |                     |                     |
| Previous              | 132     | 1524                  | 1424                  |                       |                        |                        |                        |              | (0.35.0.83) |     |                     |                     |
|                       |         |                       |                       | 4.7                   |                        |                        | 8.2                    | 0.54         |             |     |                     |                     |
|                       |         |                       |                       |                       |                        |                        |                        |              | 1/5         | 1/2 |                     | 2                   |

|                             |         | Chemotherapy (N=98)   | Chemotherapy (N=98)   | Chemotherapy (N=98)   | Atezolizumab (N=107)   | Atezolizumab (N=107)   | Atezolizumab (N=107)   |              |                         |                     |                     |
|-----------------------------|---------|-----------------------|-----------------------|-----------------------|------------------------|------------------------|------------------------|--------------|-------------------------|---------------------|---------------------|
| Subgroups                   | Total n | n                     | Events                | Median (Months)       | n                      | Events                 | Median (Months)        | Hazard Ratio | 95%Wald CI              | Atezolizumab better | Chemotherapy better |
| AllPatients                 | 205     | 98                    | 79                    | 5.0                   | 107                    | 67                     | 8.1                    | 0.59         | (0.43.0.82)             |                     |                     |
| BaselineECOGfromeCRF        |         |                       |                       |                       |                        |                        |                        |              |                         |                     |                     |
|                             | 73      | 38                    | 31                    | 5.0                   | 35                     | 20                     | 9.5                    | 0.46         | (0.26,0.82)             |                     |                     |
| 1                           | 132     | 60                    | 48                    | 5.0                   | 72                     | 47                     | 72                     | 0.66         | (0.44.1.00)             |                     |                     |
| ECOGPSfromIxRS              |         |                       |                       |                       |                        |                        |                        |              |                         |                     |                     |
| 0 1                         | 71 134  | 38 09                 | 31 48                 | 5.0                   | 34                     | 18 49                  | 2                      | 0.43 0.67    | (0.23.0.77) (0.45.1.01) |                     |                     |
| Pathology/HistologyfromeCRF |         |                       |                       |                       |                        |                        |                        |              |                         |                     |                     |
| Squamous Non-squamous       | 155     | 号                     | 198                   | 5.5 4.9               | 2                      | 29                     |                        | 0.67 0.55    | (0.36.1.28) (0.37.0.81) |                     |                     |
| Pathology/HistologyfromIxRS |         |                       |                       |                       |                        |                        |                        |              |                         |                     |                     |
| Squamous                    | 49      |                       |                       | 5.5                   |                        | 19                     | 72                     | 0.64         | (0.33.1.22)             |                     |                     |
| Non-squamous                | 156     | 2号                    | 198                   | 4.9                   | 208                    | 48                     | 8.1                    | 0.56         | (0.38,0.83)             |                     |                     |

|                                           |         | (N=98)   | (N=98)   | (N=98)          | Atezolizumab (N=107)   | Atezolizumab (N=107)   | Atezolizumab (N=107)   |              |                         |                     |                     |
|-------------------------------------------|---------|----------|----------|-----------------|------------------------|------------------------|------------------------|--------------|-------------------------|---------------------|---------------------|
| Subgroups                                 | Total n | n        | Events   | Median (Months) | n                      | Events                 | Median (Months)        | Hazard Ratio | 95%Wald CI              | Atezolizumab better | Chemotherapy better |
| AllPatients                               | 205     | 98       | 79       | 5.0             | 107                    | 67                     | 8.1                    | 0.59         | (0.43.0.82)             |                     |                     |
| Lung Metastasis atEnrollment Yes No       | 175     | 87       | 6        | 5.4             | 8                      |                        | 8.1                    | 0.62         | (0.43.0.88) (0.18,1.09) |                     |                     |
| LiverMetastasisatEnrollment Yes No        | 1725    | 17 81    | 14 65    | 55              | 18 68                  | 13 54                  | 2                      | 0.86 0.55    | (0.39.1.87) (0.38,0.80) |                     |                     |
| LymphNodeMetastasis at Enrollment Yes No  | 149 56  |          | 50       | 5.1             | 789                    | 50                     | 73                     | 0.59 090     | (0.41,0.87) (0.30.1.17) |                     |                     |
| AdrenalGlandMetastasisatEnrollment Yes No | 146     |          | 39       |                 | 22                     | 21                     | .9                     | 0.98         | (0.47,1.47) (0.37.0.84) |                     |                     |
| Brain MetastasisatEnrollment Yes No       | 假       |          |          | #               | 16                     | 59                     |                        | 0.98         | (8.37. .58)             |                     |                     |
| BoneMetastasisatEnrollment Yes No         | 1       | 4        | 18       |                 | 6                      | 9                      | .9                     | .58          | (0.26.1.23) (0.42,0.87) |                     |                     |
| MetastaticSitesCategoryatEnrollment 3 >=3 | 69 136  | 28       |          | 7.0 4.1         | 41 66                  | 20 47                  | 11.4 6.8               | 0.56 0.63    | (0.30.1.04) (0.43.0.93) |                     |                     |
| Sumof LongestDiameteratBaseline >=86 <86  | 115 90  | 32       | 28       | 7.2             | 543                    | 22                     | 15.0 5.5               | 0.71 0.50    | (0.47,1.09) (0.29.0.87) |                     |                     |

NE=Notestimable;MedianProgression-FreeSurvivalwasestimatedfromKaplan-Meiermethod.Unstratified hazardratiorelativeto Chemotherapyand95%CiforthehazardratiowereestimatedusingCoxregression.Theverticaldashedlineindicates

thehazardratioforallpatients.Thediameterofthecircleisproportionaltothesquarerootof thetotalnumberofevents. Randomizedtreatmentsaredisplayed. IntenttoTreatWildTypePatientsarepopulationsexcludingpatientswithasensitizingEGFRmutationorALKtranslocation.

DataExtractionDate-31AUG2019;DataCutoffDate-10SEP2018.

<div style=\"page-break-after: always\"></div>

Figure 7: Subgroup analysis of PFS by selected demographics and baseline disease characteristics (TC3 or IC3-WT population) - CCOD: 10 September 2018

## Efficacy by PD-L1 Status (SP263 and 22c3 Assays) and bTMB Status

Pre-specified OS and PFS-INV subgroup analyses using the SP263 and 22C3 assays as well as bTMB were conducted within the enrolled SP142-selected TC1/2/3 or IC1/2/3-WT patients.  OS and PFS improvement with atezolizumab treatment was observed in PD-L1-high patients (TC ≥ 50% for SP263 and TPS ≥ 50% for 22C3; Table 5.4.13) using both SP263 and 22c3 assays.  Likewise, an improvement in OS and PFS was observed in high bTMB (≥ 16) patients treated with atezolizumab compared with chemotherapy .

Alternative, validated PD-L1 IHC assays (SP263 and 22C3) were used to define PD-L1 subgroups based on PD-L1 expression specifically on TCs.

Within the IMpower110 enrolled WT population (TC1/2/3 or IC1/2/3-WT; N=554), 54% of patients had tumors with SP263 ≥ 50% TC expression and 49% of patients had tumors with 22C3 ≥ 50% TPS compared to 39% as selected with SP142-assay.  In these two PD-L1 high subgroups, improvements in OS and PFS were observed in the atezolizumab arm compared with the chemotherapy arm (Table 31). Both TC specific PD-L1 IHC assays identify a broader patient population compared to SP142 TC3 or IC3.

Table 19: OS and PFS by High PD-L1 Expression Subgroups (Defined by the SP263 and 22C3 Assays) and bTMB Subgroup (TC1/2/3 or IC1/2/3 WT Population)

|                                                                           | OS                                                                        | OS                                                                        | OS                                                                        | OS                                                                        | OS                                                                        | PFS                                                                       | PFS                                                                       | PFS                                                                       | PFS                                                                       | PFS                                                                       |
|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|
| Subgroup                                                                  | Atezolizumab                                                              | Atezolizumab                                                              | Chemotherapy                                                              | Chemotherapy                                                              | HR c 95% CI                                                               | Atezolizumab                                                              | Atezolizumab                                                              | Chemotherapy                                                              | Chemotherapy                                                              | HR c 95% CI                                                               |
|                                                                           | n                                                                         | Median (Months)                                                           | n                                                                         | Median (Months)                                                           | HR c 95% CI                                                               | N                                                                         | Median (Months)                                                           | n                                                                         | Median (Months)                                                           | HR c 95% CI                                                               |
| PD-L1 Subgroups Defined by the VENTANA SP142 Assay (BEP, n = 554)         | PD-L1 Subgroups Defined by the VENTANA SP142 Assay (BEP, n = 554)         | PD-L1 Subgroups Defined by the VENTANA SP142 Assay (BEP, n = 554)         | PD-L1 Subgroups Defined by the VENTANA SP142 Assay (BEP, n = 554)         | PD-L1 Subgroups Defined by the VENTANA SP142 Assay (BEP, n = 554)         | PD-L1 Subgroups Defined by the VENTANA SP142 Assay (BEP, n = 554)         | PD-L1 Subgroups Defined by the VENTANA SP142 Assay (BEP, n = 554)         | PD-L1 Subgroups Defined by the VENTANA SP142 Assay (BEP, n = 554)         | PD-L1 Subgroups Defined by the VENTANA SP142 Assay (BEP, n = 554)         | PD-L1 Subgroups Defined by the VENTANA SP142 Assay (BEP, n = 554)         | PD-L1 Subgroups Defined by the VENTANA SP142 Assay (BEP, n = 554)         |
| ITT (TC1/2/3 or IC1/2/3) WT a                                             | 277                                                                       | 17.5                                                                      | 277                                                                       | 14.1                                                                      | 0.83 (0.65, 1.07)                                                         | 277                                                                       | 5.7                                                                       | 277                                                                       | 5.5                                                                       | 0.77 (0.63, 0.94)                                                         |
| TC3 or IC3 WT b                                                           | 107                                                                       | 20.2                                                                      | 98                                                                        | 13.1                                                                      | 0.59 (0.40, 0.89)                                                         | 107                                                                       | 8.1                                                                       | 98                                                                        | 5.0                                                                       | 0.63 (0.45, 0.88)                                                         |
| PD-L1 Subgroups Defined by the Dako 22C3 Assay (BEP, n = 534 d )          | PD-L1 Subgroups Defined by the Dako 22C3 Assay (BEP, n = 534 d )          | PD-L1 Subgroups Defined by the Dako 22C3 Assay (BEP, n = 534 d )          | PD-L1 Subgroups Defined by the Dako 22C3 Assay (BEP, n = 534 d )          | PD-L1 Subgroups Defined by the Dako 22C3 Assay (BEP, n = 534 d )          | PD-L1 Subgroups Defined by the Dako 22C3 Assay (BEP, n = 534 d )          | PD-L1 Subgroups Defined by the Dako 22C3 Assay (BEP, n = 534 d )          | PD-L1 Subgroups Defined by the Dako 22C3 Assay (BEP, n = 534 d )          | PD-L1 Subgroups Defined by the Dako 22C3 Assay (BEP, n = 534 d )          | PD-L1 Subgroups Defined by the Dako 22C3 Assay (BEP, n = 534 d )          | PD-L1 Subgroups Defined by the Dako 22C3 Assay (BEP, n = 534 d )          |
| 22C3 BEP                                                                  | 268                                                                       | 17.5                                                                      | 266                                                                       | 14.1                                                                      | 0.82 (0.64, 1.06)                                                         | 268                                                                       | 5.8                                                                       | 266                                                                       | 5.6                                                                       | 0.76 (0.62, 0.93)                                                         |
| TPS ≥ 50%                                                                 | 134                                                                       | 20.2                                                                      | 126                                                                       | 11.0                                                                      | 0.60 (0.42, 0.86)                                                         | 134                                                                       | 7.3                                                                       | 126                                                                       | 5.4                                                                       | 0.61 (0.46, 0.82)                                                         |
| PD-L1 Subgroups Defined by the VENTANA SP263 Assay (BEP, n = 546 d )      | PD-L1 Subgroups Defined by the VENTANA SP263 Assay (BEP, n = 546 d )      | PD-L1 Subgroups Defined by the VENTANA SP263 Assay (BEP, n = 546 d )      | PD-L1 Subgroups Defined by the VENTANA SP263 Assay (BEP, n = 546 d )      | PD-L1 Subgroups Defined by the VENTANA SP263 Assay (BEP, n = 546 d )      | PD-L1 Subgroups Defined by the VENTANA SP263 Assay (BEP, n = 546 d )      | PD-L1 Subgroups Defined by the VENTANA SP263 Assay (BEP, n = 546 d )      | PD-L1 Subgroups Defined by the VENTANA SP263 Assay (BEP, n = 546 d )      | PD-L1 Subgroups Defined by the VENTANA SP263 Assay (BEP, n = 546 d )      | PD-L1 Subgroups Defined by the VENTANA SP263 Assay (BEP, n = 546 d )      | PD-L1 Subgroups Defined by the VENTANA SP263 Assay (BEP, n = 546 d )      |
| SP263 BEP                                                                 | 271                                                                       | 17.2                                                                      | 275                                                                       | 14.9                                                                      | 0.85 (0.66, 1.09)                                                         | 271                                                                       | 5.7                                                                       | 275                                                                       | 5.5                                                                       | 0.77 (0.63, 0.94)                                                         |
| TC ≥ 50%                                                                  | 150                                                                       | 19.5                                                                      | 143                                                                       | 16.1                                                                      | 0.71 (0.50, 1.00)                                                         | 150                                                                       | 7.0                                                                       | 143                                                                       | 4.9                                                                       | 0.67 (0.51, 0.89)                                                         |
| bTMB Subgroups Defined by the Foundation Medicine Assay (BEP, n = 389 d ) | bTMB Subgroups Defined by the Foundation Medicine Assay (BEP, n = 389 d ) | bTMB Subgroups Defined by the Foundation Medicine Assay (BEP, n = 389 d ) | bTMB Subgroups Defined by the Foundation Medicine Assay (BEP, n = 389 d ) | bTMB Subgroups Defined by the Foundation Medicine Assay (BEP, n = 389 d ) | bTMB Subgroups Defined by the Foundation Medicine Assay (BEP, n = 389 d ) | bTMB Subgroups Defined by the Foundation Medicine Assay (BEP, n = 389 d ) | bTMB Subgroups Defined by the Foundation Medicine Assay (BEP, n = 389 d ) | bTMB Subgroups Defined by the Foundation Medicine Assay (BEP, n = 389 d ) | bTMB Subgroups Defined by the Foundation Medicine Assay (BEP, n = 389 d ) | bTMB Subgroups Defined by the Foundation Medicine Assay (BEP, n = 389 d ) |
| bTMB BEP                                                                  | 196                                                                       | 13.3                                                                      | 193                                                                       | 15.3                                                                      | 0.98 (0.74, 1.30)                                                         | 196                                                                       | 5.5                                                                       | 193                                                                       | 5.4                                                                       | 0.88 (0.70, 1.11)                                                         |
| ≥ 16                                                                      | 42                                                                        | 13.9                                                                      | 45                                                                        | 8.5                                                                       | 0.75 (0.41, 1.35)                                                         | 42                                                                        | 6.8                                                                       | 45                                                                        | 4.4                                                                       | 0.55 (0.33, 0.92)                                                         |

BEP = biomarker-evaluable population; bTMB = blood tumor mutation burden; IC = tumor-infiltrating immune cells; PD-L1 = programmed death-ligand 1; TC = tumor cells.

a  TC1/2/3 or IC1/2/3-WT population represents the SP142-enrolled IMpower110 population without EGFR or ALK genetic alterations.

b TC3 or IC3 = TC ≥ 50% or IC ≥ 10% PD -L1.

c  Stratified HRs for SP142 and unstratified HRs for 22C3, SP263 and bTMB.

d  BEP is calculated within the WT population.

<div style=\"page-break-after: always\"></div>

Table 20: PFS-INV by PD-L1 status (SP263 and 22C3 Assays) and bTMB status (TC1/2/3 or IC1/2/3 WT Population)

<!-- image -->

## Early deaths

A higher proportion of patients experienced death within the first 2.5 months in the atezolizumab arm (16/107, 15.0%) as compared to the chemotherapy arm (10/98, 10.2%).

Subgroup Analyses of Efficacy Endpoints by Treatment-Emergent ADA Status

<div style=\"page-break-after: always\"></div>

In  unadjusted  exploratory  analyses,  which  did  not  take  into  account  the  imbalances  in  baseline characteristics between ADA subgroups, for both PFS and OS, the percentage of patients with events was numerically higher for ADA-positive patients, and the median time to event was shorter (Table 33). The proportion of responders was numerically lower in the ADA-positive subgroup compared with ADAnegative.

Table 21: OS, PFS, and ORR by Atezolizumab ADA Status, Atezolizumab ADA-Evaluable Patients in the TC3 or IC3-WT Population

|                                        | AtezolizumabArm   | AtezolizumabArm   |
|----------------------------------------|-------------------|-------------------|
| Efficacy Endpoint                      | ADA- (N=75)       | ADA+ (N=23)       |
| OS                                     |                   |                   |
| Patients with event (%)                | 39 (52.0%)        | 17 (73.9%)        |
| Median time to event - months (95% CI) | 27.1 (20.2, NE)   | 13.8 (4.9, 23.1)  |
| PFS:INV-assessed                       |                   |                   |
| Patientswith event (%)                 | 42 (56.0%)        | 18 (78.3%)        |
| Mediantime toevent - months (95% CI)   | 9.6 (7.7, 17.5)   | 4.5 (2.3, 8.2)    |
| Confirmed ORR                          |                   |                   |
| Responders (%)                         | 34 (45.3%)        | 7 (30.4%)         |
| 95%CI for response rates               | (33.79, 57.25)    | (13.21, 52.92)    |

ADA = anti-drug antibody; CI = confidence interval; INV-PFS = investigator-assessed progression-free survival; NE = not estimable; OS = overall survival.

OS data is per CCOD of 4FEB2020 and ADA status is per CCOD of 10SEP2018.

## Early deaths by ADA status

The MAH submitted a listing of early deaths according to ADA status (data not shown). Overall, there were 44 deaths within the first 5 months after randomization; 21 in the chemotherapy arm vs. 23 in the atezolizumab arm. Of the 23 early deaths in the atezolizumab arm, the ADA status was as follows: 8 ADA-positive (including 4 patients who subsequently tested ADA-negative at later timepoints), 9 ADAnegative, and 6 patients with missing postbaseline ADA results.

## Summary of main study- IMpower110

The following table summarises the efficacy results from the main studies supporting the present application. This summary should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 22: Summary of Efficacy for IMpower110

| Title: IMpower110:   | Title: IMpower110:                                                                                                                                                                                                                      |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier     | GO29431                                                                                                                                                                                                                                 |
| Design               | Phase III, open-label, randomised study of atezolizumab compared with a platinum agent in combination with either pemetrexed or gemcitabine for PD-L1-selected chemotherapy-naïve patients with stage IV non-squamous or squamous NSCLC |
| Design               | Duration of main phase: 31 months Duration of Run-in phase: not applicable Duration of Extension phase: not applicable                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| Hypothesis                                              | Superiority                                                                                   |                   |                                                                                                                                                  |              |                    |
|---------------------------------------------------------|-----------------------------------------------------------------------------------------------|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------------|
| Treatments groups                                       | Atezolizumab monotherapy                                                                      |                   | Atezolizumab 1200 mg Q3W until PD or loss of clinical benefit, number randomized: 107                                                            |              |                    |
|                                                         | Chemotherapy                                                                                  |                   | A platinum agent (cisplatin or carboplatin) in combination with either pemetrexed or gemcitabine treatment for 4-6 cycles, number randomized: 98 |              |                    |
| Endpoints and definitions                               | Primary endpoint                                                                              | OS                | Overall survival in the TC3 or IC3-WT population                                                                                                 |              |                    |
|                                                         | Secondary endpoint                                                                            | PFS-INV           | PFS by investigator in the TC3 or IC3-WT population                                                                                              |              |                    |
|                                                         | Secondary other:                                                                              | ORR, DOR          | Overall response rate, Duration of response                                                                                                      |              |                    |
| Database lock                                           | 10 September 2018                                                                             |                   |                                                                                                                                                  |              |                    |
| Results and Analysis                                    |                                                                                               |                   |                                                                                                                                                  |              |                    |
| Analysis description                                    | Primary Analysis                                                                              |                   |                                                                                                                                                  |              |                    |
| Analysis population and time point description          | The TC3 or IC3-WT population                                                                  |                   |                                                                                                                                                  |              |                    |
| Effect estimate per comparison and estimate variability | Number of                                                                                     | subjects          |                                                                                                                                                  |              |                    |
|                                                         | Treatment group Atezolizumab Chemotherapy Hazard ratio                                        |                   |                                                                                                                                                  |              |                    |
|                                                         | OS (months) 95% CI PFS                                                                        | N=107 20.2        | N=98                                                                                                                                             | 13.1         | 0.59* 0.40; 0.89   |
|                                                         | (months)                                                                                      | 16.5; NE          | 7.4; 16.5                                                                                                                                        | 5.0          | 0.63               |
|                                                         | 95% CI                                                                                        | 8.1 6.8; 11.0     | 4.2;                                                                                                                                             | 5.7 28.6     | 0.45; 0.88         |
|                                                         | ORR confirmed (%) 95% CI                                                                      | 38.3 29.08; 48.22 |                                                                                                                                                  | 19.90; 38.58 | NA                 |
|                                                         | DOR (months 95% CI 6.7                                                                        | NE 11.8; NE       | 5.5;                                                                                                                                             | 17.3         | NA                 |
| Notes                                                   | *The OS KM curves crossed, so the proportional hazard assumption for calculating HR           |                   |                                                                                                                                                  |              |                    |
| Analysis description                                    | was not met. Secondary analysis:                                                              |                   |                                                                                                                                                  |              |                    |
| Analysis population and time point description          | The TC3 or IC3-WT population, updated DCO 4 Feb 2020                                          |                   |                                                                                                                                                  |              |                    |
| Effect estimate per                                     |                                                                                               |                   |                                                                                                                                                  |              |                    |
| comparison and                                          |                                                                                               |                   |                                                                                                                                                  |              |                    |
| estimate variability                                    |                                                                                               |                   |                                                                                                                                                  |              |                    |
|                                                         | group Atezolizumab Chemotherapy Hazard ratio Number of subjects N=107 N=98 OS 20.2 14.7 0.764 |                   |                                                                                                                                                  |              |                    |
|                                                         | (months)                                                                                      |                   |                                                                                                                                                  |              |                    |
|                                                         | Treatment                                                                                     |                   |                                                                                                                                                  |              |                    |
|                                                         | 95% CI 7.4; PFS                                                                               | 16.5; NE 8.2      |                                                                                                                                                  | 17.7 5.0     | 0.536; 1.087 0.592 |
|                                                         | 95% CI                                                                                        | 6.8;              | 11.4                                                                                                                                             | 4.2; 5.7     | 0.432; 0.812       |
|                                                         | ORR (%)                                                                                       | 30.82;            |                                                                                                                                                  | 28.6         | NA                 |
|                                                         | 95% CI                                                                                        |                   | 50.11                                                                                                                                            | 19.90;       |                    |
|                                                         | DOR (months                                                                                   | 38.9              |                                                                                                                                                  | 8.3          |                    |
|                                                         | 95% CI                                                                                        | 16.1; NE          |                                                                                                                                                  | 5.6; 11.0    |                    |
|                                                         |                                                                                               |                   |                                                                                                                                                  |              | NA                 |
|                                                         |                                                                                               | 40.2              |                                                                                                                                                  |              |                    |
|                                                         |                                                                                               |                   |                                                                                                                                                  | 38.58        |                    |
|                                                         | confirmed                                                                                     |                   |                                                                                                                                                  |              |                    |

<div style=\"page-break-after: always\"></div>

## Clinical studies in special populations

The consistency of OS, PFS-INV, and ORR results was investigated by estimating the treatment effect in pre-defined subgroups based on key demographics (age, sex, race/ethnicity) and baseline prognostic characteristics (e.g., histology, ECOG performance status, smoking history, number of metastatic sites, location of metastases, size of primary tumor, etc.). Randomization was not stratified by all those predefined subgroups and some groups included small sample size. The MAH did not provide data in the paediatric population.

Separate efficacy data in elderly patients have not been provided. However, subgroup analyses in subjects ≤ 65 and 65-74 years indicate a similar efficacy for both age groups regarding OS and lower HR values for the higher age group (for PFS). Limited data are available for ≥ 75 years (Figure 17 and Figure 18).

## 2.4.3. Discussion on clinical efficacy

The MAH applied for the first-line treatment with atezolizumab monotherapy of a PD-L1 selected patient population with metastatic NSCLC based on the multicenter, randomised, phase 3 IMpower110 trial, which is comparing atezolizumab monotherapy with platinum-based chemotherapy in chemotherapy-naïve patients. In total, 572 patients in the pivotal trial were recruited from 144 centres across 19 countries, which is acceptable as a relevant number of patients were from regions comparable to the EU. The study was fully recruited by 31 months and updated efficacy data are presented with a median follow-up time for survival was ~31 months and used the data cut-off 04 February 2020.

## Design and conduct of clinical studies

The design of the pivotal study is in principle acceptable; however, it is noted that the design and the protocol were changed multiple times during the study in particular after the data cut-off date. The SAP was also amended to incorporate the changes made in the protocol. The initial data cut-off date was 10 September 2018, and the SAP was updated on the 2 April 2019. The primary endpoint was changed three times; from PFS only to PFS and OS as co-primary endpoints and lastly to OS only.

Enrolment was restricted to subjects with PD-L1 positive tumours (Tumour PD-L1 expression (TC1/2/3 or IC1/2/3; corresponding to ≥1% PD L1 expressing TCs and ≥1% of tumo ur area occupied by PD-L1 expressing ICs). Only patients in good performance status (ECOG performance status of 0 or 1) with only  mild  renal  or  hepatic  insufficiency  were  included  (GFR  ≥60  mL/min;  AST/ALT  ≤1.5XULN,  ALP ≤2.5XULN) .

The patient population was expanded to include patients with squamous NSCLC, and this subgroup ended up  comprising  24%  of  the  targeted  study  population.  Patients  with  CNS  metastases  were  eligible provided that certain criteria were met, and this is endorsed. The key exclusion criteria are also endorsed.

The primary endpoint was to be tested in three different populations. To keep the type I error control at 5%, the Applicant defined a hierarchical testing. The strategy chosen to control for multiple endpoints is agreed. The Applicant planned for an interim analysis of OS. To correct for multiple looks, the LanDeMets approximation to the Pocock boundary was implemented. The Applicant added the TC3 or IC3 population as the first testing hierarchy in Protocol Version 9 (finalized on 14 March 2019). Before this, the TC2/3 or IC2/3 population had been defined as the primary analysis population.

The very late time point of this update in the open-label study and the inadvertent data access by statisticians in December 2018 raised concerns that these changes could have been driven by knowledge

<div style=\"page-break-after: always\"></div>

of the pivotal IMpower110 study results and thus, a GCP inspection was triggered by the CHMP. The GCP inspection team was not able to exclude that protocol amendment V9 was not influenced by knowledge based on internal study data and the decision-making process was not documented adequately. Because the 'Biostats team working on this study had - by error - access to RAVE data, including the actual exposure/treatment', the GCP inspectors considered it possible that 'population-level efficacy analyses by actual treatment were performed prior to the database lock and Treatment Assignment Information (TAI)  release'.  The  MAH  has  argued  that  the  'extracted  RAVE  data  did  not  contain  any  Treatment Assignment Information, i.e. no IxRS randomization code, nor did it contain PD-L1 status linked to an actual patient ID. The biostatistics team could therefore not have performed any analyses in the TC2/3 or IC2/3-wild type (WT) population or the TC3 or IC3-WT population.' The MAH claimed that the key changes implemented in protocol version 9, including incorporation of TC3 or IC3-WT population into the testing hierarchy, were driven by data external to Study IMpower110, mainly from three anti-PD-1/PDL1 monotherapy 1L NSCLC studies (Checkmate-026, KEYNOTE-042 and MYSTIC), indicating that OS benefit was greatest in patients that express higher levels of PD-L1. Moreover, a detailed biomarker review  of  IMpower150  study  and  biomarker  status  in  the  external  studies  suggested  that  TC3/IC3 population had the highest probability of response. Relevant for these analyses are the MYSTIC study results by PD-L1 expression subgroups (Rizvie et al 2018) and a presentation at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress on 13 December 2018 including additional analyses by PDL1 status in the TC≥50%, TC≥1% and TC &lt;1% for subgroups treated with durvalumab versus chemotherapy. Hence, it was agreed that these external data could have led to the changes made by the Applicant later on. Since the Applicant has provided an explanation and clarification for the chain of  events that  led  to  the  changes  of  the  testing  hierarchy  of  the  results  of  Impower110,  the  CHMP concluded that it seems scientifically based that external data did lead to the decision to introduce the changes to the protocol, etc. However, the practice of changing the primary endpoint and hierarchical testing  in  an  ongoing  open-label  study  is  still  criticized  and  the  Applicant  should  refrain  from  this approach in future open-label clinical studies. GCP issues should also be addressed as recommended in the GCP inspection report and the Applicant can expect that in future applications, there will be continued focus on GCP compliance.

The  sample  size  calculations  presented  in  the  latest  version  of  the  protocol  seem  adequate.  The stratification factors were sex, ECOG performance status, histology and PD-L1 tumour expression status, and they are all considered relevant from a clinical point of view. However, when considering the limited sample size of the relevant PD-L1 selected target population i.e. 205 patients randomised, the number of stratification factors should have been more limited.

The comparator of platinum-based chemotherapy is no longer standard of care for the targeted PD-L1 selected patient population; and at the time of study design, promising efficacy results were already emerging  with  immunotherapy.  For  a  while  now,  the  SOC  for  the  targeted  PD-L1  selected  patient population has included immunotherapy either as monotherapy or in combination with chemotherapy, but this change in SOC was not obvious at the time of study initiation in 2015, so the choice of comparator is acceptable.

The objective of the pivotal trial is OS as primary endpoint and key secondary endpoints were INV-PFS, INV-ORR,  DOR  by  RECIST  1.1,  and  efficacy  according  to  PD-L1  expression.  It  is  acceptable  to  use investigator-assessed objectives as secondary objectives, if the primary objective is measured by a hard endpoint  such  as  OS.  However,  the  robustness  of  the  PFS  result  in  this  open-label  study  allowing treatment with atezolizumab beyond progression could have been greatly improved by the use of an independent review of the scan results, which was not done. The secondary endpoints were not controlled for multiplicity and therefore the p-values are considered descriptive.

<div style=\"page-break-after: always\"></div>

Exclusion of patients with ALK-positive or EGFR mutated tumours are endorsed, as several studies have not  established  efficacy  of  atezolizumab  in  these  sub-populations.  Prior  neo-adjuvant,  adjuvant chemotherapy, radiotherapy, or chemoradiotherapy with curative intent for non-metastatic disease were allowed, as long as the treatment-free interval was of at least 6 months from randomization. This led to the inclusion of patients, who might not benefit from re-introduction of platinum-based chemotherapy.

## Efficacy data and additional analyses

The primary endpoint of OS benefit in the PD-L1 selected population was met. However, the KM OS curves  cross  after  approximately  4  months  of  therapy,  so  initially,  treatment  with  chemotherapy  is superior  to  atezolizumab  monotherapy  and  the  shape  of  the  curve  indicate  early  deaths  with atezolizumab. This is concerning and the higher number of deaths within 2.5 months after randomisation observed  with  atezolizumab  compared  with  chemotherapy  (potentially  due  a  delayed  onset  of atezolizumab effect) is reflected in section 4.4 of the SmPC for the prescribers to consider, although no risk factors could be identified.

The updated KM OS curves begin to separate approximately 5 months after treatment initiation and from then on, atezolizumab monotherapy is superior to chemotherapy. At the IA of IMpower110 (CCOD 10 September 2018), a statistically significant and clinically meaningful OS benefit was demonstrated with first-line (1L) atezolizumab monotherapy compared to platinum-based chemotherapy in the TC3 or IC3WT population (median OS: 20.2 vs. 13.1 months, HR 0.595 [95%CI: 0.398, 0.890]; p-value=0.0106). Because the OS data were not fully mature at this analysis time point (around 50% event rates), the Applicant presented an OS update after an additional 17 months of follow-up (CCOD: 4 February 2020).

Updated efficacy data in the TC3 or IC3-WT population showed an OS HR of 0.764 [95%CI, 0.563, 1.087 ] with a median OS of 20.2 vs. 14.7 months, respectively. Thus, the point estimate of the OS HR increased and OS analysis was not nominal significant with longer follow-up. Considering the shapes of the KM curves and the median OS, it appears that this change was mainly driven by the performance of the comparator arm. The median OS became longer only in the chemotherapy arm (13.1 months at IA and 14.7 months at the updated analysis). The Applicant argued that this may be due to the use of subsequent immunotherapy (34.7% in the chemotherapy arm), which was substantiated by additional analysis via discount method and RPSFT method and can be followed in general. Considering that only one third of the patients received immunotherapy post-progression, this might not be sufficient to fully explain the catching up of the chemotherapy control arm. However, this does not impact the benefit in OS shown for atezolizumab monotherapy.

The key secondary endpoint PFS-INV was reached in both treatment arms; however, the difference could not be formally tested, since the pre-specified IA alpha boundary was not crossed for the TC2/3 or  IC2/3-WT  population.  The  initially  observed  INV-PFS  benefit  (HR  0.63)  was  confirmed  with  the updated data and showed a difference of 3.2 months (HR 0.59 [95%CI: 0.43, 0.81]. Updated confirmed ORR was also increased from 28.6% with chemotherapy to 40.2% with atezolizumab and it is noted, that the increase was due to more patients achieving a PR with atezolizumab. The updated median DOR was statistically significantly increased from 8.3 months (95%CI: 5.6; 11.0) to 38.9 months (95%CI: 16.1; NE) with atezolizumab. Taking into account that the sample sizes are small i.e. 43 responders on atezolizumab, the induced responses were durable and DOR were clinically meaningfully prolonged with atezolizumab  monotherapy.  In  addition,  it  has  to  be  acknowledged  that  the  efficacy  results  of atezolizumab  monotherapy  appear  consistent  with  published  external  data  from  other  PD1/PDL1inhibitors in similar treatment settings, despite the limitations of cross-trial comparisons.

<div style=\"page-break-after: always\"></div>

Additional pre-specified analyses were conducted to evaluate efficacy by PD-L1 status assessed by the VENTANA PD-L1 (SP263) Assay and by the PD-L1 IHC 22C3 pharmDxTM Kit in all randomised patients (n=554), but the assay data is considered exploratory and is therefore not presented in the SmPC.

The incidence of treatment-emergent ADA in the population of IMpower110 was 24.3% (23.5% in the TC3  or  IC3-WT  population).  These  high  rates  of  treatment-emergent  ADA  in  patients  treated  with atezolizumab remains somewhat worrisome; nevertheless, the OS and ORR results for the targeted population  could  be  regarded  as  comparable  to  those  of  the  SOC  platinum-based  chemotherapy. Therefore, in 1L NSCLC the incidence of ADA+ and the reduced efficacy in ADA positive patients is not an objection for the currently applied patient population. The small numbers and missing values make this  analysis  difficult  to  interpret,  but  ADA  status  does  not  seem  to  have  a  major  impact  on  early mortality. However, this does not preclude a detrimental effect on longer-term efficacy and as ADA often takes time to develop. This was reflected in section 4.8 of the SmPC.

PRO data have also been presented and results indicate no detrimental effects of either of the study treatments. However, these data should be interpreted with caution and are therefore not presented in the SmPC.

## 2.4.4. Conclusions on the clinical efficacy

The efficacy results from the pivotal IMpower110 study shows superior efficacy in terms of OS of atezolizumab monotherapy compared to platinum-based chemotherapy for the first-line treatment of PD-L1 selected patients with metastatic NSCLC.

## 2.5. Clinical safety

## Introduction

Safety data for the use of atezolizumab in patients with chemotherapy-naive squamous or non-squamous metastatic NSCLC in the IMpower110 are presented versus the chemotherapy arm; hence, Atezolizumab versus Cisplatin/Carboplatin + Pemetrexed/Gemcitabine.

The safety database includes data from 549 patients, who received any amount of study treatment in the  IMpower110  study  (286 patients  treated  with  atezolizumab  and  263 patients  treated  with chemotherapy). The Atezo Mono Pooled population (n=3854) includes the data from the 286 patients treated in the atezolizumab arm of IMpower110 and the 3568 patient-pooled monotherapy population as currently presented in the approved Tecentriq SmPC.

<div style=\"page-break-after: always\"></div>

## Patient exposure

Table 23: Exposure to study treatment (safety-evaluable population) - CCOD: 10 September 2018

|                                                                                                                                      | Chemotherapy n=263              | Chemotherapy n=263               | Chemotherapy n=263               | Chemotherapy n=263                         | Atezolizumab n=286                             |
|--------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|----------------------------------|----------------------------------|--------------------------------------------|------------------------------------------------|
|                                                                                                                                      | Cisplatin n=90                  | Carboplatin n=177                | Gemcitabine Pemetrexed n=75      | n=191                                      |                                                |
| Treatment duration (M) Median                                                                                                        | 2.1                             | 2.3 0-5                          | 2.6 0-5                          | 3.5                                        | 5.3                                            |
| Min - Max                                                                                                                            | 0-5                             |                                  |                                  | 0-20                                       | 0-33                                           |
| Treatment duration (M) 0to≤2months >2to≤4months >4 to ≤6 months Treatment duration (M) 0 to ≤3 months >3to≤6 months >6 to ≤12 months | 29 ( 32.2%) 59 (65.6%) 2 (2.2%) | 55 (31.1%) 113 (63.8%) 9 ( 5.1%) | 23 (30.7%) 42 (56.0%) 10 (13.3%) |                                            |                                                |
| >12 months                                                                                                                           |                                 |                                  |                                  | 84 (44.0%) 50 (26.2%) 42 (22.0%) 15 (7.9%) | 97 ( 33.9%) 52 ( 18.2%) 81 ( 28.3%) 56 (19.6%) |
| Median Min - Max Number of doses Median                                                                                              | 98.8 71-102                     | 97.7 67-102                      | 92.1 64- 101                     | 97.7 67-102                                | 99.4                                           |
| received                                                                                                                             | 4.0                             | 4.0                              | 8.0                              |                                            | 55 -108                                        |
|                                                                                                                                      |                                 |                                  |                                  | 6.0                                        | 8.0                                            |
| Min - Max                                                                                                                            | 1-6                             | 1-6                              | 1-12                             | 1-28                                       | 1-49                                           |

Source:t\\_ex\\_atz\\_SE\\_10Sep2018\\_29431,t\\_ex\\_car\\_SE\\_10Sep2018\\_29431, t\\_ex\\_cis\\_SE\\_10Sep2018\\_29431, t\\_ex\\_gem\\_SE\\_10Sep2018\\_29431, t\\_ex\\_pem\\_SE\\_10Sep2018\\_29431

Table 24: Exposure to study treatment (safety-evaluable population)

|                                 | InterimAnalysis (CC0D:10September2018)   | InterimAnalysis (CC0D:10September2018)   | InterimAnalysis (CC0D:10September2018)   | InterimAnalysis (CC0D:10September2018)   | InterimAnalysis (CC0D:10September2018)   | Updated Analysis (CCOD:4February 2020)   | Updated Analysis (CCOD:4February 2020)   | Updated Analysis (CCOD:4February 2020)   | Updated Analysis (CCOD:4February 2020)   | Updated Analysis (CCOD:4February 2020)   |
|---------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|
|                                 | Chemotherapy n= 263                      | Chemotherapy n= 263                      | Chemotherapy n= 263                      | Atezolizumal n= 286                      | Atezolizumal n= 286                      | Chemotherapy n= 263                      | Chemotherapy n= 263                      | Chemotherapy n= 263                      | Atezolizumab* n=286                      | Atezolizumab* n=286                      |
|                                 | Cisplatin n=90                           | Carboplatin n=177                        | n=75                                     | GemcitabinePemetrexed n= 191             |                                          | Cisplatin n=90                           | Carboplatin n= 177                       | Gemcitabine n=75                         | Pemetrexed n= 191                        |                                          |
| MedianTreatmentduration (Month) | 2.1                                      | 2.3                                      | 2.6                                      | 3.5                                      | 5.3                                      | 2.1                                      | 2.3                                      | 2.6                                      | 3.5                                      | 5.3                                      |
| Min -Max                        | 0-5                                      | 0-5                                      | 0-5                                      | 0-20                                     | 0-33                                     | 0-5                                      | 0-5                                      | 0-5                                      | 0-30                                     | 0-50                                     |
| MedianDose intensity (%)        | 98.8                                     | 97.7                                     | 92.1                                     | 97.7                                     | 99.4                                     | 98.8                                     | 97.7                                     | 92.1                                     | 97.7                                     | 98.8                                     |
| Min -Max                        | 71 - 102                                 | 67- 102                                  | 64 - 101                                 | 67-102                                   | 55-108                                   | 71 - 102                                 | 67 -102                                  | 64 - 101                                 | 67 - 102                                 | 55-108                                   |
| Numberofdoses(Median)           | 4                                        | 4                                        | 8                                        | 6                                        | 8                                        | 4                                        | 4                                        | 8                                        | 6                                        | 8                                        |
| Min-Max                         | 1-6                                      | 1-6                                      | 1 -12                                    | 1-28                                     | 1-49                                     | 1-6                                      | 1-6                                      | 1-12                                     | 1 -44                                    | 1-73                                     |

CCoD=clinical cut-offdate;Min=minimum;Max=maximum.

* Two patients in the atezolizumab am also received gemcitabine and carboplatin treatment.

Source:CSRTable39andAppendix4,Appendix5,Appendix6,Appendix7,Appendix8.

<div style=\"page-break-after: always\"></div>

## Adverse events

## Table 25: Overall summary of adverse events (safety-evaluable population)

|                                                                             | Overall (N=549)      | Overall (N=549)      | Overall (N=549)      |
|-----------------------------------------------------------------------------|----------------------|----------------------|----------------------|
|                                                                             | Chemotherapy (N=263) | Chemotherapy (N=263) | Atezolizumab (N=286) |
| Totalnumber ofpatients withat least oneadverse event Total number of events | 250                  | (95.18) 2092         | 263 (92.0号) 2237     |
| Total number of patients with at least one                                  |                      |                      |                      |
| Treatment-related AE                                                        | 224                  | (85.28)              | 180 (62.98) 97       |
| Grade3-4AE                                                                  | 140                  | (53.2%)              | (33.9号)              |
| Treatment-related Grade 3-4AE                                               | 118                  | (44.98)              | 41 (14.38)           |
| Grade 5 AE                                                                  | 11                   | 4.2%)                | 12 4.28)             |
| Treatment-related Grade 5 AE                                                |                      | 0.48)                |                      |
| Serious Adverse Event                                                       | 77                   | (29.3号)              | 91 (31.8号)           |
| Treatment-Related Serious Adverse Event                                     | 41                   | (15.68)              | 27 9.48)             |
| AE leading to any treatment withdrawal                                      | 45                   | (17.18)              | 21 7.3号)             |
| Atezolizumab                                                                | 0                    |                      | 7.38)                |
| Cisplatin                                                                   | 10                   | 3.88)                | 21 0                 |
| Carboplatin                                                                 | 16                   | 6.18)                | 0 0                  |
| Pemetrexed                                                                  | 30                   | (11.48)              |                      |
| Gemcitabine                                                                 | 13                   | 4.9%)                | 0                    |
| AE leading to dose modification/interruption                                | 117                  | (44.58)              | 90 (31.58)           |
| Atezolizumab                                                                | 0                    |                      | 68 (31.18)           |
| Cisplatin                                                                   | 27                   | (10.38)              | 0                    |
| Carboplatin                                                                 | 64                   | (24.3%)              | 0.38)                |
| Pemetrexed                                                                  | 78                   | (29.78)              | 0                    |
| Gemcitabine                                                                 | 37                   | (14.18)              | (0.38)               |

Investigator text for AEs encoded using MedDRA v22.l. Percentages are based on N in the column headings. Multiple occurrences of the same AE in one individual are counted only once except for \"Total number of events\" row in which multiple occurrences of the same AE are counted separately. Counts in \"Grade 3-4 AE\" are number of patients whose highest grades of AE are 3 or 4. Data Extraction Date - 24MAR2020 ; Data Cutoff Date - 04FEB2020.

<div style=\"page-break-after: always\"></div>

Table 26: Adverse events with an incidence rate of at least 10% in any treatment arm by system organ class and preferred term (safety-evaluable population)

ae  e e e e o r    a Preferred Term, Safety-Evaluable Patients Protoco1:G029431

|                                                           | Overall (N=549)      | Overall (N=549)      | Overall (N=549)      |
|-----------------------------------------------------------|----------------------|----------------------|----------------------|
| MedDRA System Organ Class MedDRA Preferred Term           | Chemotherapy (N=263) | Chemotherapy (N=263) | Atezolizumab (N=286) |
| Totalnumber of patients withatleast one adverse event     |                      | 219 (83.38)          | 194 (67.8%)          |
| Gastrointestinal _disorders                               |                      |                      |                      |
| Total number of patients with at least one adverse event  | 134                  | (51.0%)              | 91 (31.8%)           |
| Nausea                                                    | 68                   | (33.8%)              | 39 (13.6%)           |
| Constipation                                              | 57                   | (21.7%)              | 35 (12.2%)           |
| Diarrhoea                                                 | 31                   | (11.8%)              | 32 (11.28)           |
| Vomiting                                                  | 34                   | (12.9%)              | 18 (6.3%)            |
| Blood and lymphatic system disorders                      |                      |                      |                      |
| Total number of patients with at least one adiverse event | 161                  | (61.28)              | 50 (17.58)           |
| Anaemia                                                   | 125                  | (47.58)              | 44 (15.48) 4         |
| Neutropenia                                               | 74                   | (28.18)              | (1.4%)               |
| Thrombocytopenia                                          | 44                   | (16.78)              | 7 （ 2.4%)            |
| General disorders and administration site conditions      |                      |                      |                      |
| Total number of patients with at least one adverse event  | 102                  | (38.8号)              | 98(34.38)            |
| Asthenia                                                  | 46                   | (17.5%)              | 37 (12.98)           |
| Fatigue                                                   | 46                   | (17.5%)              | 37 (12.9%)           |
| Pyrexia                                                   | 23                   | (8.7%)               | 39 (13.6%)           |
| Respiratory, thoracic and mediastinal disorders           |                      |                      | 59                   |
| Totalnumber ofpatients withatleast oneadverseevent        | 42                   | (16.0%)              | (20.6%)              |
| Dyspnoea                                                  | 26                   | 9.98)                | 40 (14.0%)           |
| Cough                                                     | 25                   | 9.58)                | 34 (11.98)           |
| Metabolism and nutrition disorders                        |                      |                      |                      |
| Totalnumber of patients withatleast oneadverseevent       | 50                   | (19.0%)              | 44 (15.48)           |
| Decreased appetite                                        |                      | 50 (19.0%)           | 44 (15.48)           |
| Investigations                                            |                      |                      |                      |
| Totalnumberofpatients withat least oneadverseevent        | 15                   | 5.7%)                | 30 (10.58)           |
| Alanine aminotransferase increased                        | 15                   | 5.78)                | 30 (10.58)           |

occurrences of the sameAEin one

Overall row counts, a patient collected after first treatment dose areincluded.

contributes only with the AE occurring with the highest grade within the SoC.Percentages are based on N in the column headings.AEs

Data Extraction Date - 3lAUG20l9 ; Data Cutoff Date - 10SEP2018.

<div style=\"page-break-after: always\"></div>

Table 27: Adverse events with at least 5% difference between treatment arms by system organ class and preferred term (safety-evaluable population)

AdverseEvents withaDifference of atLeast5&amp;between TreatmentArms bySystem Organ Class and Preferred Term, Safety-Evaluable Patients

Protoco1:G029431

|                                                          | Overall (N=549)   | Overall (N=549)   | Overall (N=549)      |
|----------------------------------------------------------|-------------------|-------------------|----------------------|
| MedDRA System Organ Class MedDRA Preferred Term          | Chemotherapy      | (N=263)           | Atezolizumab (N=286) |
| Totalnumber ofpatientswith atleast one adverse event     |                   | 249 (94.78)       | 258 (90.2%)          |
| Overalltotalnumber of events                             |                   | 1994              | 1839                 |
| Gastrointestinal disorders                               |                   |                   |                      |
| Total number of patients with at least one acverse event | 143               | (54.48)           | 124 (43.48)          |
| Total number of events                                   |                   | 369               | 230                  |
| Nausea                                                   | 68                | (33.8号)           | 39 (13.6%)           |
| Constipation                                             | 57                | (21.7%)           | 35 (12.28)           |
| Vomiting                                                 | 34                | (12.9%)           | 18 (6.38)            |
| Investigations                                           |                   |                   |                      |
| Totalnumber ofpatientswith atleast one adverse event     | 97                | (36.9%)           | 79 (27.6%)           |
| Totalnumber of events                                    |                   | 199               | 204                  |
| Aspartate aminotransferase i increased                   | 6                 | (3.4%)            | 28 (9.8%)            |
| Blood creatinine increased                               | 23                | 8.7%)             | 8 2.8%)              |
| Platelet count decreased                                 | 22                | 8.4%)             | 1 0.38)              |
| Neutrophil count decreased                               | 19                | ( 7.2%)           | 0                    |
| Skin and subcutaneous tissue disorders                   |                   |                   |                      |
| Totalnumber ofpatients withat least one adverse event    | 46                | 6 (17.5%)         | 76 (26.6%)           |
| Total number of events                                   |                   | 59                | 112                  |
| Pruritus                                                 |                   | (1.58)            | 19 9(6.68)           |
| Blood and lymphatic system disorders                     |                   |                   |                      |
| Totalnumber ofpatients with at least one adverse event   | 168               | (63.98)           | 55 (19.28)           |
| Totalnumber ofevents                                     |                   | 416               | 66                   |
| Anaemia                                                  | 125               | (47.5%)           | 44 (15.48)           |
| Thrombocytopenia                                         | 44                | (16.7%)           | 7 (2.48)             |
| Neutropenia                                              | 74                | (28.18)           | 1.48)                |
| Leukopenia                                               | 21                | (8.0%)            | 4 3 (1.0%)           |
| Endocrine disorders                                      |                   |                   |                      |
| Totalnumber ofpatientswith atleast one adverse event     | 4                 | (1.58)            | 35 (12.28)           |
| Totalnumber of events                                    |                   | 4                 | 40                   |
| Hypothyroidism                                           | 2                 | (0.8%)            | 22 ( 7.78)           |

occurrencesofthesameAEinone

contributes only with the AE occurring with the highest grade within the SoC.Percentages are based on N in the column headings. AEs

individual are counted once at the highest grade for this patient.To the SOC (System Organ Class) Overall row counts, a patient

collected after first treatment dose are included.

Data ExtractionDate-3lAUG20l9;Data Cutoff Date-10SEP2018.

<div style=\"page-break-after: always\"></div>

## Table 28: Adverse events related to any study treatment with an incidence rate of at least 10% by system organ class and preferred term (safety-evaluable population)

Adverse Events Related to Any Study Treatment with an Incidence Rate of at Least los by System Organ Class and Preferred Term, Safety- Evaluable Patients Protoco1:G029431

|                                                           | Overall (N=549)      | Overall (N=549)      | Overall (N=549)      |
|-----------------------------------------------------------|----------------------|----------------------|----------------------|
| MedDRA System Organ Class MedDRA Preferred Term           | Chemotherapy (N=263) | Chemotherapy (N=263) | Atezolizumab (N=286) |
| Blood and lymphatic system disorders                      |                      |                      |                      |
| Totalnumber ofpatients withat least oneadverseevent       | 155                  | (58.98)              | 16 5.6%)             |
| Anaemia                                                   | 119                  | (45.2%)              | 10 3.5%)             |
| Neutropenia                                               | 72                   | (27.4%)              | 35 1.0%)             |
| Thrombocytopenia                                          | 44                   | (16.7%)              | 1.7%)                |
| Gastrointestinal disorders                                |                      |                      | 29                   |
| Total number of patients with at least one adiverse event | 103                  | (39.28)              | (10.1%)              |
| Nausea                                                    | 83                   | (31.6%)              | 02 7.0%)             |
| Constipation                                              | 35                   | (13.38)              | 10 (3.58)            |
| Vomiting                                                  | 32                   | (12.28)              | 4 (1.48)             |
| General disorders and administration site conditions      |                      |                      |                      |
| Totalnumber ofpatients with at least one adverse event    | 59                   | (24.7%)              | 42(14.7%)            |
| Asthenia                                                  | 35                   | (13.3号)              |                      |
| Fatigue                                                   | 32                   | (12.2%）              |                      |
| Metabolism and nutrition disorders                        |                      |                      |                      |
| Totalnumberofpatientswithatleastoneadverseevent           | 42                   | (16.0%)              |                      |
| Decreased appetite                                        | 42                   | (16.08)              | 8:21器                |

Investigator text for AEs encoded using MedDRA v22.0.Percentages are based on N in the column headings, For frequency\\_counts

\"Totalnumber of events\"rows，themultiple occurrences of the sameAE in an individualare counted\\_separately.

by preferred term, multiple occurrences of the same AE in an individual are counted only once.For frequency counts of

Data Extraction Date-3lAUG2019 ;Data Cutoff Date-10SEP2018.

## Table 29: Grade 3-4 adverse events with an incidence of at least 5% in any treatment arm (safetyevaluable population)

Grade 3 or\\_4 Adverse Events, Incidence of at Least 58 in Any Treatment Arm by System Organ Class and Preferred Term,Safety-Evaluable Patients

Protoco1:G029431

|                                                   | Overall (N=549)      | Overall (N=549)      |
|---------------------------------------------------|----------------------|----------------------|
| MedDRA System Organ Class MedDRA Preferred Term   | Chemotherapy (N=263) | Atezolizumab (N=286) |
| Totalnumberofpatientswithatleastoneadverseevent   | 87 (33.18)           | 7(2.48)              |
| Blood and lymphatic system disorders              |                      |                      |
| Totalnumberofpatientswithatleast oneadverse event | 87 (33.1%)           | 7 (2.4%)             |
| Anaemia                                           | 48 (18.3%)           | 5 (1.7%)             |
| Neutropenia                                       | 46 (17.5%)           | ② (0.7%)             |
| Thrombocytopenia                                  | 19 7.2%）             | (0.38)               |

Investigator text for AEs encoded using MedDRAv22.0.Percentages are based on N in the column headings.For frequency counts freqency counts of \"Totalnumber of events\" rows, the multiple occurrences of the same AE in an individual are counted separately.

bypreferred term,multiple occurrences of the sameAE in an individualare countedonly once.For

Total Number of Patients and Total Number of Events sunmary rows include patients who have a maximum grade of 3 or 4 in any one Preferred Term.

For accurate totals for only maximum grades 3 and 4 Patients please refer to the t\\_ae\\_ctc\\_3catv\\_SE table.

Data Extraction Date-3lAUG20l9 ;Data Cutoff Date-10SEP2018.

<div style=\"page-break-after: always\"></div>

Table 30: Grade 3-4 adverse events with a difference of at least 2% between treatment arms (safetyevaluable population)

Grade 2.4 Adverse. Eventswith aDifference of atIeast 2&amp;betweenTreatment ArmsbyPreferred erm, G829431 yaluablePatients Protocol:

|                                                                                                                 | (Ne49)              | (Ne49)                            |
|-----------------------------------------------------------------------------------------------------------------|---------------------|-----------------------------------|
| MedDRA Preferred Term                                                                                           | (N=263)             | Chemotherapy Atezolizumab (N=286) |
| Total number of patients with at least one adverse event Anaemia number of events leutropenia hromb pocytopenia | 141 53.68) 94949 3号 | 91 5:21000                        |
| platelet. coint decreased                                                                                       |                     |                                   |
| Febriie neutropenia leutrophil                                                                                  |                     |                                   |

<!-- image -->

Table 31: Overview of safety profile (Safety-evaluable population)

|                                                     | Interim Analysis (CC0D:10September2018)   | Interim Analysis (CC0D:10September2018)   | Updated Analysis (CCOD:4February2020)   | Updated Analysis (CCOD:4February2020)   |
|-----------------------------------------------------|-------------------------------------------|-------------------------------------------|-----------------------------------------|-----------------------------------------|
| Parameter                                           | Chemotherapy (n=263)                      | Atezolizumab (n=286)                      | Chemotherapy (n=263)                    | Atezolizumab (n=286)                    |
| Total number of patientswith at least one AE        | 249 (94.7%)                               | 258 (90.2%)                               | 250 (95.1%)                             | 263 (92.0%)                             |
| Treatment-related AE                                | 224 (85.2%)                               | 173 (60.5%)                               | 224 (85.2%)                             | 180 (62.9%)                             |
| Grade 3-4 AE                                        | 138 (52.5%)                               | 86 (30.1%)                                | 140 (53.2%)                             | 97 (33.9%)                              |
| Treatment-relatedGrade3- 4 AE                       | 116 (44.1%)                               | 37 (12.9%)                                | 118 (44.9%)                             | 41 (14.3%)                              |
| Grade5 AE                                           | 11 (4.2%)                                 | 11 (3.8%)                                 | 11 (4.2%)                               | 12 (4.2%)                               |
| Treatment-related Grade5 AE                         | 1 (0.4%)                                  | 0                                         | 1 (0.4%)                                | 0                                       |
| Serious AE                                          | 75 (28.5%)                                | 81 (28.3%)                                | 77 (29.3%)                              | 91 (31.8%)                              |
| Treatment-relatedserious AE                         | 41 (15.6%)                                | 24 (8.4%)                                 | 41 (15.6%)                              | 27 (9.4%)                               |
| AE leading to any treatment withdrawal              | 43 (16.3%)                                | 18 (6.3%)                                 | 45 (17.1%)                              | 21 (7.3%)                               |
| AEleading toany dose modification/interruption      | 116*(44.1%)                               | 74 (25.9%)                                | 117 (44.5%)                             | 90 (31.5%)                              |
| AESI                                                | 44 (16.7%)                                | 115 (40.2%)                               | 48 (18.3%)                              | 132 (46.2%)                             |
| Grade 3-4 AESI                                      | 4 (1.5%)                                  | 19 (6.6%)                                 | 4 (1.5%)                                | 25 (8.7%)                               |
| Serious AESI                                        | 3 (1.1%)                                  | 15 (5.2%)                                 | 3 (1.1%)                                | 19 (6.6%)                               |
| AESls leading to any study drug withdrawal          | 3 (1.1%)                                  | 7 (2.4%)                                  | 3 (1.1%)                                | 8 (2.8%)                                |
| All GradeAtezoAESI requiring use of corticosteroids | 3 (1.1%)                                  | 30 (10.5%)                                | 4 (1.5%)                                | 38 (13.3%)                              |

AE=adverse event; AESl=adverse event of special interest; CCOD=clinical cut-off date.

* Due to a data entry issue, this number also includes one patient that did not have a dose modification/interruption.

Source:CSR Table 38 and 50,Appendix 1,Appendix 2,Appendix 3

<div style=\"page-break-after: always\"></div>

## Adverse events of special interest

Table 32: Summary of adverse events of special interest (safety-evaluable population)

|                                                                              | Overall (N=549)      | Overall (N=549)      |
|------------------------------------------------------------------------------|----------------------|----------------------|
|                                                                              | Chemotherapy (N=263) | Atezolizumab (N=286) |
| Totalnumber ofpatients withatleast oneAESI                                   | 48 (18.38)           | 132 (46.28)          |
| Total number of AESI events                                                  | 74                   | 254                  |
| Total number of patients with at least one                                   |                      |                      |
| Treatment-related AESI                                                       | 28 (10.68)           | 101 (35.38)          |
| Grade 3-4AESI                                                                | 4 1.58)              | 25 8.7%)             |
| Treatment-related Grade3-4 AESI                                              | 3 1.18)              | 19 6.6%)             |
| Serious AESI                                                                 | 3 1.18)              | 19 6.68)             |
| Treatment-Related Serious AESI                                               | 0.8%)                | 17 5.98)             |
| AESI leading to any treatment withdrawal/dose modification/dose interruption | 25302 1.9%)          | 39 (13.6%)           |
| AESI leading to any withdrawal from treatment                                | 1.18)                | 8 2.88)              |
| Atezolizumab                                                                 |                      | 8 2.8%)              |
| Canboplatin                                                                  | 0.88)                | 0                    |
| Pemetrexed                                                                   | 0.48)                | 0                    |
| Gemcitabine                                                                  | 0.8号)                | 0                    |
| AESI leading to any dose modification/interruption                           | 1220 0.88)           | 35                   |
| -Atezolizumab                                                                |                      | 35                   |
| Cisplatin                                                                    | 0.48)                | 0                    |
| Gemcitabine                                                                  | 2 0.8%)              | 0                    |
| AE of Special Interest Medical Concepts: patients with at least one          |                      |                      |
| Inmune-Mediated Hep.(Diag & Lab Ab)                                          | 25 (9.58）            | 47 (16.48)           |
| Inmune-MediatedRash                                                          | 20 7.6%)             | 53 (18.5%)           |
| Inmune-Mediated  Hepatitis (Lab Abnormal)                                    | 25 9.58)             | 46 (16.1%)           |
| Inmune-Mediated H Hypothyroidism                                             | 52 1.98)             | 30 (10.5%)           |
| Inmune-Mediated Hyperthyroidism                                              | 0.8%)                | 14 4.98)             |
| Inmune-Mediated Pneumonitis                                                  | 1 0.48)              | 12 4.28)             |
| Inmune-MediatedDiabetes Mellitus                                             | 0.4%)                | 5 1.78)              |
| Infusion-Related Reactions                                                   | 0                    | 1.4%)                |
| Inmune-Mediated Hepatitis (Diagmosis)                                        | 200 (0.8%)           | 2 0.78)              |
| Inmune-Mediated Adrenal Insufficiency                                        |                      | 3 1.0%)              |
| Inmune-Mediated Colitis                                                      |                      | 3 1.08)              |
| Inmune-Mediated Pancreatitis                                                 | 0                    | 3 1.0%)              |
| Inmune-Mediated Myositis                                                     | 1 0.4%)              | 0.3%)                |
|                                                                              | 0.48)                | 1                    |
| Immune-Mediated Nephritis                                                    |                      | 0.38)                |
| Inmune-Mediated Ocular Inflam.Toxic Inmune-Mediated Severe Cutaneous React.  | 00                   | 2 0.7%) 2 0.7%)      |
| Inmune-Mediated Myositis+Rhabdomyolysis                                      | (0.48)               | 1 0.38) 0.38)        |
| Inmune-Mediated Vasculitis                                                   | 0                    | 0.3%)                |
| Inmune-Mediated Myocarditis                                                  | 0                    |                      |
| Haemophagocytic Lymphohistiocytosis                                          | 0                    | 0.38)                |

same AEinone individualare counted only once except for \"Total number of events\" row in whichmultiple occurrences of the same AE are counted separately.AEs\\_collected after first treatment dose are included. Data Extraction Date-24MAR2020;Data Cutoff Date-04FEB2020.

## Adverse drug reactions

The table below reflects the adverse drug reactions related to Tecentriq as identified in the pooled safety dataset for atezolizumab monotherapy (n=3854).

Table 33: Adverse drug reactions for atezolizumab monotherapy (n= 3854)

| Atezolizumab monotherapy (n=3,854)   | Atezolizumab monotherapy (n=3,854)   | System Organ Class ADR               |
|--------------------------------------|--------------------------------------|--------------------------------------|
| Frequency (All Grades)               | Incidence% (All Grades)              | System Organ Class ADR               |
| Infections and infestations          | Infections and infestations          | Infections and infestations          |
| Very common                          | 478 (12.4%)                          | urinary tract infection a            |
| Blood and lymphatic system disorders | Blood and lymphatic system disorders | Blood and lymphatic system disorders |
| Common                               | 140 (3.6%)                           | thrombocytopenia b                   |
| Immune system disorders              | Immune system disorders              | Immune system disorders              |
| Common                               | 63 (1.6%)                            | infusion-related reaction c          |
| Endocrine disorders                  | Endocrine disorders                  | Endocrine disorders                  |
| Common                               | 244 (6.3%)                           | hypothyroidism d                     |
| Common                               | 61 (1.6%)                            | hyperthyroidism e                    |
| Uncommon                             | 16 (0.4%)                            | diabetes mellitus f                  |
| Uncommon                             | 15 (0.4%)                            | adrenal insufficiency g              |
| Rare                                 | 3 (<0.1%)                            | hypophysitis h                       |

<div style=\"page-break-after: always\"></div>

| Metabolism and nutrition disorders                   | Metabolism and nutrition disorders                   | Metabolism and nutrition disorders                   |
|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
| Very common                                          | 904 (23.5%)                                          | decreased appetite                                   |
| Common                                               | 159 (4.1%)                                           | hypokalemia i                                        |
| Common                                               | 193 (5.0%)                                           | hyponatremia j                                       |
| Common                                               | 134 (3.5%)                                           | hyperglycaemia                                       |
| Nervous system disorders                             | Nervous system disorders                             | Nervous system disorders                             |
| Very common                                          | 419 (10.9%)                                          | headache                                             |
| Uncommon                                             | 5 (0.1%)                                             | Guillain-Barré syndrome k                            |
| Uncommon                                             | 14 (0.4%)                                            | meningoencephalitis l                                |
| Rare                                                 | 1 (<0.1%)                                            | myasthenic syndrome m                                |
| Rare                                                 | Eye disorders 3 (<0.1%)                              | uveitis                                              |
| Rare                                                 | 1 (<0.1%)                                            | myocarditis n                                        |
| Common                                               | Vascular disorders 109 (2.8%)                        | hypotension                                          |
| Respiratory, thoracic, and mediastinal disorders     | Respiratory, thoracic, and mediastinal disorders     | Respiratory, thoracic, and mediastinal disorders     |
| Very common                                          | 742 (19.3%)                                          | cough                                                |
| Very common                                          | 719 (18.7%)                                          | dyspnoea                                             |
| Common                                               | 111 (2.9%)                                           | pneumonitis o                                        |
| Common                                               | 75 (1.9%)                                            | hypoxia p                                            |
| Common                                               | 113 (2.9%)                                           | nasal congestion                                     |
| Common                                               | 182 (4.7%)                                           | nasopharyngitis                                      |
| Gastrointestinal disorders                           | Gastrointestinal disorders                           | Gastrointestinal disorders                           |
| Very common                                          | 841 (21.8%)                                          | nausea                                               |
| Very common                                          | 525 (13.6%)                                          | vomiting                                             |
| Very common                                          | 745 (19.3%)                                          | diarrhoea q                                          |
| Common                                               | 306 (7.9%)                                           | abdominal pain                                       |
| Common                                               | 46 (1.2%)                                            | colitis r                                            |
| Common                                               | 92 (2.4%)                                            | dysphagia                                            |
| Common                                               | 153 (4.0%)                                           | oropharyngeal pain s                                 |
| Uncommon                                             | 30 (0.8%)                                            | pancreatitis t                                       |
| Hepatobiliary disorders                              | Hepatobiliary disorders                              | Hepatobiliary disorders                              |
| Common                                               | 229 (5.9%)                                           | AST increased                                        |
| Common                                               | 222 (5.8%)                                           | ALT increased                                        |
| Common                                               | 68 (1.8%)                                            | hepatitis u                                          |
| Skin and subcutaneous tissue disorders               | Skin and subcutaneous tissue disorders               | Skin and subcutaneous tissue disorders               |
| Very common                                          | 758 (19.7%)                                          | rash v                                               |
| Very common                                          | 522 (13.5%)                                          | pruritus                                             |
| Common                                               | 225 (5.8%)                                           | dry skin                                             |
| Uncommon                                             | 20 (0.5%)                                            | psoriasis                                            |
| Uncommon                                             | 26 (0.7%)                                            | severe cutaneous adverse reactions w                 |
| Rare                                                 | 1 (<0.1%)                                            | pemphigoid                                           |
| Musculoskeletal and connective tissue disorders      | Musculoskeletal and connective tissue disorders      | Musculoskeletal and connective tissue disorders      |
| Very common                                          | 506 (13.1%)                                          | arthralgia                                           |
| Very common                                          | 539 (14.0%)                                          | back pain                                            |
| Very common                                          | 551 (14.3%)                                          | musculoskeletal pain x                               |
| uncommon                                             | 16 (0.4%)                                            | myositis y                                           |
| Renal and urinary disorders                          | Renal and urinary disorders                          | Renal and urinary disorders                          |
| Common                                               | 220 (5.7%)                                           | blood creatinine increased z                         |
| Uncommon                                             | 9 (0.2%)                                             | nephritis aa                                         |
| General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions |
| Very common                                          | 760 (19.7%)                                          | pyrexia                                              |
| Very common                                          | 1275 (33.1%)                                         | fatigue                                              |
| Very common                                          | 537 (13.9%)                                          | asthenia                                             |
| Common Common                                        | 212 (5.5%) 236 (6.1%)                                | influenza like illness chills                        |

a. Includes reports of urinary tract infection, cystitis, pyelonephritis, escherichia urinary tract infection, urinary tract infection bacterial, kidney infection, pyelonephritis acute, pyelonephritis chronic, pyelitis, renal abscess, streptococcal urinary tract infection, urethritis, urinary tract infection fungal, urinary tract infection pseudomonal.

b. Includes reports of thrombocytopenia, platelet count decreased.

c. Includes reports of infusion related reaction, cytokine release syndrome, hypersensitivity, anaphylaxis.

d. Includes reports of autoimmune hypothyroidism, autoimmune thyroiditis, blood thyroid stimulating hormone abnormal, blood thyroid stimulating hormone decreased, blood thyroid stimulating hormone increased, euthyroid sick syndrome, goitre,

<div style=\"page-break-after: always\"></div>

hypothyroidism, immune-related hypothyroidism, myxedema, myxoedema coma, thyroid disorder, thyroid function test abnormal, thyroiditis, thyroiditis acute, thyroxine decreased, thyroxine free decreased, thyroxine free increased, thyroxine increased, tri-iodothyronine decreased, tri-iodothyronine free abnormal, tri-iodothyronine free decreased, tri-iodothyronine free increased, silent thyroiditis, thyroiditis chronic.

- e. Includes reports of hyperthyroidism, Basedow's disease, endocrine ophthalmopathy, exophthalmos.
- f. Includes reports of diabetes mellitus, type 1 diabetes mellitus, diabetic ketoacidosis, ketoacidosis.
- g. Includes reports of adrenal insufficiency, glucocorticoid deficiency, primary adrenal insufficiency.
- h. Includes reports of hypophysitis, temperature regulation disorder.
- i. Includes reports of hypokalaemia, blood potassium decreased.
- j. Includes reports of hyponatraemia, blood sodium decreased.
- k. Includes reports of Guillain Barré syndrome, demyelinating polyneuropathy.
- l. Includes reports of encephalitis, meningitis, photophobia.
- m. Includes reports of myasthenia gravis.
- n. Includes reports of autoimmune myocarditis.
- o. Includes reports of pneumonitis, lung infiltration, bronchiolitis, immune-related pneumonitis, interstitial lung disease, lung opacity, pulmonary toxicity, radiation pneumonitis.
- p. Includes reports of hypoxia, oxygen saturation decreased, pO2 decreased.
- q. Includes reports of diarrhoea, defaecation urgency, frequent bowel movements, diarrhoea haemorrhagic, gastrointestinal hypermotility.
- r. Includes reports of colitis, autoimmune colitis, colitis ischaemic, colitis microscopic, colitis ulcerative, immune-related enterocolitis.
- s. Includes reports of oropharyngeal pain, oropharyngeal discomfort, throat irritation.
- t. Includes reports of autoimmune pancreatitis, pancreatitis, pancreatitis acute, lipase increased, amylase increased.
- u. Includes reports of ascites, autoimmune hepatitis, hepatocellular injury, hepatitis, hepatitis acute, hepatotoxicity, liver disorder, drug-induced liver injury, hepatic failure, hepatic steatosis, hepatic lesion, oesophageal varices haemorrhage, varices oesophageal.
- v. Includes reports of acne, acne pustular, blister, blood blister, dermatitis, dermatitis acneiform, dermatitis allergic, dermatitis exfoliative, drug eruption, eczema, eczema infected, erythema, erythema of eyelid, eyelid rash, fixed eruption, folliculitis, furuncle, hand dermatitis, lip blister, oral blood blister, palmar-plantar erythrodysaesthesia syndrome, rash, rash erythematous, rash follicular, rash generalised, rash macular, rash maculo-papular, rash papular, rash papulosquamous, rash pruritic, rash pustular, rash vesicular, scrotal dermatitis, seborrhoeic dermatitis, skin exfoliation, skin toxicity, skin ulcer.
- w. Includes reports of dermatitis bullous, exfoliative rash, erythema multiforme, dermatitis exfoliative generalised, toxic skin eruption, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, toxic epidermal necrolysis, cutaneous vasculitis.
- x. Includes reports of musculoskeletal pain, myalgia, bone pain.
- y. Includes reports of myositis, rhabdomyolysis, polymyalgia rheumatica, dermatomyositis, muscle abscess, myoglobin urine present.
- z. Includes reports of blood creatinine increased, hypercreatininaemia.
23. aa. Includes reports of autoimmune nephritis, nephritis, Henoch-Schonlein Purpura nephritis, paraneoplastic glomerulonephritis, tubulointerstitial nephritis.

## Serious adverse event/deaths/other significant events

## Table 34 : Serious adverse events reported in ≥ 2% of patients in either treatment arms (safetyevaluable population)

Serious Adverse Events,\\_Incidence of at Least 2&amp; in Any Treatment Arm by System Organ Class and Preferred Term, Safety-Evaluable Patients

Protoco1:G029431

|                                                          | Overall (N=549)      | Overall (N=549)      |
|----------------------------------------------------------|----------------------|----------------------|
| MedDRA System Organ_Class MedDRA Preferred Term          | Chemotherapy (N=263) | Atezolizumab (N=286) |
| Totalnumber ofpatientswithatleastoneadverseevent         | 28 (10.6%)           | 19 (6.68)            |
| Infections and infestations                              |                      |                      |
| Total number of patients with at least one adverse event | 4.28）                | 8 (2.8%)             |
| Pneumonia                                                | 11 (4.2%)            | (2.8%)               |
| Blood and lymphatic system disorders                     |                      |                      |
| Total number of patients with at least one adverse event | 16 6.1%) 9           | 2 (0.78)             |
| Anaemia                                                  | 3.4%)                | (0.3%)               |
| Thrombocytopenia                                         | 9 (3.4%)             | (0.38)               |
| Respiratory, thoracic and mediastinal disorders          |                      |                      |
| Total number of patients with at least one adverse event | 0.48)                | 11 (3.8%)            |
| Pneumonitis                                              | 0.48)                | 6 (2.18)             |
| Chronic obstructive pulmonary disease                    | 0                    | 6 (2.1%)             |

Investigator text for Aes encoded usingMedDRA v22.0.Percentages are based on N in the column headings. For frequency counts by preferred term, multiple occurrences of the same AE in an individual are counted only once. For frequency counts of \"Total number of events\" rows, the multiple occurrences of the same AE in an indivicual are counted separately. DataExtractionDate-3lAUG2019;DataCutoff Date-10SEP2018.

<div style=\"page-break-after: always\"></div>

|                    | Chemotherapy (N=263)   | Chemotherapy (N=263)   | Atezolizumab (N=286)   | Atezolizumab (N=286)   | AllPatients (N=549)   | AllPatients (N=549)   |
|--------------------|------------------------|------------------------|------------------------|------------------------|-----------------------|-----------------------|
| All Deaths         |                        | 126(47.98)             | 125                    | (43.78)                | 251                   | (45.78)               |
|                    | AdverseEvent           | 11（4.2)                | 11                     | （3.8%）                 | 22                    | （4.0%）                |
| ProgressiveDisease |                        | 107(40.78)             | 103                    | (36.0号)                | 210                   | (38.38)               |
| Other              |                        | 8(3.0%)                |                        | 11（3.8)                |                       | 19(3.5)               |

Table 35: Death and the cause of death (safety-evaluable population)

<!-- image -->

Table 36: Adverse events leading to death (safety-evaluable population)

|                                                          | Overall (N=549)                   | Overall (N=549)   |
|----------------------------------------------------------|-----------------------------------|-------------------|
| MedDRA System Organ Class MedDRA Preferred Term          | Chemotherapy Atezolizumab (N=263) | (N=286)           |
| Totalnumberofpatientswithatleastoneadverseevent          | 11 (4.28)                         | 11 (3.88)         |
| Overalltotalnumberofevents                               | 11                                | 11                |
| Respiratory, thoracic and mediastinal disorders          |                                   |                   |
| Totalnumber ofpatients withatleast oneadverseevent       | 1 (0.48)                          | 3 (1.08)          |
| Total number of events                                   | 1                                 | 3                 |
| Aspiration Chronic obstructive pulmonary disease         | 0 0                               | (0.38)            |
| Pulmonary embolism                                       | 0                                 | (0.3%) (0.38)     |
| Acute pulmonary oedema                                   | (0.4%)                            | 0                 |
| Cardiac disorders                                        |                                   |                   |
| Totalnumber ofpatients with atleast oneadverse event     | 3 (1.18)                          | 2 (0.7%)          |
| Total number of events                                   | 3                                 | 2                 |
| Acute myocardial infarction                              | 0                                 | (0.38)            |
| Cardiac arrest                                           | 2 (0.8%)                          | 1 (0.3%)          |
| Cardiac failure                                          | (0.48)                            | 0                 |
| General disorders and administration site conditions     |                                   |                   |
| Total number of patients with at least one adverse event | 3 (1.1%)                          | 2 (0.78)          |
| Total number of events                                   | 3                                 | 2                 |
| Death                                                    | (1.18)                            | (0.78)            |
| Gastrointestinal disorders                               |                                   |                   |
| Total number of patients with at least one adverse event |                                   | (0.3号)            |
| Total number of events                                   |                                   | 1                 |
| Mechanical ileus                                         | 0                                 | (0.3号)            |
| Infections and infestations                              |                                   |                   |
| Totalnumber ofpatients with atleastoneadverse event      | (1.1%) 3                          | (0.38) 1          |
| Total number of events Sepsis                            | 0                                 | 1 (0.3%)          |
| Pneumonia                                                | (0.48)                            | 0                 |
| Respiratory tract infection                              | (0.48)                            | 00                |
| Tuberculosis                                             | (0.4%)                            |                   |
| Nervous system disorders                                 |                                   |                   |
| Total number of patients with at least one adverse event | 0                                 | (0.38)            |
| Totalnumber of events                                    |                                   | 1                 |
| Cerebral infarction                                      | 0                                 | 1 (0.38)          |
| Product issues                                           |                                   |                   |
| Totalnumber ofpatientswith atleast oneadverse event      | 0                                 | (0.38)            |
| Total number of events Device occlusion                  | 0 0                               | 1 (0.38)          |
| Blood and lymphatic system disorders                     |                                   |                   |
| Totalnumberofpatientswithatleastoneadverseevent          | 1 (0.48)                          | 0                 |
| Total number of events                                   |                                   |                   |
| Pancytopenia                                             | (0.4%)                            | 0                 |

Investigator text for AEs encoded using MedDRA v22.0.Percentages are based on N in the column headings. For frequency counts by preferred term, multiple occurrences of the same AE in an individual are counted only once. For frequency counts of \"Total number of events\" rows, the multiple occurrences of the same AE in an individual are counted separately. Data ExtractionDate-3lAUG2019;Data Cutoff Date-10SEP2018.

<div style=\"page-break-after: always\"></div>

## Laboratory findings

| Laboratory Test Category Laboratory Test   | Grade Direction                             | Chemotherapy (N=263)        | Atezolizumab (N=286)       |
|--------------------------------------------|---------------------------------------------|-----------------------------|----------------------------|
| Chemistry Albumin  (g/L)                   |                                             |                             |                            |
|                                            | Low                                         | 3/255 (1.28)                | 1/281 (0.48)               |
| Alkaline Phosphatase (U/L)                 | High                                        | 1/255 (0.48)                | 7/281 (2.5%)               |
| Bilirubin (umol/L)                         | High                                        | 1/259(0.48)                 | 9/280(3.28)                |
| Calcium (mmol/L)                           | High Low                                    | 1/258 (0.4号) 6/257 (2.3%)   | 10/279(3.6%) 3/279 (1.18)  |
| Creatinine (umol/L)                        | High                                        | 5/259 (1.98)                | 2/281 (0.78)               |
| Glucose (mmol/L)                           | Low                                         | 1/257 (0.48)                | 1/280 (0.4%)               |
| Magmesium (mmol/L)                         | High Low                                    | 5/255 (2.0号) 4/257 (1.6%)   | 12/277(4.38) 1/280 (0.4%)  |
| Phosphorus (mmol/L)                        | Low                                         | 4/254 (1.68)                | 10/279 (3.6%)              |
| Potassium (mmol/L)                         | High Low                                    | 7/256 (2.78) 6/257 (2.38)   | 11/281 (3.98) 3/281 (1.18) |
| SGOT/AST (U/L)                             | High                                        | 2/259 (0.8%)                | 9/281 (3.2%)               |
| SGPI/ALT (U/L)                             | High                                        | 2/259 (0.88)                | 9/281 (3.2%)               |
| Sodium (mmol/L)                            | High Low                                    | 0/259 12/252 (4.88)         | 0/281 24/277 (8.78)        |
| Coagulation                                | Activated Partial Thromboplastin Time (sec) |                             |                            |
|                                            | High                                        | 1/141 (0.7%)                | 0/107                      |
| InternationalNormalized Ratio              | (FRACTION) High                             | 2/151 (1.38)                | 2/114 (1.8%)               |
| Hematology Hemoglobin (g/L)                | High Low                                    | 1/260 (0.4%) 53/260 (20.4%) | 1/281(0.48) 5/281 (1.8%)   |
| Lymphocytes Abs (10^9/L)                   | High Low                                    | 0/259 44/259 (17.08)        | 0/278 25/277 (9.08)        |
| Neutrophils, Total, Abs (10^9/L)           | Low                                         |                             | 69/260（26.58)2/281(0.78）   |
| Platelet (10^9/L)                          | Low                                         |                             | 34/260 (13.18)2/281 (0.78) |
| White Blood Cel1 Count (10^9/L)            | High Low                                    | 1/257(0.48) 40/260 (15.48)  | 0/281 1/281 (0.48)         |

Table 37: Summary of clinically relevant laboratory shifts from baseline

<!-- image -->

Two patients in the atezolizumab arm had laboratory abnormalities suggestive of Hy's law, however none of  these  cases  qualified  as  true  Hy's  law  as  the  liver  function  abnormalities  could  be  attributed  to alternate etiologies. One patient developed elevated liver function tests after 1 cycle of atezolizumab on study Day 16, which was confounded by his liver metastasis at enrollment and the development of new liver lesion revealed by tumor assessment on study Day 19. Atezolizumab was permanently discontinued. The patient received treatment with systemic corticosteroids, after which his ALT and AST followed a downward trend though bilirubin remained at a high level on study Day 21.

Another patient developed elevated liver function tests after 1 cycle of atezolizumab on study Day 23, which was confounded by his liver metastasis at enrollment and a concurrently developed cholangitis associated  with  the  self-administered  herbal  treatment  after  study  treatment  initiation.  The  patient

<div style=\"page-break-after: always\"></div>

continued receiving Cycle 2 treatment on Study Day 23. His cholangitis and transaminitis were managed with percutaneous transhepatic biliary drainage without systemic corticosteroid treatment.

## Shifts in Thyroid Stimulating Hormone

The majority of patients with normal thyroid stimulating hormone (TSH) at baseline maintained normal TSH post-baseline. A higher proportion of patients in the atezolizumab arm had treatment-emergent TSH abnormalities  (defined  as  normal  at  baseline  and  abnormal  at  post-baseline)  compared  to  the chemotherapy arm (TSH high: 5% chemotherapy vs. 13% atezolizumab; TSH low: 9% vs. 11%).

## ECG/Vital signs

The overall incidence of clinically-significant ECG abnormalities post-baseline was low and was balanced between  the  two  treatment  arms.  Four  patients  in  the  chemotherapy  arm  and  1  patient  in  the atezolizumab arm had a clinically significant ECG abnormality at baseline. No post-baseline clinically significant ECG abnormalities were reported among these patients.

Post baseline, clinically significant ECG abnormalities were reported in 2 patients in the chemotherapy arm and 3 patients in the atezolizumab arm, although the baseline ECG results of these patients were either normal or abnormal but not clinically significant. In the chemotherapy arm, one patient developed a  Grade  2  myocardial  ischaemia  and  a  Grade  1  atrioventricular  block  on  Study  Days  64  and  85, respectively, with clinically significant ECG abnormalities reported on the same day. The other patient developed  a  Grade  1  ejection  fraction  decreased  on  Study  Day  27  and  clinically  significant  ECG abnormality was reported on Study Day 127. In the atezolizumab arm, one patient developed a Grade 1 atrial fibrillation on Study Day 621, with clinically significant ECG abnormalities reported on Study Days 631 and 673. The other patient developed a Grade 2 atrial fibrillation on Study Day 363, with clinically significant ECG abnormalities reported 1 day later. The third patient did not have reported AEs under the Cardiac Disorders SOC.

No clinically relevant difference in vital signs was observed between the two treatment arms.

## Anti-Drug Antibodies

## Subgroup Analyses of Safety by Treatment-Emergent ADA Status

In the ADA evaluable population, the atezolizumab ADA incidence rate was 24.3% post-baseline. The post-baseline ADA incidence rate in the TC3 or IC3 WT population was 23.5%. Among ADA-evaluable patients in  the  safety  evaluable  population,  ADA-negative  and  ADA-positive  patients  received atezolizumab for a median duration of 6.8 and 4.9 months (median of 10 and 8 cycles), respectively. An overview of safety by ADA status is shown in Table 50.

<div style=\"page-break-after: always\"></div>

Table 38: Safety Summary Profile by Atezolizumab ADA Status (ADA-Evaluable Atezolizumab Patients in Safety Evaluable Population)

|                                                                              | ADA- (N=202)   | ADA- (N=202)     | ADA+ (N=65)        |
|------------------------------------------------------------------------------|----------------|------------------|--------------------|
| Total number of patients with at least one adverse event Totalnumberofevents |                | 182 (90.1%) 1332 | 64 (98.5%) 473     |
| Totalnumber of patientswithatleastone Treatment-relatedAE                    | 128 58         | (63.4%)          | 41 (63.1%)         |
| Grade3-4AE Treatment-related Grade 3-4 AE                                    | 23             | (28.7%)          | 26 (40.0%) (16.9%) |
|                                                                              |                | (11.4%)          | 11 2               |
| Grade5AE SeriousAdverseEvent                                                 | 3              | (1.5%)           | (3.1%)             |
| Treatment-RelatedSeriousAdverseEvent                                         | 45             | (22.3%)          | 25 (38.5%) 6       |
|                                                                              | 15             | (7.4%)           | (9.2%)             |
| AE leading to atezolizumab treatment withdrawal                              | 10             | (5.0%)           | 5 (7.7%)           |
| AEleadingtodosemodification/interruption                                     | 51             | (25.2%)          | 20 (30.8%)         |

Investigatortext for AEs encoded using MedDRA v22.0.Percentagesare based on Ninthecolumn headings. Multiple occurrences of the same AE in one individual are counted only once except for \"Total'number of events\" row in which multiple occurrences of the same AE are counted separately. Counts in \"Grade 3-4 AE\" are number of patients whose highest grades of AE are 3 or 4. DataExtractionDate-31AUG2019;DataCutoffDate-10SEP2018.

No preferred terms with a ≥ 5% higher incidence of Grade 3 or grade 4 AEs were seen between ADApositive and ADA-negative patients.

SAEs were observed at a higher frequency in ADA-positive compared with ADA-negative patients. These SAEs were observed in few patients and were not driven by any specific PT. The most frequent (&gt; 1 patient) SAEs reported in ADA-positive patients were pneumonia (5 [3%] ADA-negative vs 3 [5%] ADApositive patients), and respiratory tract infection (0 vs 3 patients [5%], respectively). All other SAEs reported in the ADA-positive patients were single occurrences and distributed across multiple SOCs.

Infusion related reactions were infrequent and observed in both ADA- and ADA+ patients; all cases were of grade 1 or 2 intensity (Table 51) and none of the patient withdrew atezolizumab due to an infusion related reaction.

A grade 4 anaphylactic reaction was reported in the ADA-positive subgroup; the event occurred on Day 22 (ADAs were detected in this patient on Day 21). The event was considered by the investigator as related to atezolizumab treatment and atezolizumab was discontinued. The event resolved within 1 day.

A grade 4 haemophagocytic lymphohistiocytosis event was reported in the ADA-positive subgroup; the event occurred on Day 115 (ADAs were detected in this patient on Days 21 and 63). The event was considered by the investigator as related to atezolizumab treatment. The event resolved after 27 days.

Table 39: Selected Adverse Events by Highest NCI CTCAE Grade by ADA Status (ADA Evaluable Atezolizumab Patients in Safety Evaluable Population)

|                                     |       | ADA- (N=202)   | ADA+ (N=65)   |
|-------------------------------------|-------|----------------|---------------|
| MedDRApreferredterm                 | Grade |                |               |
| Infusionrelatedreaction             | 1     | 0              | 1 ( 1.5%)     |
|                                     | 2     | 1 (0.5%)       | 2 ( 3.1%)     |
| Hypersensitivity                    | 2     | 0              | 1 (1.5%)      |
|                                     | 3     | 1 ( 0.5%)      | 0             |
| Anaphylacticreaction                | 4     | 0              | 1 ( 1.5%)     |
| Haemophagocytic lymphohistiocytosis | 4     | 0              | 1 ( 1.5%)     |

Two grade 5 events were seen in ADA-positive patients. These patients both had early ADA-positive samples but had subsequent ADA-negative sample results which were taken prior to the grade 5 AE.

<div style=\"page-break-after: always\"></div>

The  incidence  of AESIs was  lower  in  ADA-positive  (36.9%)  compared  with  ADA-negative  patients (44.6%),  as  were  the  incidence  of  treatment-related  AESIs  (26.2%  vs.  35.1%).  Nonetheless,  the incidence of grade 3-4 AESIs (6.4% ADA- vs. 7.7% ADA+), serious AESIs (5.4% vs. 4.6%), and AESIs leading to treatment discontinuation (2.5% vs. 1.5%) was overall balanced between the ADA- and ADA+ patients. There were no AESI medical concepts with ≥ 5% difference in incidence between patients with different ADA status.

AESI PTs with incidence ≥ 2% higher in the ADA+ patients included ALT increased (10.4% vs. 13.8%), AST increased (9.4% vs. 13.8%), erythema (1.0 vs. 3.1%), and infusion related reaction (0.5% vs. 4.6%);  with  incidence ≥ 2%  higher  in  the  ADA-  patients  included  GGT  increased  (2.5%  vs.  0), hyperthyroidism (5.4% vs. 1.5%), of which events of grade 3-4 severity were overall balanced.

Table 40: Overview of AESI, ADA Evaluable Atezolizumab Treated Patients

|                                                                              | ADA- (N=202)                                                        | ADA+ (N=65)                                                         |
|------------------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|
| Total number of patients with at least one AEsI                              | 90 (44.6%)                                                          | 24 (36.9%)                                                          |
| Total number of AEsI events                                                  | 161                                                                 | 52                                                                  |
| Totalnumber of patientswith at least one                                     | Totalnumber of patientswith at least one                            | Totalnumber of patientswith at least one                            |
| Treatment-related AESI                                                       | 71 (35.1%)                                                          | 17 (26.2%)                                                          |
| Grade 3-4 AESI                                                               | 13 6.4%)                                                            | 5 7.7%)                                                             |
| Treatment-related Grade 3-4 AESI                                             | 9 4.5%)                                                             | 5 (7.7%)                                                            |
| Serious AESI                                                                 | 11 5.4%)                                                            | 3 4.6%)                                                             |
| Treatment-Related Serious AESI                                               | 9 4.5%)                                                             | 3 (4.6%)                                                            |
| AESI leading to any treatment withdrawal/dose modification/dose interruption | 22 (10.9%)                                                          | 9 (13.8%)                                                           |
| AESI leading to any withdrawal from treatment                                | 5 2.5%）                                                             | 1 （1.5%）                                                            |
| -Atezolizumab                                                                | 5 2.5%)                                                             | 1 (1.5%)                                                            |
| AEsI leading to anydosemodification/interruption                             | 19 9.4%)                                                            | 8 (12.3%)                                                           |
| -Atezolizumab                                                                | 19 9.4%)                                                            | 8 (12.3%)                                                           |
| AE of Special Interest Medical Concepts: patients with at least one          | AE of Special Interest Medical Concepts: patients with at least one | AE of Special Interest Medical Concepts: patients with at least one |
| Immune-Mediated Hep.（Diag & Lab Ab)                                          | 32 (15.8%)                                                          | 13 (20.0%)                                                          |
| Immune-Mediated Hepatitis (Lab Abnormal)                                     | 31 (15.3%)                                                          | 13 (20.0%)                                                          |
| Immune-Mediated Rash                                                         | 35 (17.3%)                                                          | 9 (13.8%)                                                           |
| Immune-Mediated Hypothyroidism                                               | 21 (10.4%)                                                          | 6 （9.2%)                                                            |
| Immune-Mediated Hyperthyroidism                                              | 11 5.4%)                                                            | 2 3.1%)                                                             |
| Immune-Mediated Pneumonitis                                                  | 8 4.0%)                                                             | 2 3.1%)                                                             |
| Infusion-Related Reactions                                                   | 1 0.5%)                                                             | 3 4.6%)                                                             |
| Immune-Mediated Colitis                                                      | 3 1.5%)                                                             | 0                                                                   |
| Immune-Mediated Diabetes Mellitus                                            | 0                                                                   | 2 (3.1%）                                                            |
| Immune-Mediated Adrenal Insufficiency                                        | 2 1.0%)                                                             | 0                                                                   |
| Immune-Mediated Myositis                                                     | 1 0.5%)                                                             | 0                                                                   |
| Immune-Mediated Severe Cutaneous React.                                      | 1 0.5%)                                                             | 1 （1.5%)                                                            |
| Immune-Mediated Hepatitis (Diagnosis)                                        | 1 0.5%）                                                             | 0                                                                   |
| Immune-MediatedMyositis+Rhabdomyolysis                                       | 1 0.5%)                                                             | 0                                                                   |
| Immune-Mediated Nephritis                                                    | 1 0.5%）                                                             | 0                                                                   |
| Immune-Mediated Vasculitis                                                   | 1 0.5%)                                                             | 0                                                                   |
| Immune-Mediated Myocarditis                                                  | 1                                                                   | 0                                                                   |
|                                                                              | 0.5%)                                                               |                                                                     |

<div style=\"page-break-after: always\"></div>

## Safety in special populations

## Intrinsic factors

## Table 41: Overview of safety by age (safety-evaluable population)

|                                                        |              |              |                  |                 | Overall (N=549)   |                      |                      |                      |                      |
|--------------------------------------------------------|--------------|--------------|------------------|-----------------|-------------------|----------------------|----------------------|----------------------|----------------------|
|                                                        | Chemotherapy | Chemotherapy | Chemotherapy     | Chemotherapy    | Chemotherapy      | Atezolizumab (N=286) | Atezolizumab (N=286) | Atezolizumab (N=286) | Atezolizumab (N=286) |
|                                                        | <65 (N=127)  | >=65 (N=136) | 65 to 74 (N=114) | 75 to 84 (N=21) | >=85 (N=1)        | <65 (N=149)          | >= 65 (N=137)        | 65 to 74 (N=109)     | 75 to 84 (N=28)      |
| Totalnumber of patientswith at least one adverse event | 121（95.3）128 | (94.1%)      | 106 (93.0%)      | 21 (100.0%)     | 1(100.0%)         | 134(89.9%)           | 124 (90.5)           | 101 (92.7%)          | 23 (82.1)            |
| Totalnumber of events Total number of patients with at | 942          | 1052         | 861              | 187             | 4                 | 977                  | 862                  | 688                  | 174                  |
| least one                                              |              |              |                  |                 |                   |                      |                      |                      |                      |
| Treatment-related AE                                   | 111 (87.4)   | 113 (83.18)  | 92 (80.7%)       | 20 （95.2%)      | 1 (100.0%)        | 85 (57.0%)           | 88 (64.2%)           | 70(64.2%)            | 18 (64.3%)           |
| Grade 3-4 AE                                           | 70 (55.1%)   | 68 (50.0%)   | 53(46.5）         | 14 ( 66.78)     | 1 (100.0%)        | 44(29.5%)            | 42 (30.7%)           | 36( (33.0%)          | (21.4%)              |
| Treatment-related Grade 3-4 AE                         | 57 (44.9%)   | 59 (43.4%)   | 44 (38.68）       | 14 ( 66.78)     | 1 (100.0%)        | 14 (9.4%)            | 23 (16.8%)           | 19 (17.4%)           | 4 (14.3%)            |
| Grade 5 AE                                             | 53.9%)       | 6 (4.4%)     | 5 (4.48)         | 1 （ 4.8%)       | 0                 | 6 (4.0%)             | 5 (3.6%)             | 4 (3.7%)             | 1 (3.6%)             |
| Treatment-related Grade 5 AE                           | 1（0.8%）      | 0            | 0                | 0               |                   | 0                    | 0                    | 0                    | 0                    |
| Serious Adverse Event                                  | 34(26.8%)    | 41 (30.1%)   | 32 (28.1%)       | 9 42.98)        | 0 0 0             | 44 (29.5%)           | 37 (27.0%)           | 31 (28.4%)           | 6 (21.4%)            |
| Treatment-RelatedSerious Adverse                       | 18 (14.2%)   | 23 (16.9%)   | 15 (13.2)        | 8 38.18)        |                   | 12 (8.1)             | 12 (8.8%)            | 10 (9.2%)            | (7.1%)               |
| Event AE leading to any treatment                      | 13 (10.2%)   | 30(22.1%)    | 25 (21.9%)       | 4（19.0%）        | 1(100.0%)         | 5(3.4%)              | 13 ( 9.5)            | 11 (10.1)            | 2( 7.1%)             |
| withdrawal Atezolizumab Cisplatin                      | 0 5 3.98)    | 0 5 (3.7%)   | 0 5 (4.4%)       | 0 0             | 0 0               | 53.48） 0             | 13 (9.5%) 0          | 11 (10.1%) 0         | 2 (7.1%) 0           |
| Carboplatin                                            | 21.6%)       | 13 (9.6%)    | 11 (9.6%)        | 2 ( 9.5%)       | 0                 | 0                    | 0                    | 0                    | 0                    |
| Pemetrexed                                             | 97.18)       | 19 (14.0%)   | 16 (14.0%)       | 2 9.5%)         | 1 (100.0%)        | 0                    | 0                    | 0                    | 0                    |
| -Gemcitabine                                           | 43.18)       | 9 (6.6%)     | 7 (6.1%)         | 2 ( 9.5%)       | 0                 | 0                    | 0                    | 0                    | 0                    |
| AE leading to dose modification/                       | 50(39.4%)    | 66 (48.58)   | 53 (46.5%)       | 13 61.9%)       | 0                 | 32 (21.5%)           | 42 (30.7%)           | 33 (30.3%)           | 9 (32.1%)            |
| interruption                                           |              |              |                  |                 |                   |                      |                      |                      |                      |
| -Atezolizumab                                          | 0            | 0            | 0                | 0               | 0                 | 32 (21.5%)           | 41 (29.9%)           | 32 (29.4%)           | 6 (32.1%)            |
| -Cisplatin                                             | 17 (13.4%)   | 10 (7.4%)    | 9(7.9%)          | 1 ( 4.8%)       | 0                 | 0                    | 0                    | 0                    | 0                    |
| -Carboplatin                                           | 22 (17.3%)   | 42 (30.9%)   | 32 (28.1)        | 10 ( 47.6%)     | 0                 | 0                    | 1 (0.7%)             | 1 (0.9%)             | 0                    |
| -Pemetrexed                                            | 34 (26.8%)   | 43 (31.6%)   | 33 (28.9%)       | 10 ( 47.6%)     | 0                 | 0                    | 0                    | 0                    | 0                    |
| -Gemcitabine                                           | 15 (11.8%)   | 22 (16.2%)   | 19 (16.7%)       | 3 w 14.38)      | 0                 | 0                    | 1 (0.7%)             | 1 (0.9%)             | 0                    |

Investigator text for AEs encodedusing MedDRA v22.0. Percentages are based on N in the column headings. Multiple occurrences of the same AE in one indivicual are counted only once except for Total number of eventsrow in which multiple occurrences of the same AE are counted separately. Counts in \"Grade 3-4 AE\"are number of patients whose highest grades of AE are 3 or 4. Data Extraction Date-31AUG2019w:Data Cutoff Date-10sEP2018.

## Table 42: Overview of safety by gender (safety-evaluable population)

Overall

(N=549)

|                                                                       | Chemotherapy (N=263)   | Chemotherapy (N=263)   | Atezolizumab (N=286)   | Atezolizumab (N=286)   |
|-----------------------------------------------------------------------|------------------------|------------------------|------------------------|------------------------|
|                                                                       | Female (N=81)          | Male (N=182)           | Female (N=87)          | Male (N=199)           |
| Totalnumberofpatientswithatleastoneadverseevent Totalnumber of events | 7.6 （93.8%） 678        | 173 (95.1%) 1316       | 82 (94.3%) 661         | 176 (88.4%) 1178       |
| Totalnumber of patients with at least one                             |                        |                        |                        |                        |
| Treatment-related AE                                                  | 72 (88.9%)             | 152 (83.5%)            | 54 (62.1%)             | 119 (59.8%)            |
| Grade 3-4 AE                                                          | 44 (54.3%)             | 94 (51.6%) 26          | (29.9%)                | 60 (30.2%)             |
| Treatment-related Grade 3-4 AE                                        | 36 (44.4%)             | 80 （44.0%) 16 8        | (18.4%)                | 21 (10.6%)             |
| Grade 5 AE                                                            | 3 3.7%)                | 4.4%)                  | 3 (3.4%)               | 8 (4.0%)               |
| Treatment-related Grade 5 AE                                          | 0                      | 1 0.5%）                | 0 27                   | 0                      |
| Serious Adverse Event                                                 | 23 (28.4%)             | 52 (28.6号)             | (31.0%)                | 54 (27.1%)             |
| Treatment-Related Serious Adverse Event                               | 14 (17.3%)             | 27 （14.8%)             | (12.6%)                | 13 6.5%)               |
| AE leading to any treatment withdrawal                                | 14 (17.3%)             | 11 29 (15.9%) 10       | (11.5%)                | 8 4.0%)                |
| Atezolizumab                                                          | 0                      | 0 10                   | (11.5%)                | 8 4.0%）                |
| 一 Cisplatin                                                           | 5 6.2%)                | 5 2.7%)                |                        | 0                      |
| Carboplatin                                                           | 3 3.7%）                | 12 6.6%)               | 0 0                    | 0                      |
| -Pemetrexed                                                           | 9 (11.1%)              | 19 (10.4%)             | 0                      | 0                      |
| Gemcitabine                                                           | 3 3.7%）                | 10 5.5%)               | 0                      | 0                      |
| AE leading to dose modification/interruption                          | 40 (49.4%)             | 76 (41.8%）             | 15 (17.2%)             | 59 (29.6%)             |
| -Atezolizumab                                                         | 0                      | 0                      | 15 (17.2%)             | 58 (29.1%)             |
| 一 Cisplatin                                                           | 12 (14.8%)             | 15 （8.2%）              | 0                      | 0                      |
| Carboplatin                                                           | 19 (23.5%)             | 45 (24.7%)             | 0                      | 1 （0.5%）               |
| Pemetrexed                                                            | 30 (37.0%)             | 47 (25.8%)             | 0                      | 0                      |
| -Gemcitabine                                                          | 10 (12.3%)             | 27 (14.8%)             | 0                      | 1 （0.5%）               |

Only events reported in\\_the Adverse EventsForm areincluded. Investigator text for AEs encoded using MedDRA v22.0.Percentages arebased on N in the column headings.Multiple occurrences of the same AE in one individualarecountedonlyonceexceptfor\"Totalnumberofevents\" row inwhich multipleoccurrences of thesame AE are countedseparately. Counts in \"Grade 3-4 AE\"are number of patients whose highest grades of AE are 3 or 4. Data Extraction Date-31AuG2019wData Cutoff Date-10sEP2018.

<div style=\"page-break-after: always\"></div>

Table 43: Overview of safety by race (safety-evaluable population)

Overall

(N=549)

|                                                          | Chemotherapy (N=263)   | Chemotherapy (N=263)   | Chemotherapy (N=263)   | Chemotherapy (N=263)   | Chemotherapy (N=263)   | Atezolizumab (N=286)   | Atezolizumab (N=286)   | Atezolizumab (N=286)   |
|----------------------------------------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|
|                                                          | White (N=224)          | Black (N=2)            | Asian (N=32)           | Other (N=5)            | White (N=233)          | Black (N=2)            | Asian (N=48)           | Other (N=3)            |
| Total number of patients with at least one adverse event | 210（93.8%）2（100.0%)    |                        | 32 (100.0%)            | 5(100.0%)              | 206 (88.4%)            | 2(100.0%)              | 47(97.9%)              | 3 (100.0%)             |
| Total number of events                                   | 1618                   | 18                     | 327                    | 31                     | 1444                   | 20                     | 360                    | 15                     |
| Total number of patients with at least one               |                        |                        |                        |                        |                        |                        |                        |                        |
| Treatment-related AE                                     | 186 (83.0%)            | (100.0%)               | 32 (100.0%)            | 4(80.0%)               | 132 (56.78)            | 1(50.0%)               | 38 (79.28)             | 2(66.7%)               |
| Grade 3-4 AE                                             | 111 (49.6%)            | 2 (100.0%)             | 22 68.8%)              | 3 ( 60.0%)             | 68 (29.2%)             | 0                      | 17 (35.4%)             | 1 (33.3%)              |
| Treatment-related Grade 3-4 AE                           | 91 (40.68）             | 2 (100.0%)             | 20 62.5%)              | 3 (60.0%)              | 29 (12.4%)             | 0                      | 8 (16.7%)              | 0                      |
| Grade 5 AE                                               | 10 4.58)               | 0                      | 1 （ 3.1%)              | 0                      | 11 (4.7%)              | 0                      | 0                      | 0                      |
| Treatment-related Grade 5 AE                             | 1 0.48)                | 0                      | 0                      | 0                      | 0                      | 0                      | 0                      | 0                      |
| Serious Adverse Event                                    | 65 (29.0%）             | 0                      | 8 ( 25.0%)             | 2 40.0%)               | 61 (26.2%)             | 0                      | 20 (41.7%)             | 0                      |
| Treatment-Related Serious Adverse Event                  | 33 (14.7&）             |                        | 7 ( 21.9%)             | 1 ( 20.0%)             | 15 6.4%)               | 0                      | 6 (18.8%)              | 0                      |
| AE leading to any treatment withdrawal                   | 33 (14.7&）             |                        | 7 21.9%)               | 3 60.0%)               | 12 （ 5.2%)             | 0                      | 6 (12.5%)              | 0                      |
| Atezolizumab                                             | 0                      | 0                      | 0                      | 0                      | 12 5.28)               | 0                      | 6 (12.5%)              | 0                      |
| Cisplatin                                                | 3.18) 0                |                        | 1 3.1)                 | 2 40.0%)               | 0                      | 0                      | 0                      | 0                      |
| Carboplatin                                              | 10 (4.58) 0            |                        | 4 12.5%)               | 1 ( 20.0%)             | 0                      | 0                      | 0                      | 0                      |
| 一 Pemetrexed                                             | 21 9.48)               | 0                      | 6 （ 18.8%)             | 1 ( 20.0%)             | 0                      | 0                      |                        | 0                      |
| Gemcitabine                                              | 11 498) 0              |                        | 1 （ 3.1%)              | 1 20.0%)               | 0                      | 0                      | 0 0                    | 0                      |
| AE leading to dose modification/interruption             | 93 (41.5%)             | 0                      | 20 ( 62.5%)            | 3 ( 60.0%)             | 53 (22.7%)             | 0                      | 21 (43.8%)             | 0                      |
| -Atezolizumab                                            | 0 0                    |                        | 0                      | 0                      | 52 (22.38）             |                        | 21 (43.8%)             | 0                      |
| - Cisplatin                                              | 17 76%)                | 0                      | 8 25.0%)               | 2 40.0%)               | 0                      | 0                      | 0                      | 0                      |
| -Carboplatin                                             | 52 (23.2%） 0           |                        | 11 ( 34.4%)            | 1 20.0%)               | 1 (0.4%)               | 0                      | 0                      | 0                      |
| -Pemetrexed                                              | 61 (27.28）             | 0                      | 15 ( 46.9%)            | 1 (20.0%)              | 0                      | 0                      | 0                      | 0                      |
| Gemcitabine                                              | 30 (13.48) 0           |                        | ( 15.6%)               | 2(40.0%)               | 1 0.4%)                | 0                      | 0                      | 0                      |

Only events reported in the Adverse Events Form are included.

Investigator text for AEs encoded using MedDRA v22.0. Percentages axewbased on N in the column headings.Multiple occurrences of the same AE in one individual are counted only once except for \"Total number of events\" row in which multiple occurrences of the same AE are counted separately. Counts in \"Grade 3-4 AE\"are number of patients whose highest grades of AE are3 or 4.

## Extrinsic factors

## Table 44: Overview of safety by region (safety-evaluable population)

Overall

(N=549)

|                                                      | Chemotherapy (N=263)   | Chemotherapy (N=263)             | Chemotherapy (N=263)           | Chemotherapy (N=263)   | Atezolizumab (N=286)   | Atezolizumab (N=286)             | Atezolizumab (N=286)           |                     |
|------------------------------------------------------|------------------------|----------------------------------|--------------------------------|------------------------|------------------------|----------------------------------|--------------------------------|---------------------|
|                                                      | Asia-Pacific (N=31)    | Central and South America (N=14) | Europe and Middle East (N=213) | North America (N=5)    | Asia-Pacific (N=47)    | Central and South America (N=15) | Europe and Middle East (N=215) | North America (N=9) |
| Totalnumberofpatientswith atleastw one adverse event | 31 (100.0%)            | 14 (100.0%)                      | 199 (93.4%)                    | 5 (100.0%)             | 46 (97.9%)             | 15 (100.0%)                      | 188 (87.4%)                    | 9 (100.0%)          |
| Total number of events                               | 313                    | 151                              | 1480                           | 50                     | 347                    | 119                              | 1200                           | 173                 |
| Total number of patients with at least               |                        |                                  |                                |                        |                        |                                  |                                |                     |
| one                                                  |                        |                                  |                                |                        |                        |                                  |                                |                     |
| Treatment-related AE                                 | 31 (100.0%)            | 13 92.98)                        | 175 (82.2%)                    | 5 (100.0%)             | 38 8(80.9%)            | 9(60.0%)                         | 118 (54.9%)                    | 8 (88.9%)           |
| Grade 3-4 AE                                         | 22 71.0%)              | 6 （ 64.38)                       | 105 (49.3%)                    | 2(40.0%)               | 17 (36.2%)             | 4 (26.7%)                        | 61 (28.4%)                     | 4 44.4%)            |
| Treatment-related Grade 3-4 AE                       | 20(64.5%)              | 8 57.1)                          | 86 (40.4%)                     | 2(40.0%)               | (17.0%)                | ( 6.78)                          | 25 (11.6%)                     | 3 33.3%)            |
| Grade 5 AE                                           | 1 3.2%)                | 1 7.1%)                          | 6 (4.28)                       | 0                      | 0                      | 0                                | 10 (4.7%)                      | 1 (11.1%)           |
| Treatment-related Grade 5 AE                         | 0                      | 0                                | 1 （0.5%）                       | 0                      | 0                      | 0                                | 0                              | 0                   |
| Serious Adverse Event                                | 8 25.8%)               | 5 35.7%)                         | 61 (28.6%)                     | 1(20.0%)               | 19 (40.4%)             | 1 6.7%)                          | 57 (26.5%)                     | 4 （ 44.4%)          |
| Treatment-Related Serious Adverse                    | 7 22.6%)               | 2 （ 14.3%)                       | 31 (14.6%)                     | 1 (20.0%)              | 9 (19.1%)              | 0                                | 14 （ 6.5%)                     | 1 (11.1%)           |
| Event AE leading toany treatment                     | 722.68）                | 2 2(14.3%)                       | 34 (16.0%)                     | 0                      | 6(12.8%)               | 0                                | 12 (5.6%)                      | 0                   |
| withdrawal -Atezolizumab                             | 0                      | 0                                | 0                              | 0                      | 6 (12.8%)              | 0                                | 12 5.6%)                       | 0                   |
| -Cisplatin                                           | 1 3.28)                | 0                                | 9 (4.2%)                       | 0                      | 0                      | 0                                | 0                              | 0                   |
| -Carboplatin                                         | 4                      | 1 7.1%)                          | 10 ( 4.7%)                     | 0                      | 0                      | 0                                | 0                              | 0                   |
| -Pemetrexed                                          | 619.48)                | 2 (14.3%)                        | 20 ( 9.48)                     |                        | 0                      | 0                                | 0                              | 0                   |
| - Gemcitabine                                        | 13.28)                 | 0                                | 12 ( 5.6%)                     | 0 0                    | 0                      | 0                                | 0                              | 0                   |
| AE leading to dose modification/                     | 19(61.3)               | 5 (35.7%)                        | 90 (42.3%)                     | 2(40.0%)               | 21 (44.7&)             | 4(26.7%)                         | 48 (22.3%)                     | 1 (11.1%)           |
| interruption                                         |                        |                                  |                                |                        |                        |                                  |                                |                     |
| -Atezolizumab                                        | 0                      | 0                                | 0                              | 0                      | 21 (44.7%)             | 4(26.7%)                         | 47 (21.9%)                     | 1 (11.1%)           |
| -Cisplatin                                           | (25.8%)                | 0                                | 19 (8.9%)                      |                        | 0                      | 0                                | 0                              | 0                   |
| Carboplatin                                          | 10 （ 32.3)             | 3 (21.4%)                        | 49 (23.0%)                     | 0 2 (40.0%)            | 0                      | 0                                | 1 (0.5%)                       | 0                   |
| Pemetrexed                                           | 14 (45.2%)             | 3 (21.4%)                        | 58 (27.2%)                     | (40.0%)                | 0                      | 0                                | 0                              | 0                   |
| -Gemcitabine                                         | 5 (16.1)               | 2 (14.3%)                        | 30 (14.1%)                     | 0                      | 0                      | 0                                | 1 (0.5%)                       | 0                   |

Data Extraction Date - 31AUG2019 ;Data Cutoff Date - 10sEP2018.

<div style=\"page-break-after: always\"></div>

Table 45: Overview of safety by tobacco use history (safety-evaluable population)

Overall

(N=549)

|                                                                 |              | Chemotherapy (N=263)   | Chemotherapy (N=263)   | Chemotherapy (N=263)   | Atezolizumab (N=286)   | Atezolizumab (N=286)   | Atezolizumab (N=286)   |
|-----------------------------------------------------------------|--------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|
|                                                                 | Never (N=40) |                        | Current (N=73)         | Previous (N=150)       | Never (N=44)           | Current (N=75)         | Previous (N=167)       |
| Totalnumberofpatientswithatleastoneadverseeventw35              | (87.5%)      |                        | 68 (93.2%)             | 146 (97.3%) 1169       | 41(93.2%) 266          | 63 (84.0%) 463         | 154 (92.2%)            |
| Total number of events                                          | 326          |                        | 499                    |                        |                        |                        | 1110                   |
| Total number of patients with at least one Treatment-related AE | 33 （82.58）   | 62                     | (84.9%)                | 129 (86.0%)            | 26 (59.1%)             | 42 (56.0%)             | 105 (62.9%)            |
| Grade 3-4 AE                                                    | 21 （52.5%）   | 37                     | (50.7%)                | 80 (53.3%)             | 11 (25.0%)             | 25 (33.3%)             | 50 (29.9%)             |
| Treatment-related Grade 3-4 AE                                  | 18 （45.0%）   | 29                     | (39.7%)                | 69 (46.0%)             | 5 (11.4%)              | 10 (13.3%)             | 22 (13.2%)             |
| Grade 5 AE                                                      | 1 2.5%)      | 4                      | (5.5%)                 | 6 (4.0%)               | 1 (2.3%)               | 3 (4.0%)               | 7 (4.2%)               |
| Treatment-related Grade 5 AE                                    | 1 (2.5%)     |                        |                        | 0                      | 0                      | 0                      | 0                      |
| Serious Adverse Event                                           | 11 (27.5%）   | 25                     | (34.2%)                | 39 (26.0%)             | 12 (27.3%)             | 20 (26.7%)             | 49 (29.3%)             |
| Treatment-Related Serious Adverse Event                         | 9 (22.5%）    | 11                     | (15.1)                 | 21 (14.0%)             | 6 (13.6%)              | 4 （ 5.3%)              | 14 (8.4%)              |
| AE leading to any treatment withdrawal                          | 6 (15.0%）    | 14                     | (19.2%)                | 23 (15.3%)             | 3 6.8%)                | 1 （ 1.3%)              | 14 （ 8.4%)             |
| Atezolizumab                                                    | 0            | 0                      |                        | 0                      | 3 6.8%)                | 1 1.3%)                | 14 (8.4%)              |
| Cisplatin                                                       | 2 5.0%）      | 5                      | (6.8%)                 | 3 (2.0%)               | 0                      | 0                      | 0                      |
| Carboplatin                                                     | 0            | 5                      | 6.8%)                  | 10 ( 6.78)             | 0                      | 0                      | 0                      |
| -Pemetrexed                                                     | 4 (10.0%）    | 10                     | (13.78)                | 14 ( 9.3%)             | 0                      | 0                      | 0                      |
| Gemcitabine                                                     | 1 （2.5%）     | 4                      | (5.5%)                 | 8 ( 5.3%)              | 0                      | 0                      | 0                      |
| AE leading to dose modification/interruption                    | 18           | （45.0%） 36             | (49.3%)                | 62 (41.3%)             | 7 (15.9%)              | 16 (21.3%)             | 51 (30.5%)             |
| 一 Atezolizumab                                                  | 0            | 0                      |                        | 0                      | 7 (15.9%)              | 15 (20.0%)             | 51 (30.5%)             |
| 一 Cisplatin                                                     | 7            | (17.5%)                | 7 9.68)                | 13 (8.7%)              | 0                      | 0                      | 0                      |
| Carboplatin                                                     | 7            | (17.5%） 19             | (26.0%)                | 38 (25.3%)             | 0                      | 1 (1.3%)               | 0                      |
| Pemetrexed                                                      | 13           | (32.58） 24             | (32.9%)                | 40 (26.7%)             | 0                      | 0                      | 0                      |
| -Gemcitabine                                                    |              | 5（12.5） 11             | (15.1%)                | 21 (14.0%)             | 0                      | 1 (1.3%)               | 0                      |

Only eventsreported in the Adverse EventsForm areincludled.

Investigator text for AEs encoded using MedDRA v22.0.Percentages arebased on N in the column headings.Multiple occurrences of the same AE in one individual are counted only once except for \"Total number ofevents\"row inwhich multiple occurrences of the same AEare counted separately. Counts in \"Grade 3-4 AE\"are number of patients whose highest grades of AE are3 or 4. Data Extraction Date 31AUG2019:Data Cutoff Date-10SEP2018.

Table 46: Overview of safety by ECOG (safety-evaluable population)

Overall

(N=549)

|                                                                                 | Chemotherapy (N=263)   | Chemotherapy (N=263)   | Atezolizumab (N=286)   | Atezolizumab (N=286)   | Atezolizumab (N=286)   |
|---------------------------------------------------------------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|
|                                                                                 | 0 (N=98)               | 1 (N=165)              | 0 (N=102)              | 1 (N=184)              |                        |
| Total number of patients with at least one adverse event Total number of events | 94 (95.9%) 829         | 155 (93.9%) 1165       | 93 (91.2%) 714         | 165 (89.7) 1125        |                        |
| Total number of patients with at least one                                      |                        |                        |                        |                        |                        |
| Treatment-related AE                                                            | 80 (81.6%)             | 144 (87.3%)            | 70 (68.68)             | 103 (56.0%)            |                        |
| Grade 3-4 AE                                                                    | 50 (51.0%)             | 88 (53.3%）             | 35 (34.38)             | 51 (27.7%)             |                        |
| Treatment-related Grade 3-4 AE                                                  | 40 (40.8%)             | 76 (46.18)             | 15 (14.78)             | 22 (12.0%)             |                        |
| Grade 5 AE                                                                      | 2 2.0%)                | 9 ( 5.5%)              | 0                      | 11 (6.0%)              |                        |
| Treatment-related Grade 5 AE                                                    | 0                      | 1 0.6%)                | 0                      | 0                      |                        |
| Serious Adverse Event                                                           | 19 (19.4%)             | 56 (33.9%)             | 27 (26.5%)             | 54 (29.38)             |                        |
| Treatment-Related Serious Adverse Event                                         | （9.28)                 | 32 (19.4%)             | 11 (10.8%)             | 13 7.1%)               |                        |
| AE leading to any treatment withdrawal                                          | 17 (17.38)             | 26 (15.8%)             | 6 5.9%)                | 12 6.5%)               |                        |
| -Atezolizumab                                                                   | 0                      | 0                      | 6 5.98)                | 12 6.58)               |                        |
| - Cisplatin                                                                     | 6618)                  | 4 (2.4%)               | 0                      | 0                      |                        |
| 一 Carboplatin                                                                   | 441%)                  | 11 6.7%)               | 0                      | 0                      |                        |
| Pemetrexed                                                                      | 10 (10.2%)             | 18 (10.9%)             | 0                      | 0                      |                        |
| Gemcitabine                                                                     | 6（618）                 | 7 (4.2%)               | 0                      | 0                      |                        |
| AE leading to dose modification/interruption                                    | 43 (43.9%)             | 73 (44.2%)             | 29 (28.4%)             | 45 (24.5%)             |                        |
| -Atezolizumab                                                                   | 0                      | 0                      | 28 (27.5%)             | 45 (24.5%)             |                        |
| Cisplatin                                                                       | 11 (11.2%)             | 16 (826m               | 0                      | 0                      |                        |
| Carboplatin                                                                     | 22 (22.4%)             | 42 (25.5%)             | （1.0%)                 | 0                      |                        |
| Pemetrexed                                                                      | 30 (30.6%)             | 47 (28.5%)             | 0                      | 0                      |                        |
| Gemcitabine                                                                     | 13 (13.3)              | 24 (14.5%)             | 1.0%）                  | 0                      |                        |

Investigator text for AEs encoded usingMedDRA v22.0.Percentages arewbased on N in the column headings.Multiple occurrences of the same AE in one individual are counted only once except forTotal number of events\"row in which multiple occurrences of the same AE are counted separately. Counts in \"Grade 3-4 AE\"are number of patients whose highest grades of AE are3 or 4.

## Safety related to drug-drug interactions and other interactions

No pharmacokinetic drug-drug interaction studies have been submitted with this application.

<div style=\"page-break-after: always\"></div>

## Discontinuation due to adverse events

Table 47 : Adverse events leading to dose modification/interruption reported in ≥ 2% of patients in either treatment arm (safety-evaluable population)

| MedDRA System Organ Class MedDRAPreferred Term          | Chemotherapy n=263   | Atezolizumab n=286   |
|---------------------------------------------------------|----------------------|----------------------|
| Total number of patients with at least one adverseevent | 115 (43.7%)          | 74 (25.9%)           |
| BLOODANDLYMPHATICSYSTEM DISORDERS                       |                      |                      |
| Neutropenia                                             | 37 (14.1%)           | 2 ( 0.7%)            |
| Anaemia                                                 | 21 ( 8.0%)           | 3 ( 1.0%)            |
| Thrombocytopenia                                        | 21 ( 8.0%)           | 1 ( 0.3%)            |
| Leukopenia                                              | 8 (3.0%)             | 0                    |
| INVESTIGATIONS                                          |                      |                      |
| Blood creatinine increased                              | 10 (3.8%)            | 2 (0.7%)             |
| Platelet count decreased                                | 11 (4.2%)            | 0                    |
| Neutrophil count decreased                              | 10 ( 3.8%)           | 0                    |
| White blood cell count decreased                        | 8 (3.0%)             | 1 ( 0.3%)            |
| Alanine aminotransferaseincreased                       | 2 (0.8%)             | 6 (2.1%)             |
| Aspartateaminotransferaseincreased                      | 2 ( 0.8%)            | 6 (2.1%)             |
| RESPIRATORY,THORACICAND MEDIASTINALDISORDERS            |                      |                      |
| Pneumonitis                                             | 0                    | 6 (2.1%)             |

Source: t\\_ae\\_dosint\\_SE\\_10Sep2018\\_29431

Table 48: Safety summary (safety evaluable population)

|                                                                     |                      |                      | Pooled Population   | Pooled Population         | Pooled Population       | Pooled Population       | Pooled Population   | Pooled Population   |
|---------------------------------------------------------------------|----------------------|----------------------|---------------------|---------------------------|-------------------------|-------------------------|---------------------|---------------------|
|                                                                     | IMpower110           | IMpower110           |                     | Atezo Mono NSCLC (N=1636) |                         |                         |                     |                     |
|                                                                     | Chemotherapy (N=263) | Atezolizumab (N=286) |                     |                           | Atezo Mono [1] (N=2616) | Atezo Mono [2] (N=3178) |                     |                     |
| Total number of patients with at least one AE Totalnumber of events | 249(94.7%) 1994      | 258 (90.2%) 1839     | 15964               | 1554(95.0%)2510(95.9%)    | 27653                   | 3051 (96.0%) 33364      |                     |                     |
| Total number of patients with at least one                          |                      |                      |                     |                           |                         |                         |                     |                     |
| Related AE                                                          | 224 (85.2%)          | 173 (60.5%)          |                     | 1076(65.8%)1760(67.3%)    |                         | 2168 (68.2%)            |                     |                     |
| Grade 3-4 AE                                                        | 138 (52.5%)          |                      | 86 (30.1%)          | 665 (40.6%）               | (45.9%)                 | 1482 (46.6%)            |                     |                     |
| Related Grade 3-4 AE                                                | 116 (44.1%)          |                      | 37 (12.9%)          | 226 (13.8%)               | 1200 382 (14.6%)        | 496 (15.6%)             |                     |                     |
| Grade 5 AE                                                          | 11(4.2%）             |                      | 11 ( 3.8%)          | 67 ( 4.1%)                | 87 ( 3.3%)              | 119 ( 3.7%)             |                     |                     |
| Related Grade 5 AE                                                  | 1 （0.4%)             |                      | 0                   | 3 (0.2%)                  | 7 (0.3%)                | 11 ( 0.3号)              |                     |                     |
| Serious AE                                                          | 75 (28.5%)           |                      | 81 (28.3%)          | 627(38.3号) 1065           | （40.7%)                 | 1309 (41.2%)            |                     |                     |
| Related serious AE                                                  | 41 (15.6%)           |                      | 24(8.4%）            | 166 (10.1%)               | 266 (10.2%)             | 353 (11.1)              |                     |                     |
| AE leading to any Study Treatment withdrawal                        | 43 (16.3%)           |                      | 18(6.3)             | 129 (7.9%)                | 182 ( 7.0%)             | 226 ( 7.1%)             |                     |                     |
| AEleading toany Study Treatmentmodification/intermuotionwl15        | （43.7%)              |                      | 74(25.9%)           | 436 (26.7%)               | 718 (27.4%)             | 882 (27.8%)             |                     |                     |

G028915(QAK); Pooled Atezo Mono[1]: Pooled Atezo Mono NSCLC + GO27831(PCD4989g non-NSCIC Cohort) + GO29293(IMVIGOR210) ; Pooled Atezo Mono[2]: Pooled Atezo Mono [1]+ GO29294(IMVIGOR211) + WO29074(IMMOTION150 Arm B) .

Only events reported in the Adverse Events Form are included.

same AE in one individual are counted only once except for \"Total number of events\" row in which multiple occurrences of the same AE

Clinical cut-off dates: G029431:10SEP2018, G027831:31MAR2016, G028625:07JAN2015, G028753:01DEC2015, GO28754:01DEC2015, GO28915:07JUL2016,G029293:04JUL2016,G029294:13MAR2017,W029074:17OCT2016

## Post marketing experience

Atezolizumab has been globally approved for the treatment of a variety of cancers, including NSCLC, UC, and triple-negative breast cancer. The full list of the 93 countries in which atezolizumab is approved can be found in the most recent Periodic Benefit Risk Evaluation Report (PBRER) (PBRER 1094093).

<div style=\"page-break-after: always\"></div>

Since the International Birth Date (18 May 2016) through 17 May 2019, an estimated cumulative total of 106,316 patients have received atezolizumab from marketing experience.  During the PSUR covering the  period  17  May  2019  to  17  May  2020  (EMEA/H/C/PSUSA/00010644/202005),  pemphigoid  was considered as a new adverse drug reaction.

## 2.5.1. Discussion on clinical safety

The safety database of patients, who received atezolizumab in the pivotal IMpower110 study, consisted of  286  patients.  The  updated  median  exposure  of  atezolizumab  was  5.3  months  (range  0-50)  and atezolizumab monotherapy was given until progressive disease or loss of clinical benefit. Considering the known safety profile of atezolizumab monotherapy in both the targeted disease as well as other tumour types, this is considered acceptable.

The Applicant has provided updated safety data based on the clinical cut-off date of 4 February 2020. As expected, incidences of AEs increased with the longer follow-up. These increases are more apparent in the atezolizumab arm, likely associated with later onset of some of the immune-related AEs and the longer exposure of atezolizumab compared with chemotherapy agents (only for pemetrexed, that is given as maintenance therapy, the maximum number of doses increased with the updated CCOD).

In the pivotal study IMpower110, nearly all patients had adverse events and ~63% of the AEs with atezolizumab were treatment-related vs 85% of the ADRs observed with chemotherapy. Grade 3 AEs were observed in more patients on chemotherapy (53% vs 34%); as well as treatment-related grade 3 events (45% vs 14%). Overall, more discontinuations occurred with chemotherapy too, i.e. 17.1% vs 7.3% of patients. Dose modifications/interruptions were also more frequent with chemotherapy (44.5% vs 31.5%). However, SAEs occurred in a similar incidence in both treatment arms (~29%).

The  most  common  TEAEs  by  PT  (not  updated)  in  both  treatment  arms  (atezo  vs  chemo)  were  GI disorders (51.0% vs 31.8%); blood and lymphatic system (61.2% vs 17.5%); and general disorders such as asthenia (17.5% vs 12.9%), fatigue (17.5% vs 12.9%) and pyrexia (8.7% vs 13.6%). Dyspnoea (9.9% vs 14.0%) and cough (9.5% vs 11.9%) were also common events, which is reflective of the patient population and the underlying disease. The clinically meaningful differences observed between the  treatment  arms  were  typically  chemotherapy-related  AEs,  such  as  nausea,  vomiting,  decreased platelets and neutrophil count versus immunotherapy-related hypothyroidism observed frequently with atezolizumab.  Similar treatment-related  AEs were  observed  in  the  two  treatment  arms,  most frequently anaemia (45.2% vs 3.5%), neutropenia (27.4% vs 1.0%), and nausea (31.6% vs 7.0%), but were much more commonly observed with chemotherapy. Grade 3-4 treatment-related adverse events were most commonly haematological toxicity observed in the chemotherapy arm.

Adverse  events  of  special  interest (AESIs)  were  immune-related  events,  such  as  hepatitis  (lab abnormalities), rash, hypo- or hyperthyroidism, and pneumonitis and were more frequently observed with atezolizumab vs chemotherapy (46.2% vs 18.3%). Grade 3-4 events were observed in 8.7% vs 1.5% of the patients, while serious AESIs were observed in 6.6% vs 1.1% of the patients, respectively. Systemic corticosteroids were required for ~13% of the patients who received atezolizumab. This is in line with the well-known safety profile of atezolizumab monotherapy and the level of immune-related toxicity is considered acceptable.

Serious adverse events were a little more common with chemotherapy (10.6% vs 6.6%) and it is noted  that  especially  pneumonia,  anaemia,  and  thrombocytopenia  were  frequent  events.  However, pneumonitis and COPD were more commonly observed with atezolizumab. Overall, the risk of SAEs is acceptable and the nature of the events are well-known with both of the study treatments. A total of 22 patients died from adverse events in the study, but none were treatment-related deaths .

<div style=\"page-break-after: always\"></div>

A shift to a clinically relevant change in laboratory findings with atezolizumab vs chemotherapy was more commonly observed regarding alkaline phosphatase, bilirubin, high calcium, low phosphorus, high AST,  and  ALT.  As  expected,  increased  haematological  toxicity  was  observed  with  chemotherapy. Although two cases were suggestive of Hy's law, it is agreed that they should be attributed to the underlying cancer disease and not atezolizumab treatment. No new unknown laboratory toxicities were observed with atezolizumab in the pivotal study, and the laboratory findings are acceptable for the patient population in this palliative setting.

Adverse events leading to discontinuation of atezolizumab was rare and observed in only 7.3% of the patients in the IMpower110 study, which is also in line with the available monotherapy safety data; hence, monotherapy with atezolizumab is usually a tolerable treatment and the rate of discontinuations are acceptable. AEs leading to dose interruptions with atezolizumab were observed in 31.5% of the patients,  and  were  most  commonly  due  to  pneumonitis,  increased  AST/ALAT  or  anaemia,  which  is acceptable and consistent with the events observed in the monotherapy pools presented.

Safety by region, smoking status or EGOC PS status did not show any clinically significantly differences.

In the ADA evaluable population, the atezolizumab ADA incidence rate was 24.3% post-baseline. Higher incidences of grade 3-4 AEs (40% vs 29%), treatment-related grade 3-4 AEs (17% vs. 11%), SAEs (39% vs. 22%), and AE leading to dose modification/interruption (31% vs. 25%) were observed in the ADA-positive  patients  compared  to  the  ADA-negative  patients.  This  is  especially  noteworthy  in  the context of the lower exposure in the ADA-positive patients and the most pronounced difference was observed in the SOC infections and infestations (SAEs 15% vs. 7%; grade 3-4 AEs 11% vs. 6%). The incidence of AESIs was lower in ADA-positive (36.9%) compared with ADA-negative patients (44.6%); but grade 3-4 AESIs, serious AESIs, and AESIs leading to withdrawal were comparable. In conclusion, the safety profile appears to be overall unfavourable in the ADA-positive population compared to the ADA-negative population; however, no firm conclusions can be drawn in view of the overall small sample size of the ADA-positive patients (n=65) and the general distribution across different PTs (reflected in section 4.8 of the SmPC).

## 2.5.2. Conclusions on clinical safety

Overall, the safety profile of both chemotherapy and atezolizumab are consistent with previous observations and the known safety profiles of the treatments, while no new safety signals were observed. The treatment-emergent and the treatment-related AEs were more commonly observed with chemotherapy as expected; however, a similar incidence of SAEs were observed in both arms. Adverse events of special interest were immune-related events, which were more commonly observed with atezolizumab, but still within an acceptable and expected range. The toxicity profile appeared worse in the ADA-positive compared to the ADA-negative population with the limitations of small patient numbers.

In conclusion, the safety profile of atezolizumab monotherapy is considered acceptable and no new safety issues have been raised during the safety assessment.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

<div style=\"page-break-after: always\"></div>

## 2.6. Risk management plan

The MAH submitted an updated RMP version with this application.

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 12.1 is acceptable.

No new safety concerns were identified as part of this extension of indication. Therefore, the list of safety concerns, the pharmacovigilance plan and the risk minimisation measures remain unchanged and sufficient to address and mitigate the risks in all approved indications.

The CHMP endorsed the Risk Management Plan version 12.1 with the following content:

## Safety concerns

| Summary of safety concerns   | Summary of safety concerns                                                                                                                                                                                                                                                                                                                                                                                                                               |
|------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | Immune-related hepatitis Immune-related pneumonitis Immune-related colitis Immune-related pancreatitis Immune-related endocrinopathies (diabetes mellitus, hypothyroidism, hyperthyroidism, adrenal insufficiency and hypophysitis) Immune-related neuropathies (Guillain-Barré syndrome, and myasthenic syndrome / myasthenia gravis) Immune-related meningoencephalitis Infusion-related reactions Immune-related myocarditis Immune-related nephritis |
| Important potential risks    | Anti-drug antibodies Embryo-fetal toxicity                                                                                                                                                                                                                                                                                                                                                                                                               |
| Missing information          | Long term use Concomitant or sequential use of atezolizumab with intra- vesical Bacillus Calmette-Guérin vaccine for the treatment of urothelial carcinoma                                                                                                                                                                                                                                                                                               |

.

## Pharmacovigilance plan

| Study Status                                                                                                               | Summary of Objectives                                                                                                      | Safety concerns addressed                                                                                                  | Milestones                                                                                                                 | Due dates                                                                                                                  |
|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|
| Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization |
| There are no Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization | There are no Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization | There are no Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization | There are no Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization | There are no Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization |

<div style=\"page-break-after: always\"></div>

| Study Status                                                                                                                                                                                                               | Summary of Objectives                                                                                                                                                                                                                                                              | Safety concerns addressed                                                                                                                                                                                                  | Milestones                                                                                                                                                                                                                 | Due dates                                                                                                                                                                                                                  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional               | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional                                                                       | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional               | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional               | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional               |
| There are no Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | There are no Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances                                                         | There are no Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | There are no Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | There are no Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances |
| Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                                                                      | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              |
| WO29635: A Phase IB/II, Open-Label Study of the Safety and Pharmacology of Atezolizumab Administered with or without Bacille Calmette-Guérin in Patients with High Risk Non Muscle-Invasive Bladder Cancer                 | To evaluate the safety and tolerability of atezolizumab as a single agent and in combination with BCG. To identify the DLTs and to determine the MTD or tolerability at the MAD of BCG in combination with atezolizumab                                                            | Concomitant or sequential use of atezolizumab with intra-vesical BCG vaccine for the treatment of urothelial carcinoma                                                                                                     | Final CSR                                                                                                                                                                                                                  | June 2022                                                                                                                                                                                                                  |
| Ongoing MO39171 (TAIL): Single-Arm Long-Term Safety and Efficacy Study of atezolizumab in previously treated NSCLC Patients Ongoing                                                                                        | To evaluate the long-term safety of atezolizumab on the bases of the following endpoints: The incidence of all serious adverse events (SAEs) related to atezolizumab treatment and the incidence of immune-related adverse events (irAEs) related to atezolizumab treatment        | Long-term use                                                                                                                                                                                                              | Final CSR                                                                                                                                                                                                                  | May 2022                                                                                                                                                                                                                   |
| MO29983: (SAUL): An Open-Label, Single Arm, Multicenter, Safety Study of atezolizumab in Locally Advanced or Metastatic Urothelial or Non- Urothelial Carcinoma of the Urinary Tract Ongoing                               | To evaluate the safety of atezolizumab based on the following endpoints: Nature, severity, duration, frequency and timing of adverse events (AEs) and changes in vital signs, physical findings, and clinical laboratory results during and following atezolizumab administration. | Long-term use                                                                                                                                                                                                              | Final CSR                                                                                                                                                                                                                  | Q1 2023                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

ADAs = anti-drug antibodies; BCG = bacillus Calmette-Guerin; CSR = Clinical Study Report; DLT = dose-limiting toxicity;MAD = maximum administered dose; MTD = maximum tolerated dose; NSCLC = non-small cell lung cancer; OS = overall survival; RCC = renal cell carcinoma; TBD = to be determined

## Risk minimisation measures

| Safety concern             | Risk minimization measures                                                                                                                                                                                                                                                                                             | Pharmacovigilance activities                                                                                                                     |
|----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|
| Immune-Related Hepatitis   | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.2 Posology and method of administration Section 4.4 Special Warnings and Precautions for Use Section 4.8 Undesirable effects Additional risk minimization measures: • Patient alert cards | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None |
| Immune-Related Pneumonitis | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.2 Posology and method of administration Section 4.4 Special Warnings and Precautions for Use Section 4.8 Undesirable effects Additional risk minimization measures: • Patient alert cards | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None |
| Immune-Related Colitis     | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC                                                                                                                                                                                                                                   | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection:                                                    |

<div style=\"page-break-after: always\"></div>

| Safety concern                                                                                                                 | Risk minimization measures                                                                                                                                                                                                                                                                                             | Pharmacovigilance activities                                                                                                                     |
|--------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                | under the following sections: Section 4.2 Posology and method of administration Section 4.4 Special Warnings and Precautions for Use Section 4.8 Undesirable effects Additional risk minimization measures: • Patient alert cards                                                                                      | None Additional pharmacovigilance activities: None                                                                                               |
| Immune-Related Pancreatitis                                                                                                    | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.2 Posology and method of administration Section 4.4 Special Warnings and Precautions for Use Section 4.8 Undesirable effects Additional risk minimization measures:                       | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None |
| Immune-Related Endocrinopathies (Diabetes Mellitus, Hypothyroidism, Hyperthryroidism, Adrenal Insufficiency, and Hypophysitis) | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.2 Posology and method of administration Section 4.4 Special Warnings and Precautions for Use Section 4.8 Undesirable effects Additional risk minimization measures: • Patient alert cards | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None |

<div style=\"page-break-after: always\"></div>

| Safety concern                                                              | Risk minimization measures                                                                                                                                                                                                                                                                                             | Pharmacovigilance activities                                                                                                                     |
|-----------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|
| Immune-Related Neuropathies (Guillain-Barre Syndrome and Myasthenia Gravis) | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.2 Posology and method of administration Section 4.4 Special Warnings and Precautions for Use Section 4.8 Undesirable effects Additional risk minimization measures:                       | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None |
| Immune-Related Meningoencephalitis                                          | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.2 Posology and method of administration Section 4.4 Special Warnings and Precautions for Use Section 4.8 Undesirable effects Additional risk minimization measures: • Patient alert cards | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None |
| Infusion-Related Reactions                                                  | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.2 Posology and method of administration Section 4.4 Special Warnings and Precautions for Use Section 4.8 Undesirable effects                                                              | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None |

<div style=\"page-break-after: always\"></div>

| Safety concern             | Risk minimization measures                                                                                                                                                                                                                                                                                              | Pharmacovigilance activities                                                                                                                     |
|----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|
|                            | Additional risk minimization measures: • Patient alert cards                                                                                                                                                                                                                                                            |                                                                                                                                                  |
| Immune-Related Myocarditis | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.2 Posology and method of administration Section 4.4 Special Warnings and Precautions for Use Section 4.8 Undesirable effects Additional risk minimization measures:                        | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None |
| Immune-related nephritis   | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.2 Posology and method of administration Section 4.4 Special Warnings and Precautions for Use Section 4.8 -Undesirable effects Additional risk minimization measures: • Patient alert cards | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None |

<div style=\"page-break-after: always\"></div>

| Safety concern          | Risk minimization measures                                                                                                                                                                                                                                                                       | Pharmacovigilance activities                                                                                                                     |
|-------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|
| Immune-related myositis | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.2 Posology and method of administration Section 4.4 Special Warnings and Precautions for Use Section 4.8 Undesirable effects Additional risk minimization measures: | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None |
| Anti-drug Antibodies    | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.8 Undesirable effects No additional risk minimization measures                                                                                                      | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities:      |
| Embryo-fetal toxicity   | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.6 Fertility, pregnancy and lactation Section 5.3 Preclinical safety data No additional risk minimization measures                                                   | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None |
| Long-term use           | Routine risk minimization measures:                                                                                                                                                                                                                                                              | Routine pharmacovigilance                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| Safety concern                                                                                                                               | Risk minimization measures                                                                                                                                                                                                                                                                                                                                           | Pharmacovigilance activities                                                                                                                              |
|----------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                              | Proposed text in E.U. SmPC: None No Additional risk minimization measures                                                                                                                                                                                                                                                                                            | activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: Studies: • MO29983                      |
| Concomitant or sequential use of atezolizumab with intra-vesical Bacillus Calmette-Guérin vaccine for the treatment of urothelial carcinoma. | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.4 Special Warnings and Precautions for Use: Includes language that patients who were administered a live attenuated vaccine with 28 days prior to enrolment were excluded from clinical trials No Additional risk minimization measures | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: Study WO29635 |

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC have been updated. Particularly, physicians are warned about the delayed onset of atezolizumab effect as a higher number of deaths within 2.5 months after randomisation was observed with atezolizumab compared with chemotherapy in study IMpower110 although it was followed by a long-term survival benefit. The Package Leaflet has been updated accordingly.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable for the following reasons:

No significant changes impacting the readability of the package leaflet are made. In particular, key

<div style=\"page-break-after: always\"></div>

safety messages are not affected by this extension. The new additions follow the same structure and use similar descriptions and terminology as used in the approved package leaflet. Also, the target group of users will be similar between the approved NSCLC indications and the applied NSCLC indication, with no significant age difference. Moreover, the posology proposed in this application is the same as for the approved indications for Tecentriq as monotherapy.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

Tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic nonsmall cell lung cancer (NSCLC) whose tumours have a PDL1 expression ≥ 50% tumour cells (TC) or ≥ 10% tumour -infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC (see section 5.1).

## 3.1.2. Available therapies and unmet medical need

Other  available  standard  therapies  for  the  first-line  treatment  of  metastatic  NSCLC  (without  EGFR mutations  or  ALK  translocations)  are  platinum-based  combination  chemotherapy  using  cisplatin  or carboplatin combined with agents such as taxanes, vinorelbine, gemcitabine, or pemetrexed, with or without bevacizumab. These therapies results in overall response rates of approximately 20% and 1year survival ranging from 31% to 36% (Schiller et al. 2002).

Moreover, for the targeted PD-L1 selected patient population immune checkpoint inhibitors, as either monotherapy or in combination with platinum-based chemotherapy, have shown improved outcomes in terms of OS and progression-free survival (PFS) (Reck et al. 2016; Gandhi et al. 2018; Socinski et al. 2018; Mok et al. 2019; West et al. 2019). Therefore, immune-therapy containing regimens have become the  current  standard  of  care  for  patients,  who  have  tumors  with  high  expression  of  PD-L1  and consequently  the  median  OS  have  greatly  improved  by  this  approach,  e.g.  to  30  months  with pembrolizumab monotherapy (Reck et al. 2019).

Hence, the targeted PD-L1 selected patient population have several other first-line treatment options, usually either an immune checkpoint inhibitor given as monotherapy or in combination with different chemotherapies. Additional treatment options are still needed for patients with metastatic NSCLC and especially for the patients, who are considered ineligible for combination therapy, and for them monotherapy with an immune checkpoint inhibitor such as atezolizumab would be a valuable treatment option.

## 3.1.3. Main clinical studies

The  pivotal  trial  for  this  application  is  the  randomized,  phase  III,  global,  multicenter,  open-label IMpower110 study, which is designed to evaluate the efficacy and safety of atezolizumab monotherapy compared  with  platinum-based  chemotherapy  in  PD-L1-selected,  chemotherapy-naïve  patients  with metastatic NSCLC. In total, 572 patients were randomised 1:1; however, the relevant targeted PD-L1 selected study population for the applied indication covers only 205 patients, of which 107 patients with mixed histology were randomised to atezolizumab.

<div style=\"page-break-after: always\"></div>

## 3.2. Favourable effects

The primary endpoint is OS and key secondary endpoints are INV-PFS, INV-ORR, DOR by RECIST 1.1, and analysis according to PD-L1 expression. The primary endpoint of OS was met in the PD-L1 selected patient population (TC3 or IC3-WT) at the time of the primary analysis. The KM OS curves first cross, and then they later  begin  to  separate  after  approximately  5  months  of  therapy,  and  from  then  on atezolizumab monotherapy is superior to chemotherapy, and updated data shows a numerical difference in median OS of 5.5 months, which is an improvement from 14.7 months to 20.2 months, HR 0.764 (95%CI: 0.536; 1.087).

The secondary endpoint PFS-INV was improved 3.2 months i.e. from 5.0 months with chemotherapy to 8.2 months with atezolizumab monotherapy, HR 0.592 (95%CI: 0.432; 0.812).

Confirmed ORR was numerically increased from 28.6% with chemotherapy to 40.2% with atezolizumab. More patients achieved a PR with atezolizumab.

The median DOR was statistically significantly increased from 8.3 months (95%CI: 5.6; 11.0) to 38.9 (16.1; NE) with atezolizumab.

## 3.3. Uncertainties and limitations about favourable effects

The sample size of the pivotal study was large (n=572), but the relevant PD-L1 selected study population was smaller and comprised 205 patients, of which 107 patients with mixed histology were randomised to the atezolizumab arm. Hence, the data is limited in the subgroup of interest (TC3 or IC3) due to small patient numbers.

Additionally, the KM OS curves cross after approximately 4 months of therapy, so initially, treatment with chemotherapy seems superior to atezolizumab monotherapy and the shape of the curve indicate early deaths with atezolizumab. This is reflected in the SmPC.

The design of the pivotal study and the protocol were changed multiple times during the study. Concerns were raised that these changes could have been driven by knowledge of the pivotal IMpower110 study results  and thus,  a  GCP  inspection  was  initiated.  Although  the  GCP  inspection  couldn't  exclude  that protocol amendment was not influenced by knowledge based on internal study data and the decisionmaking process was not documented adequately, this change was accepted by the CHMP as being driven by external data, mainly from three anti-PD-1/PD-L1 monotherapy 1L NSCLC studies (Checkmate-026, KEYNOTE-042 and MYSTIC), indicating that OS benefit was greatest in patients that express higher levels of PD-L1. The CHMP considered that external data did lead to the decision to introduce the changes to the protocol.

Treatment until loss of clinical benefit i.e. beyond progression was allowed, so the robustness of the PFS result in this open-label study could have been greatly improved by the use of an independent review of PFS as well, which was not done.

Atezolizumab exposure is lower and the efficacy seems reduced in ADA-positive patients. The incidences of ADAs and the impact of efficacy for the TC3/IC3 population are reflected in the SmPC.

## 3.4. Unfavourable effects

In the pivotal study IMpower110, nearly all patients had adverse events and ~63% of the AEs with atezolizumab  were  treatment-related.  The  most  common  treatment-emergent  AEs  by  PT  in  both treatment arms (atezo vs chemo) were GI disorders (51.0% vs 31.8%); blood and lymphatic system (61.2% vs  17.5%);  and  general  disorders  such  as  asthenia  (17.5%  vs  12.9%),  fatigue  (17.5%  vs

<div style=\"page-break-after: always\"></div>

12.9%), and pyrexia (8.7% vs 13.6%). Dyspnoea (9.9% vs 14.0%) and cough (9.5% vs 11.9%) were also commonly observed and reflective of the patient population and the underlying disease.

Similar treatment-related AEs were observed in the two treatment arms, most frequently anaemia (45.2% vs 3.5%), neutropenia (27.4% vs 1.0%), and nausea (31.6% vs 7.0%), but were much more commonly  observed  with  chemotherapy.  Grade  3-4  treatment-related  AEs  were  most  commonly haematological toxicity observed in the chemotherapy arm.

Adverse events of special interest (AESIs) include immune-related events, such as hepatitis (lab abnormalities), rash, hypo- or hyperthyroidism, and pneumonitis and were more frequently observed with atezolizumab vs chemotherapy (46% vs 18.3%). Grade 3-4 events were observed in 8.7% vs 1.5% of  the  patients,  while  serious  AESIs  were  observed  in  6.6%  vs  1.1%  of  the  patients,  respectively. Systemic corticosteroids were required for ~13% of the patients who received atezolizumab.

Serious  adverse  events were  a  little  more  common  with  chemotherapy  (10.6%  vs  6.6%)  and especially pneumonia, anaemia, and thrombocytopenia were frequent events. Moreover, pneumonitis and COPD were more commonly observed with atezolizumab. A total of 22 patients died from adverse events in the study, but none were treatment-related deaths .

A shift to a clinically relevant change in laboratory findings with atezolizumab vs chemotherapy was more commonly observed regarding alkaline phosphatase, bilirubin, high calcium, low phosphorus, high AST and ALT. No new unknown laboratory toxicities were observed with atezolizumab in the pivotal study.

Adverse events leading to discontinuation of atezolizumab were observed in 7.3% of the patients in the IMpower110 study. AEs leading to dose interruptions with atezolizumab were observed in 31.5% of the patients, and were most commonly due to pneumonitis, increased AST/ALAT, and anaemia.

## 3.5. Uncertainties and limitations about unfavourable effects

The toxicity profile of atezolizumab appeared worse in the ADA-positive compared to the ADA-negative population with the limitations of small patient numbers (see section 4.8 of the SmPC).

## 3.6. Effects Table

Table 49: Effects Table for Tecentriq for first-line treatment of metastatic NSCLC (TC3 or IC3-WT) (IMpower110 data cut-off: 04 February 2020)

| Effect               | Short description       | Unit                 | Treatment Tecentriq   | Control Chemotherapy   | Uncertainties / Strength of evidence                                                     |
|----------------------|-------------------------|----------------------|-----------------------|------------------------|------------------------------------------------------------------------------------------|
| Favourable Effects   | Favourable Effects      | Favourable Effects   | Favourable Effects    | Favourable Effects     | Favourable Effects                                                                       |
| Primary endpoint     | Primary endpoint        | Primary endpoint     | Primary endpoint      | Primary endpoint       | Primary endpoint                                                                         |
| OS                   | Overall survival        | Months               | 20.2                  | 14.7                   | HR 0.764 (0.536;1.087)                                                                   |
| Secondary endpoints  | Secondary endpoints     | Secondary endpoints  | Secondary endpoints   | Secondary endpoints    | Secondary endpoints                                                                      |
| INV-PFS              | Investigator- assessed  | Months               | 8.2                   | 5.0                    | HR 0.592 (0.432;0.812)                                                                   |
| ORR                  | Confirmed response rate | %                    | 40.2                  | 28.6                   | NS                                                                                       |
| DOR                  | Duration of response    | Months               | 38.9 (16.1; NE)       | 8.3 (5.6;11.0)         |                                                                                          |
| Unfavourable Effects | Unfavourable Effects    | Unfavourable Effects | Unfavourable Effects  | Unfavourable Effects   | Unfavourable Effects                                                                     |
| Gr 3/4 AE            | Gr 3/4 AE               | %                    | 33.9                  | 53.2                   |                                                                                          |
| SAEs                 | SAEs                    | %                    | 31.8                  | 29.3                   |                                                                                          |
| AE leading to disc   | AE leading to disc      | %                    | 7.3                   | 17.1                   |                                                                                          |
| AESI Grade 3/4       | AESI Grade 3/4          | %                    | 8.7                   | 1.5                    | Higher rates of all-grade AESIs compared with chemotherapy; Severe AESIs comparable with |

CHMP extension of indication variation assessment report

<div style=\"page-break-after: always\"></div>

Abbreviations: AE: Adverse event; ADR: treatment-related AE; SAEs: Serious AEs; Gr.: grade; disc: leading to treatment discontinuation.

| Effect               | Short description    | Unit   | Treatment Tecentriq   | Control Chemotherapy   | Uncertainties / Strength of evidence                 |
|----------------------|----------------------|--------|-----------------------|------------------------|------------------------------------------------------|
| Safety by ADA-status | Safety by ADA-status |        | ADA-pos. (n=65)       | ADA-neg. (n=202)       | Safety profile appears unfavourable for ADA-positive |
| All grade AE         | All grade AE         | %      | 99                    | 90                     | compared to ADA-negative                             |
| Grade 3/4 AE         | Grade 3/4 AE         | %      | 40                    | 29                     | population despite lower                             |
| SAEs                 | SAEs                 | %      | 39                    | 22                     | exposure with limitation of small sample size        |

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

The  target  population  of  PD-L1  selected  chemotherapy-naïve  patients  with  metastatic  NSCLC  have several  effective  first-line  treatment  options,  which  most  often  consists  of  an  immune  checkpoint inhibitor in monotherapy or in combination with chemotherapy. Hence, atezolizumab monotherapy would be another possible option to the existing therapies, especially for patients who are not eligible for combination therapy.

Efficacy of atezolizumab monotherapy was compared to platinum-based chemotherapy in the first-line setting using OS as the primary objective. The design of the pivotal study and the protocol were changed multiple times during the study; e.g. the Applicant added the TC3 or IC3 population as the first testing hierarchy in Protocol Version 9 (finalized on 14 March 2019). Before this, the TC2/3 or IC2/3 population had been defined as the primary analysis population. The very late time point of this update in the openlabel study and the inadvertent data access by statisticians in December 2018 raised concerns that these changes could have been driven by knowledge of the pivotal IMpower110 study results and thus, a GCP inspection was initiated. However, this change was accepted by the CHMP as being driven by external data, mainly from three anti-PD-1/PD-L1 monotherapy 1L NSCLC studies (Checkmate-026, KEYNOTE042 and MYSTIC), indicating that OS benefit was greatest in patients that express higher levels of PDL1. Moreover, a detailed biomarker review of IMpower150 study and biomarker status in the external studies suggested that TC3/IC3 population had the highest probability of response. Relevant for these analyses are the MYSTIC study results by PD-L1 expression subgroups, and the MAH provided efficacy results from a publication by Rizvie et al 2018 and an oral presentation from ESMO-IO which included additional analyses by PDL1 status in the TC≥50%, TC≥1% and TC &lt;1% for subgroups treated with durvalumab versus chemotherapy. Hence, the CHMP concluded that it is plausible that these external data could have led to the changes made by the MAH later on. Based on the elements provided by the MAH, the CHMP considered that external data did lead to the decision to introduce the changes to the protocol. However, the practice of changing the primary endpoint and hierarchical testing in an ongoing open-label study is still criticized and the MAH should refrain from this approach in future open-label clinical studies. GCP issues should also be addressed as recommended during the GCP inspection and the MAH can expect that in future applications, there will be continued focus on GCP compliance.

At the primary analysis of the pivotal study IMpower110 (CCOD 10 September 2018), a statistically significant  and  clinically  meaningful  OS  benefit  was  demonstrated  with  first-line  (1L)  atezolizumab monotherapy compared to platinum-based chemotherapy in the targeted TC3 or IC3-WT population (median OS: 20.2 vs. 13.1 months, HR 0.595 [95%CI: 0.398, 0.890]; p-value=0.0106). Because the OS data were not fully mature at this analysis time point (around 50% event rates), an OS update after an additional 17 months of follow-up (CCOD: 4 February 2020) was submitted.

<div style=\"page-break-after: always\"></div>

A numerical and clinically relevant OS benefit of 5.5 months (HR of 0.764 [95%CI, 0.563, 1.087] was observed, although no longer statistically significant. This change was mainly driven by the performance of the comparator arm, which may  have been impacted by subsequent therapies (mainly immunotherapy). Moreover, the OS benefit is supported by a clinically relevant improvement of INV-PFS of 3.2 months (HR 0.592) and durable responses (DOR 38.9 months) for patients in the atezolizumab arm.

Considering also the different and overall more tolerable safety profile of atezolizumab monotherapy compared to chemotherapy (lower incidences of treatment discontinuations, dose modifications, Grade 3-4 AEs, and treatment-related SAE), the overall benefit risk is considered favourable.

## 3.7.2. Balance of benefits and risks

Efficacy  data  show  superior  efficacy  of  atezolizumab  monotherapy  compared  to  platinum-based chemotherapy for the first-line treatment of PD-L1 selected patients with metastatic NSCLC.

The safety profile of monotherapy with atezolizumab in the targeted population is well-established from several clinical studies and no new safety concerns were observed in the pivotal study.

Hence, the B/R balance for the applied indication is positive; although the changes made to the single open-label pivotal study while ongoing is criticized and the MAH should refrain from this approach in future clinical studies.

## 3.7.3. Additional considerations on the benefit-risk balance

Not applicable

## 3.8. Conclusions

The overall B/R of atezolizumab monotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression ≥ 50% tumour cells (TC) or ≥ 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC is positive.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours express PD-L1 for Tecentriq based on the results of the pivotal study

<div style=\"page-break-after: always\"></div>

GO29431 (IMpower110), comparing atezolizumab monotherapy to platinum-based chemotherapy. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated accordingly. The RMP version 12.1 has also been submitted.

The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet.

the CHMP has recommended the approval of the variation to the terms of the Marketing Authorisation.

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annex(es) I and IIIB are recommended.

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module 8 \" steps after the authorisation \" will be updated as follows:

## Scope

Please refer to the Recommendations section above.

## Summary

Please refer to Scientific Discussion 'Tecentriq-H-C-4143-II-33'

## Attachments

1. SmPC (changes highlighted) as adopted by the CHMP on 25.03.2021.